🏷

Classifications

Harrison's Chapter

ICD-O Morphology

🔗

Mappings

NCIT

NCIT:C2948 Choriocarcinoma

MONDO:0005207 lists NCIT:C2948 as an exact cross-reference and derives its textual definition from that NCI Thesaurus concept.

ICD-10-CM

ICD10CM:C58 Malignant neoplasm of placenta

ICD-10-CM C58 (malignant neoplasm of placenta) is the code used for gestational choriocarcinoma; it is a close rather than exact match because non-gestational (germ cell) choriocarcinoma is coded to its gonadal primary site instead.

NCIT

NCIT:C2948 Choriocarcinoma

MONDO:0005207 lists NCIT:C2948 as an exact cross-reference and derives its textual definition from that NCI Thesaurus concept.

◆

Subtypes

3

Gestational Choriocarcinoma NCIT:C4646

The common form, arising from the trophoblast of an antecedent gestation. Roughly half of cases follow a complete hydatidiform mole, a quarter follow a term pregnancy, and a quarter follow abortion, ectopic or other gestational events. Because the tumour genome derives wholly or partly from the paternal contribution to that gestation, it is genetically foreign to the patient — a partial or complete allograft — which underlies both its intrinsic immunogenicity and the STR-genotyping test that identifies it. Gestational choriocarcinoma is highly chemosensitive: low-risk disease is cured by single-agent methotrexate or dactinomycin, high-risk disease by EMA-CO.

Show evidence (2 references)

PMID:37758451 SUPPORT Human Clinical

"Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively."

An IGCS/ESGO Rare Tumor Working Group review quantifies the distribution of antecedent gestational events, defining the gestational subtype.

PMID:22469506 SUPPORT Human Clinical

"It is a unique malignancy that is a partial or complete allograft with a genotype that is not the same as the host genotype."

Establishes the defining genetic feature of gestational choriocarcinoma — a tumour genome distinct from (and partly paternal relative to) the host.

Non-Gestational (Germ Cell) Choriocarcinoma NCIT:C2948

A malignant germ cell tumour showing choriocarcinomatous (trophoblastic) differentiation but arising from the patient's own genome rather than from a gestation. In females it typically occurs in children or young adults, involves the ovary, and may be one component of a mixed germ cell tumour; it also occurs in the testis and at extragonadal midline sites. Management follows germ cell tumour principles — surgical staging and cytoreduction followed by bleomycin-based (BEP-type) chemotherapy — rather than the methotrexate/EMA-CO algorithm used for gestational disease. It is generally reported as having a worse outcome, but the evidence cited here supports the different treatment pathway rather than a quantified survival comparison. Note on term choice: NCIT:C39991 (Non-Gestational Ovarian Choriocarcinoma) is site-restricted, so the generic NCIT:C2948 concept is bound here with a more specific preferred_term.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Non-gestational choriocarcinoma of germ cell origin in female patients usually occurs in children or in young adults, involves the ovary, and may contain other non- choriocarcinomatous components as part of a mixed germ cell tumor"

Defines the demographic, anatomic and histologic profile of the non-gestational germ cell subtype.

PMID:32185550 SUPPORT Human Clinical

"Non-gestational ovarian choriocarcinoma (NGOC) is a rare malignant germ cell tumor."

A pooled analysis of 39 published cases classifies non-gestational ovarian choriocarcinoma as a malignant germ cell tumour, distinct from gestational disease.

Intraplacental (Early) Gestational Choriocarcinoma NCIT:C4646

An exceptionally rare early form in which choriocarcinoma is recognised within a term placenta or within the villous tissue of a complete hydatidiform mole, before or at the time the antecedent gestation is delivered or evacuated. Recognising it matters because it may already have metastasised (classically to maternal lung) at a point when the diagnosis would otherwise not be suspected.

Show evidence (1 reference)

PMID:41243514 SUPPORT Human Clinical

"Recently, extremely rare cases of GCC diagnosed in molar and in placenta specimens have been described and accepted as early forms of GCC."

Documents intraplacental/intramolar choriocarcinoma as an accepted early form of gestational choriocarcinoma.

?

Discussions and Knowledge Gaps

2

Does non-gestational (germ cell) choriocarcinoma share the pathophysiology modelled here beyond the shared trophoblastic morphology, and how much worse is its outcome once stage and burden are matched?

KNOWLEDGE GAP OPEN cc_nongestational_evidence_base

Attached to

pathophysiology#Paternal Genome Content and Semi-Allogeneic Tumour Identity

The non-gestational subtype is asserted as a mechanistically distinct arm of this entry, yet the entire arm rests on a handful of references, the largest of which is a pooled analysis of only 39 published cases. Nothing in the literature retrieved for this entry establishes whether the hCG-driven paraneoplastic axis, the PD-L1 immune-resistance mechanism, or the extreme chemosensitivity apply to the germ-cell form, and no matched comparative survival analysis against gestational disease exists. Because the gestational-versus-non-gestational call directly changes therapy, this is a consequential gap rather than an academic one.

Proposed experiments

Matched-outcome cohort of genotype-confirmed non-gestational choriocarcinoma

exp_cc_ngc_matched_outcome_cohort

Assemble a multi-centre cohort of choriocarcinomas in which STR genotyping has confirmed the absence of a paternal allele complement, and compare stage- and burden-matched survival and chemotherapy response against genotype-confirmed gestational cases treated at the same centres. This would replace the current reliance on small pooled case series and test whether the worse outcome attributed to non-gestational disease survives adjustment for stage and tumour burden.

PD-L1 and tumour-infiltrating lymphocyte profiling of non-gestational choriocarcinoma

exp_cc_ngc_pdl1_immune_profiling

Apply the PD-L1 immunohistochemistry and immune-infiltrate profiling that established the adaptive immune-resistance mechanism in gestational choriocarcinoma to genotype-confirmed non-gestational cases. Because the non-gestational tumour is autologous rather than allogeneic, this directly tests whether the immune-evasion arm of this pathograph, and therefore the rationale for checkpoint blockade, generalises to the germ cell form.

Show evidence (2 references)

PMID:32185550 SUPPORT Human Clinical

"Only 39 patients were retrieved from 36 studies in total."

The largest available synthesis of non-gestational ovarian choriocarcinoma is a pooled analysis of just 39 cases scraped from 36 separate reports, which is the direct measure of how thin the evidence base for this subtype is.

PMID:40588865 SUPPORT Human Clinical

"distinguishing gestational choriocarcinoma from nongestational mimics of germ cell or somatic origin, which have profound therapeutic and prognostic implications."

Establishes that the gestational versus non-gestational distinction carries profound therapeutic and prognostic consequences, which is what makes the thin non-gestational evidence base consequential rather than academic.

What determines which choriocarcinomas become multidrug resistant, given that no validated somatic driver gene or resistance biomarker exists?

KNOWLEDGE GAP OPEN cc_no_validated_driver_gene

Attached to

pathophysiology#Multidrug-Resistant Refractory Disease

Fewer than 5% of patients die, essentially all from multidrug-resistant disease, yet there is no recurrent somatic driver for choriocarcinoma and no validated predictor of resistance. Candidate resistance pathways surfaced in the deep-research sweep (DPP4/cholesterol synthesis, RSK2-SOX8, cfDNA signals involving BMPR1A and MAP3K1) are investigational and were deliberately not curated into the pathograph. Since the FIGO/WHO score is a clinical proxy rather than a biological one, a molecular predictor would change who is escalated up front.

Proposed experiments

Paired chemosensitive versus chemoresistant choriocarcinoma multi-omics

exp_cc_paired_resistance_multiomics

Profile matched pre-treatment and post-relapse tumour material by whole-exome and transcriptome sequencing, with serial cell-free DNA sampling through treatment, to identify somatic or transcriptional changes that accompany the emergence of multidrug resistance in an otherwise near-curable disease.

Prospective comparison of candidate resistance biomarkers against the FIGO/WHO score

exp_cc_resistance_biomarker_vs_figo

Prospectively measure candidate resistance markers at diagnosis and test whether any adds predictive value over the FIGO/WHO prognostic score for single-agent failure, which would allow biologically rather than clinically driven up-front escalation.

Show evidence (1 reference)

PMID:37758451 SUPPORT Human Clinical

"some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients."

An expert review states that multidrug resistance is the residual cause of death and explicitly frames it as an unmet need requiring novel approaches, which is the gap this discussion records.

⚙

Pathophysiology

11

Paternal Genome Content and Semi-Allogeneic Tumour Identity

Gestational choriocarcinoma derives from the trophoblast of a prior conceptus, so its genome contains a paternal allele complement that is absent from the patient's own tissues. In the most common precursor, the complete hydatidiform mole, the conceptus genome is entirely androgenetic. The tumour is therefore a partial or complete natural allograft. Two consequences follow and organise the rest of the pathograph: detection of that foreign paternal allele set by STR genotyping definitively separates gestational from non-gestational choriocarcinoma, which matters because the two are treated differently; and the allogeneic tumour is intrinsically immunogenic and must actively suppress host T cells to survive. Non-gestational (germ cell) choriocarcinoma, by contrast, carries only the patient's own genome and lacks this feature. The imprinting biology of the molar precursor itself (CDKN1C/p57 loss) is curated in Hydatidiform_Mole and Gestational_Trophoblastic_Neoplasm.

trophoblast cell CL:0000351

Downstream

Neoplastic Trophoblastic Transformation without Villous Formation Malignant transformation of the (often androgenetic) trophoblast of the antecedent gestation gives rise to the tumour cell population.

PD-L1-Mediated Adaptive Immune Resistance Allogeneic tumour identity makes the neoplasm immunogenic, creating the selective pressure for checkpoint-ligand-mediated immune evasion.

Show evidence (2 references)

PMID:22469506 SUPPORT Human Clinical

"It is a unique malignancy that is a partial or complete allograft with a genotype that is not the same as the host genotype."

Establishes the allogeneic (partly paternal) genome of gestational choriocarcinoma as its defining molecular feature.

PMID:34088998 SUPPORT Human Clinical

"Genotyping detection of a distinct paternal genetic complement not present in the patient’s normal tissues"

Confirms that a paternal allele complement absent from host tissue is the operational marker of gestational origin.

Neoplastic Trophoblastic Transformation without Villous Formation

The transformed cell population reconstitutes the two differentiation states of early implanting trophoblast — a proliferative mononuclear cytotrophoblast compartment and a fused, hormonally active syncytiotrophoblast compartment — but does so as a solid, sheet-like proliferation that never organises chorionic villi. Loss of the villous scaffold is not a cosmetic difference: villous architecture normally constrains trophoblast to a defined invasive front, and its absence accompanies unconstrained, vessel-permeating growth. The proliferative fraction is extreme (Ki-67 often above 90%), with marked nuclear atypia and atypical mitoses.

mononuclear cytotrophoblast cell CL:0000523 syncytiotrophoblast cell CL:0000525

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

hCG Hypersecretion by Neoplastic Syncytiotrophoblast The syncytiotrophoblast compartment retains and amplifies its endocrine program.

Deregulated Trophoblast Invasion and Vascular Permeation The mononuclear/intermediate trophoblast compartment retains its invasive program, now unconstrained by villous architecture.

VEGF-Driven Neoangiogenesis The transformed trophoblast population drives the VEGF-dependent neovascularisation that supplies the rapidly expanding mass.

High Proliferative Fraction and Chemosensitivity The extreme proliferative index that drives aggressiveness simultaneously creates the therapeutic vulnerability.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"the tumor consists of bi- or triphasic arrangements of mononuclear trophoblastic cells and multinucleated syncytiotrophoblast."

Establishes the two-compartment neoplastic trophoblast population that defines the tumour.

PMID:41243514 SUPPORT Human Clinical

"its main diagnostic features are a trimorphic population of trophoblast cells and an absence of chorionic villi."

Confirms the absence of chorionic villi as an intrinsic feature of the transformed trophoblast population.

hCG Hypersecretion by Neoplastic Syncytiotrophoblast

Neoplastic syncytiotrophoblast retains the endocrine function of normal placental syncytiotrophoblast and secretes human chorionic gonadotropin in quantities proportional to viable tumour burden. Because hCG is essentially absent in the non-pregnant state, this converts an internal, often radiographically occult tumour into a continuously measurable quantity: hCG establishes the diagnosis (a plateauing or rising titre after evacuation), contributes a weighted term to the FIGO/WHO prognostic score, tracks response during chemotherapy, and detects relapse. It is the reason gestational trophoblastic neoplasia can be treated to a biochemical endpoint without tissue confirmation.

syncytiotrophoblast cell CL:0000525

gonadotropin secretion GO:0032274 ↑ INCREASED

Downstream

Paraneoplastic Consequences of Extreme hCG Elevation At very high circulating concentrations hCG cross-activates receptors for structurally related glycoprotein hormones and overstimulates the ovary.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"GTN is nowadays diagnosed primarily based on serum hCG measurement combined with imaging studies."

Shows that tumour-derived hCG is sufficient in practice to diagnose and manage gestational trophoblastic neoplasia without tissue.

PMID:20673583 SUPPORT Human Clinical

"the use of human chorionic gonadotropin as a biomarker"

An authoritative Lancet review identifies tumour-secreted hCG as the central biomarker of trophoblastic neoplasia.

Paraneoplastic Consequences of Extreme hCG Elevation

hCG shares an alpha subunit with TSH, LH and FSH and is a weak agonist at the thyrotropin receptor; when tumour-derived concentrations exceed roughly 100,000 mIU/mL, that weak cross-reactivity becomes clinically significant and produces biochemical or overt hyperthyroidism. The same extreme gonadotropin-like signal overstimulates the ovaries, producing bilateral theca-lutein cysts (occasionally with virilisation), and is associated with hyperemesis and pre-eclampsia. These paraneoplastic features are a direct dose-dependent consequence of the biomarker itself rather than of tumour mass, and they resolve as hCG falls with treatment.

syncytiotrophoblast cell CL:0000525

gonadotropin secretion GO:0032274 ↑ INCREASED

Show evidence (1 reference)

PMID:38008872 SUPPORT Human Clinical

"Raised levels of human chorionic gonadotrophin (hCG) (>100,000 m IU/ml) may cause symptoms of hyperthyroidism, hyperemesis, pre-eclampsia and rarely virilization by ovarian theca lutein cyst formation"

Directly links hCG concentrations above 100,000 mIU/mL to hyperthyroidism, hyperemesis, pre-eclampsia and theca-lutein cyst formation, establishing these as dose-dependent paraneoplastic consequences of the hormone.

Deregulated Trophoblast Invasion and Vascular Permeation

Normal extravillous trophoblast is physiologically one of the most invasive cell types in human biology: it penetrates decidua and myometrium and remodels spiral arteries, and it does so as a tightly regulated, self-limiting program. Choriocarcinoma is that program run without its brakes. Tumour trophoblast permeates myometrium and directly invades vascular channels, so intravasation is an early rather than a late event — this is the mechanistic reason choriocarcinoma metastasises hematogenously at small primary volumes and may present with a metastasis before any uterine lesion is apparent. Conformance note: the module's canonical upstream driver is EMT activation in a somatic epithelium; here the invasive phenotype is a retained developmental program of trophoblast rather than a de-differentiation event, so this node conforms at the invasion/intravasation step without asserting the module's EMT trigger node.

extravillous trophoblast CL:0008036

trophoblast cell migration GO:0061450 ↑ INCREASED

uterus UBERON:0000995

Downstream

Hematogenous Dissemination and Pulmonary Colonisation Early intravasation seeds tumour emboli into the venous circulation, whose first capillary bed is the lung.

Show evidence (2 references)

PMID:40588865 SUPPORT Human Clinical

"It is characterized by aggressive, destructive growth and a marked tendency for hematogenous spread, leading to high mortality if left untreated."

A diagnostic-pathology review couples destructive local growth with a marked hematogenous (i.e., vessel-permeating) spread pattern.

PMID:36286620 SUPPORT Human Clinical

"Metastatic lesions often produce abnormal bleeding because trophoblastic tumours have frag- ile vessels."

Attributes the bleeding diathesis of choriocarcinoma deposits to the fragile, tumour-permeated vasculature they form.

VEGF-Driven Neoangiogenesis

Neoplastic trophoblast drives VEGF-dependent neovascularisation, building the fragile, disorganised tumour vasculature that both sustains the rapidly expanding mass and creates the bleeding diathesis characteristic of choriocarcinoma deposits. This is the mechanistic anchor for the antiangiogenic arm of therapy: the VEGFR-2 inhibitor apatinib is combined with PD-1 blockade in multidrug-resistant disease, so the pathograph needs a node for that drug to target.

syncytiotrophoblast cell CL:0000525

vascular endothelial growth factor signaling pathway GO:0038084 ↑ INCREASED

Downstream

Hematogenous Dissemination and Pulmonary Colonisation Tumour neovasculature provides the intravasation route for hematogenous spread.

Haemorrhagic Destruction of Colonised Organs The fragile, disorganised neovasculature is what ruptures, producing the haemorrhagic destruction characteristic of choriocarcinoma deposits.

Show evidence (2 references)

PMID:40760271 SUPPORT In Vitro

"driving choriocarcinoma cell proliferation, EMT, and angiogenesis through activation of the Rap1/VEGF axis"

Direct mechanistic evidence that a VEGF axis drives angiogenic capacity in choriocarcinoma cells. Evidence source is IN_VITRO: the work is in choriocarcinoma cell lines, not primary human tumour tissue.

PMID:41627371 PARTIAL Human Clinical

"the combination of camrelizumab plus apatinib (that potently suppresses the kinase activity of vascular endothelial growth factor 2), have demonstrated complete and durable responses in approximately 70-80% of patients with multidrug-resistant GTN"

Clinical activity of VEGFR-2 inhibition in multidrug-resistant GTN. Marked PARTIAL because response to an antiangiogenic agent is indirect evidence for the angiogenic mechanism, and the combination confounds the antiangiogenic contribution with checkpoint blockade.

Hematogenous Dissemination and Pulmonary Colonisation

Tumour emboli entering uterine veins arrive first at the pulmonary capillary bed, which is why the lung is by far the commonest metastatic site and why multiple rounded pulmonary nodules are a classic radiographic presentation. Onward arterial spread reaches vagina, liver, brain, spleen, kidney and bowel. Metastatic site is a weighted term in the FIGO/WHO prognostic score precisely because it stratifies risk: lung scores 0, spleen/kidney 1, gastrointestinal 2, and liver or brain 4. Colonisation can occur at very small primary tumour volume, so metastatic disease is a common first presentation.

trophoblast cell CL:0000351

lung UBERON:0002048 brain UBERON:0000955

Downstream

Haemorrhagic Destruction of Colonised Organs Metastatic deposits recapitulate the friable, vessel-eroding phenotype of the primary.

Show evidence (3 references)

PMID:36286620 SUPPORT Human Clinical

"The most common metastatic sites are the lungs, but metastatic lesions can also be found in vagina, liver, brain, spleen, kidneys, and bowel."

Enumerates the metastatic site distribution, with lung predominance consistent with venous drainage to the pulmonary bed.

PMID:34088998 SUPPORT Human Clinical

"the ﬁrst presentation may be extrauterine hemorrhage as a result of metastasis"

Confirms that metastatic (rather than uterine) disease is frequently the presenting event.

PMID:38008872 PARTIAL Human Clinical

"About 11% of GTN patients have brain metastasis on presentation"

Quantifies cerebral colonisation already present at diagnosis, showing that hematogenous dissemination frequently precedes clinical recognition; marked PARTIAL because the figure covers gestational trophoblastic neoplasia as a whole.

Haemorrhagic Destruction of Colonised Organs

Every choriocarcinoma deposit reproduces the vascular-erosive phenotype of the primary, so metastases behave less like space-occupying nodules and more like bleeding lesions. Pulmonary deposits cause haemoptysis and dyspnoea; vaginal deposits bleed and should not be biopsied; hepatic deposits bleed intra-abdominally; cerebral deposits may be silent or may cause fatal intracranial haemorrhage. This is also why induction chemotherapy is deliberately gentle in very-high-score disease — rapid lysis of a friable, highly vascular tumour risks catastrophic pulmonary, intraperitoneal or intracranial bleeding.

lung UBERON:0002048 brain UBERON:0000955

Show evidence (2 references)

PMID:36286620 SUPPORT Human Clinical

"Symptoms from brain metastases can also be very severe, even fa- tal if they cause intracranial haemorrhage."

Documents fatal intracranial haemorrhage as the mechanism of death from cerebral deposits.

PMID:37758451 SUPPORT Human Clinical

"at significant risk for pulmonary, intraperitoneal, or intracranial hemorrhage"

Explains that widely metastatic, very-high-score disease carries a haemorrhagic risk that dictates gentle induction chemotherapy.

PD-L1-Mediated Adaptive Immune Resistance

Gestational choriocarcinoma is an allograft growing in an immunocompetent host, which should be rejected — and occasionally is, since spontaneous regressions of metastatic disease are recorded. To survive, the tumour co-opts the same PD-1/PD-L1 axis that normal placental trophoblast uses to maintain fetomaternal tolerance: PD-L1 is expressed strongly and essentially uniformly by neoplastic trophoblast, engaging PD-1 on tumour-infiltrating T cells and shutting down the anti-tumour response. This is an unusually clean example of adaptive immune resistance, because the antigenic stimulus (a foreign paternal genome) is known rather than inferred, and it is directly druggable.

T cell CL:0000084 syncytiotrophoblast cell CL:0000525

negative regulation of T cell mediated immune response to tumor cell GO:0002841 ↑ INCREASED

Downstream

Multidrug-Resistant Refractory Disease Immune escape sustains a residual tumour population that can also evolve chemoresistance; conversely, checkpoint blockade can salvage it.

Show evidence (2 references)

PMID:30339966 SUPPORT Human Clinical

"All gestational choriocarcinomas (CCs; n = 63), epithelioid trophoblastic tumors (n = 12), and placental site trophoblastic tumors (n = 41) were PD-L1 positive, with most showing strong staining."

An immunohistochemical series of 63 gestational choriocarcinomas found uniform, mostly strong PD-L1 positivity.

PMID:37703867 SUPPORT Human Clinical

"Immune checkpoint immunotherapy (CPI) targeting programmed cell death 1 (PD-1)/ligand (PD-L1) has been shown to be an effective treatment for gestational trophoblastic neoplasia (GTN)."

Clinical efficacy of PD-1/PD-L1 blockade demonstrates that this axis is an operative, load-bearing immune-resistance mechanism rather than a passive marker.

High Proliferative Fraction and Chemosensitivity

The same feature that makes choriocarcinoma lethal untreated — a near-maximal proliferative fraction with Ki-67 frequently above 90% — makes it exceptionally vulnerable to cell-cycle-dependent cytotoxics. Antifolate (methotrexate), intercalating/transcription-blocking (dactinomycin), topoisomerase-II (etoposide), alkylating (cyclophosphamide) and antimitotic (vincristine) agents all act preferentially on rapidly cycling cells. Combined with a quantitative serum biomarker that permits treatment to a biochemical endpoint, this makes gestational choriocarcinoma one of the most curable of all solid malignancies — single-agent therapy cures low-risk disease and EMA-CO cures the great majority of high-risk disease. Non-gestational germ cell choriocarcinoma does not share this degree of sensitivity to the GTN regimens and is treated on germ cell lines. Modelling note: this node deliberately bundles a cellular property (near-maximal proliferative fraction) with the therapeutic-response property it produces, because the chemosensitivity is the clinically load-bearing consequence and three cytotoxic treatments attach to it via `target_mechanisms`. A future refactor could split it into a proliferation node and a drug-response node.

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Multidrug-Resistant Refractory Disease A minority of tumours survive selection pressure from the standard regimens and become the dominant cause of death.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Gestational choriocarcinoma is highly chemosensitive and responds well to single-agent methotrexate (low-risk disease) or EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) combination che- motherapy (high-risk disease) with an excellent prognosis"

States the exceptional chemosensitivity of gestational choriocarcinoma and the risk-stratified regimens that exploit it.

PMID:41243514 PARTIAL Human Clinical

"high mitotic activity with Ki-67 immunostaining > 90%"

Documents the very high proliferation index in a histologically confirmed case; this is the cellular substrate of the chemosensitivity claim, though a single case does not itself establish the causal link.

Multidrug-Resistant Refractory Disease

Fewer than 5% of women with gestational choriocarcinoma die, and when they do it is overwhelmingly from disease that has become resistant to multiple cytotoxic agents rather than from untreated bulk. This small refractory population — together with the inherently less chemosensitive non-gestational and intermediate-trophoblast tumours — is the entire remaining unmet need in an otherwise near-curable disease, and is the population in which PD-1/PD-L1 blockade has produced durable responses.

Show evidence (1 reference)

PMID:37758451 SUPPORT Human Clinical

"Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients."

Quantifies multidrug resistance as the residual cause of mortality and the driver of novel-therapy development.

✶

Histopathology

4

Biphasic/Triphasic Trophoblastic Proliferation without Chorionic Villi VERY_FREQUENT

The defining microscopic pattern: intimately admixed mononuclear trophoblast (cytotrophoblast and intermediate trophoblast) and multinucleated syncytiotrophoblast, recapitulating the architecture of primitive villous trophoblast but without forming chorionic villi. Absence of villi is the feature that separates choriocarcinoma from invasive mole. Term note: NCIT has no concept for this composite trophoblastic architecture, so the branch root NCIT:C35867 Morphologic Finding is bound as the closest available term with a more specific `preferred_term`.

Show evidence (2 references)

PMID:41243514 SUPPORT Human Clinical

"its main diagnostic features are a trimorphic population of trophoblast cells and an absence of chorionic villi."

States the two cardinal diagnostic histologic features of gestational choriocarcinoma.

PMID:34088998 SUPPORT Human Clinical

"the tumor consists of bi- or triphasic arrangements of mononuclear trophoblastic cells and multinucleated syncytiotrophoblast."

Confirms the bi-/triphasic trophoblastic architecture is present regardless of gestational or germ cell pathogenetic origin.

Extensive Haemorrhage and Necrosis in a Bulky Destructive Mass

Choriocarcinoma grows as a bulky, friable, destructive mass with confluent haemorrhage and necrosis, so that viable tumour is often only a thin rim at the periphery. This reflects rapid growth outstripping a vasculature the tumour itself erodes, and explains the clinical tendency to catastrophic bleeding at metastatic sites. No `frequency` band is asserted: the source says the tumour "typically forms" such masses, which does not license a quantitative band.

Show evidence (1 reference)

PMID:34088998 SUPPORT Human Clinical

"Choriocarcinoma typically forms bulky, destructive mass lesions with extensive hemorrhage and necrosis within the involved organ."

Directly describes the gross and microscopic pattern of haemorrhagic, necrotic, destructive tumour masses.

Marked Nuclear Atypia with Brisk and Atypical Mitotic Activity

Nuclei are markedly atypical, often bizarre, with a high mitotic rate including atypical mitotic figures and a very high Ki-67 proliferation index. This extreme proliferative fraction is the cytological correlate of the tumour's aggressiveness and, reciprocally, of its exceptional sensitivity to antimetabolite and antimitotic chemotherapy. No `frequency` band is asserted: the sources describe brisk mitotic activity qualitatively and report Ki-67 above 90% in a single documented case, neither of which supports a quantitative band.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"The nuclear atypia is marked, often with bizarre nuclei and there is brisk mitotic activity"

Describes the cytological grade of choriocarcinoma.

PMID:41243514 SUPPORT Human Clinical

"marked cytological atypia and high mitotic activity with Ki-67 immunostaining > 90%"

A histologically documented case shows a Ki-67 proliferation index above 90% alongside the marked atypia.

SALL4 Expression in Both Gestational and Germ Cell Choriocarcinoma

Trophoblastic immunohistochemical markers confirm trophoblastic differentiation but do not distinguish gestational from non-gestational choriocarcinoma; SALL4, a germ cell marker, is expressed in choriocarcinoma of both origins. This immunohistochemical blind spot is precisely why DNA genotyping is required to separate the two.

Show evidence (1 reference)

PMID:34088998 SUPPORT Human Clinical

"SALL4 is expressed in choriocarcinoma of both germ cell and gestational origin"

Documents that SALL4 immunostaining cannot discriminate germ cell from gestational choriocarcinoma, motivating molecular genotyping.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Digestive 1

Hepatic Metastases Neoplasm of the liver HP:0002896

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"Liver metastases are rare and often have a poor prognosis"

States that liver metastases are uncommon and prognostically adverse. No `frequency` band is asserted: the prose word "rare" carries no numerator and reported liver involvement in high-risk disease is well above the VERY_RARE (1-4%) band.

Endocrine 1

Hyperthyroidism Hyperthyroidism HP:0000836

Show evidence (1 reference)

PMID:38008872 SUPPORT Human Clinical

"Raised levels of human chorionic gonadotrophin (hCG) (>100,000 m IU/ml) may cause symptoms of hyperthyroidism"

Directly attributes hyperthyroid symptoms to markedly raised hCG in gestational trophoblastic neoplasia.

Nervous System 1

Headache Headache HP:0002315

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"Central nervous system lesions may be asymptomatic or produce subtle neuro- logic symptoms such as headache."

Documents headache as the typical (and often only) symptom of cerebral metastases.

Respiratory 2

Haemoptysis Hemoptysis HP:0002105

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"it can cause dyspnoea, coughing, chest pain, tachypnoea, and haemoptysis."

Lists haemoptysis among the respiratory manifestations of trophoblastic pulmonary involvement.

Dyspnoea Dyspnea HP:0002094

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"it can cause dyspnoea, coughing, chest pain, tachypnoea, and haemoptysis."

Directly lists dyspnoea as a manifestation of trophoblastic pulmonary involvement.

Constitutional 1

Chest Pain Chest pain HP:0100749

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"it can cause dyspnoea, coughing, chest pain, tachypnoea, and haemoptysis."

Directly lists chest pain among the respiratory manifestations.

Neoplasm 1

Pulmonary Metastases Neoplasm of the lung HP:0100526

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"The most common metastatic sites are the lungs"

Directly supports the lung as the predominant metastatic site.

Other 5

Abnormal Vaginal Bleeding FREQUENT Abnormal vaginal bleeding HP:0034263

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Although the most common clinical symptom is vaginal bleeding"

Identifies vaginal bleeding as the most common presenting symptom of gestational choriocarcinoma, supporting a FREQUENT band.

PMID:36286620 SUPPORT Human Clinical

"Vaginal metastases can present with bleeding, which can- not be distinguished from the uterine blood loss."

Notes that vaginal-metastatic and uterine bleeding are clinically indistinguishable.

Intracranial Haemorrhage Intracranial hemorrhage HP:0002170

Severity: SEVERE

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"Symptoms from brain metastases can also be very severe, even fa- tal if they cause intracranial haemorrhage."

Establishes intracranial haemorrhage as a potentially fatal consequence of cerebral metastasis.

Intra-abdominal Haemorrhage from Hepatic Metastases Hemoperitoneum HP:0011854

Severity: SEVERE

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"Liver metastases are rare and often have a poor prognosis, especially if they present with intra-abdominal bleeding, which is life-threatening."

Supports life-threatening intra-abdominal bleeding from hepatic deposits.

Theca-Lutein Ovarian Cysts Ovarian cyst HP:0000138

Show evidence (1 reference)

PMID:38008872 SUPPORT Human Clinical

"rarely virilization by ovarian theca lutein cyst formation"

Documents theca-lutein cyst formation (and occasional virilisation) as a consequence of markedly raised hCG.

Cerebral Metastases OCCASIONAL Brain neoplasm HP:0030692

Show evidence (1 reference)

PMID:38008872 PARTIAL Human Clinical

"About 11% of GTN patients have brain metastasis on presentation"

Quantifies brain metastasis at presentation at about 11%, which maps to the OCCASIONAL (5-29%) frequency band; marked PARTIAL because the figure is for gestational trophoblastic neoplasia as a whole rather than choriocarcinoma specifically.

🧬

Genetic Associations

2

Paternal (Androgenetic) Allele Complement of Gestational Choriocarcinoma

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Genotyping detection of a distinct paternal genetic complement not present in the patient’s normal tissues"

Establishes the paternal allele complement as the genetic signature of gestational origin and the basis of the genotyping assay.

PMID:34088998 SUPPORT Human Clinical

"The FIGO/WHO prognostic scoring scheme requires ascertaining the precise index gestational event and the time interval between the tumor and index gestation, where DNA genotyping can provide highly relevant information."

Shows that genotyping contributes directly to FIGO/WHO risk scoring by identifying the index gestation and interval.

Host (Non-Paternal) Genome of Non-Gestational Choriocarcinoma

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"DNA genotyping provides a decisive tool in the separation of gestational trophoblastic neoplasia from non-gestational counterparts/mimics of either germ cell or somatic origin."

Establishes genotyping as the decisive discriminator between gestational choriocarcinoma and its non-gestational germ cell and somatic mimics.

PMID:40588865 SUPPORT Human Clinical

"distinguishing gestational choriocarcinoma from nongestational mimics of germ cell or somatic origin, which have profound therapeutic and prognostic implications."

Confirms that the gestational versus non-gestational distinction changes both therapy and prognosis.

💊

Medical Actions

9

Single-Agent Methotrexate

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: methotrexate CHEBI:44185

First-line therapy for low-risk (FIGO score 0-6) gestational choriocarcinoma. Methotrexate, usually with folinic acid rescue, exploits the tumour's extreme proliferative fraction; treatment is continued to hCG normalisation plus consolidation courses. Overall survival approaches 100%, and fertility is preserved.

Mechanism Target:

INHIBITS High Proliferative Fraction and Chemosensitivity — Antifolate blockade of thymidylate and purine synthesis kills the rapidly cycling trophoblast population.

Show evidence (1 reference)

PMID:34088998 SUPPORT Human Clinical

"Gestational choriocarcinoma is highly chemosensitive and responds well to single-agent methotrexate (low-risk disease)"

Links methotrexate response directly to the chemosensitivity of the tumour.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Gestational choriocarcinoma is highly chemosensitive and responds well to single-agent methotrexate (low-risk disease)"

Establishes single-agent methotrexate as effective therapy for low-risk gestational choriocarcinoma.

PMID:34669197 SUPPORT Human Clinical

"Low-risk GTN (FIGO Stages I-III: score <7) is treated with single-agent chemotherapy but may require additional agents"

The FIGO 2021 update specifies single-agent chemotherapy for low-risk disease.

Single-Agent Dactinomycin (Actinomycin D)

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: actinomycin D CHEBI:27666

The alternative single agent for low-risk disease — used first-line in some centres and as salvage after methotrexate resistance, which is common enough at FIGO scores 5-6 that a planned second single agent is part of the low-risk algorithm.

Mechanism Target:

INHIBITS High Proliferative Fraction and Chemosensitivity — DNA intercalation and transcription blockade kill the rapidly cycling tumour population.

Show evidence (1 reference)

PMID:20739008 PARTIAL Human Clinical

"low-risk metastatic (stages II and III, score <7) GTN can be treated with single-agent chemotherapy resulting in a survival rate approaching 100%."

Establishes that single-agent chemotherapy achieves near-universal cure in low-risk disease; marked PARTIAL because the abstract says "single-agent chemotherapy" and does not name dactinomycin.

Show evidence (2 references)

PMID:20739008 PARTIAL Human Clinical

"low-risk metastatic (stages II and III, score <7) GTN can be treated with single-agent chemotherapy resulting in a survival rate approaching 100%."

Establishes single-agent chemotherapy as curative in low-risk disease; marked PARTIAL because the abstract does not name dactinomycin specifically.

PMID:34669197 PARTIAL Human Clinical

"is treated with single-agent chemotherapy but may require additional agents; although scores 5-6 are associated with more drug resistance"

Supports the need for an additional agent in the more resistance-prone low-risk band; marked PARTIAL because the source does not name dactinomycin specifically.

EMA-CO Multiagent Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632 Regimen: EMA-CO regimen Ontology label: EMA-CO Regimen NCIT:C67511

Agent: etoposide CHEBI:4911 methotrexate CHEBI:44185 actinomycin D CHEBI:27666 cyclophosphamide CHEBI:4027 vincristine CHEBI:28445

The standard first-line regimen for high-risk (FIGO score 7 or more, or stage IV) gestational choriocarcinoma: etoposide, methotrexate and dactinomycin alternating weekly with cyclophosphamide and vincristine. It is chosen for a favourable toxicity profile, high complete-response rate and high survival. In very-high-score disease gentle induction chemotherapy precedes EMA-CO to avoid catastrophic haemorrhage from rapid lysis of friable, vascular tumour.

Mechanism Target:

INHIBITS High Proliferative Fraction and Chemosensitivity — Five agents with complementary cell-cycle-dependent mechanisms are combined to suppress emergence of resistant clones.

Show evidence (1 reference)

PMID:34088998 SUPPORT Human Clinical

"EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) combination che- motherapy (high-risk disease) with an excellent prognosis"

The five-agent combination achieves an excellent prognosis in high-risk disease, evidencing the multi-mechanism attack on the proliferating tumour.

Show evidence (3 references)

PMID:34088998 SUPPORT Human Clinical

"EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) combination che- motherapy (high-risk disease) with an excellent prognosis"

Names the EMA-CO components and its role in high-risk gestational choriocarcinoma.

PMID:34669197 SUPPORT Human Clinical

"High-risk GTN (FIGO Stages II-III: score ≥7 and Stage IV) is treated with multiagent chemotherapy"

The FIGO 2021 update assigns multiagent chemotherapy to high-risk disease.

PMID:34669197 SUPPORT Human Clinical

"Gentle induction chemotherapy helps reduce early deaths in patients with extensive tumor burden"

Supports gentle induction before full-dose multiagent chemotherapy in extensive-burden disease.

Surgical Staging with Bleomycin-Based Chemotherapy (Non-Gestational Disease)

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: bleomycin CHEBI:22907 etoposide CHEBI:4911 cisplatin CHEBI:27899

Non-gestational (germ cell) choriocarcinoma is not managed on the GTN algorithm. It requires surgical staging and cytoreduction — achieving an R0 resection is a favourable prognostic factor — followed by bleomycin-based (BEP-type: bleomycin, etoposide, cisplatin) germ cell chemotherapy. Applying the methotrexate/EMA-CO pathway to a non-gestational tumour is a recognised treatment error, which is why STR genotyping precedes therapy when origin is uncertain.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"Germ cell choriocarcinoma requires surgical staging followed by bleomycin-based chemotherapy."

States the distinct germ cell treatment pathway for non-gestational choriocarcinoma.

PMID:32185550 SUPPORT Human Clinical

"Clinicians should try to achieve R0 resection to improve the prognosis for NGOC patients even among advanced patients."

A pooled analysis of 39 cases identifies complete (R0) surgical resection as a favourable prognostic factor in non-gestational ovarian choriocarcinoma.

Adjuvant Surgery (Hysterectomy or Resection of Resistant Foci)

Action: Hysterectomy NCIT:C15256

Surgery has a defined adjunctive role in gestational choriocarcinoma: excision of chemoresistant foci (uterine or pulmonary) in high-risk disease, and hysterectomy for localised drug-resistant uterine tumour or in women who have completed childbearing. It is not primary therapy for chemosensitive disease, where the goal is cure without surgery and preservation of fertility.

Show evidence (2 references)

PMID:34669197 SUPPORT Human Clinical

"with or without adjuvant surgery for excision of resistant foci of disease"

The FIGO 2021 update defines adjuvant surgery as excision of resistant disease foci in high-risk GTN.

PMID:37758451 SUPPORT Human Clinical

"Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation."

Confirms that surgery is deliberately avoided in localised chemosensitive disease so that fertility is preserved.

EMA-EP and Platinum/Taxane Salvage Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: etoposide CHEBI:4911 methotrexate CHEBI:44185 actinomycin D CHEBI:27666 cisplatin CHEBI:27899 paclitaxel CHEBI:45863

Roughly 30-40% of patients develop a rising hCG after completing EMA-CO. The first-line cytotoxic salvage is EMA-EP (etoposide, methotrexate, dactinomycin alternating with etoposide and cisplatin), which achieves a response rate near 85%. Patients progressing on EMA-EP move to platinum/taxane doublets alternating as TP/TE, and thereafter to germ-cell regimens. This cytotoxic salvage ladder sits alongside, not instead of, checkpoint blockade for the multidrug-resistant population.

Mechanism Target:

INHIBITS Multidrug-Resistant Refractory Disease — Introducing platinum and taxane mechanisms not present in EMA-CO re-establishes cytotoxic pressure on clones that survived the first-line regimen.

Show evidence (1 reference)

PMID:38008872 SUPPORT Human Clinical

"Such patients can be salvaged with EMA-EP, which shows a response rate of 84.9%"

Quantifies the salvage response rate of EMA-EP in patients whose hCG rises after EMA-CO.

Show evidence (2 references)

PMID:38008872 SUPPORT Human Clinical

"Approximately 30 – 40% of patients developed increased beta HCG levels post-completion of treatment with EMA-CO"

Establishes both the size of the post-EMA-CO relapse population and the efficacy of EMA-EP salvage.

PMID:38008872 SUPPORT Human Clinical

"Patients who develop methotrexate resistance, i.e., have also progressed on EMA-EP, can be treated with a combination of paclitaxel and cisplatin weekly alternating with paclitaxel and etoposide (TP/TE)"

Defines the next rung of the salvage ladder after EMA-EP failure.

CNS-Penetrating High-Dose Methotrexate EMA-CO for Cerebral Metastases

Action: Chemotherapy NCIT:C15632 Regimen: EMA-CO regimen Ontology label: EMA-CO Regimen NCIT:C67511

Agent: methotrexate CHEBI:44185

Contemporary first-line practice for brain metastases is CNS-penetrating systemic therapy rather than radiation by default: EMA-CO is given with a higher dose and slower infusion of methotrexate (1000 mg/m2 over 12-24 hours) to achieve adequate cerebrospinal-fluid levels, which produces complete responses and can negate the need for whole-brain radiotherapy, with reported five-year survival of 81.5%.

Mechanism Target:

INHIBITS Hematogenous Dissemination and Pulmonary Colonisation — Dose-intensified methotrexate reaches the CNS compartment that standard EMA-CO dosing does not, and so acts on colonised brain deposits rather than only on the systemic tumour burden.

Show evidence (1 reference)

PMID:38008872 SUPPORT Human Clinical

"the same regimen of EMA-CO but with a higher dose and infusion rate of methotrexate (1000mg/m2 given over 12 to 24 hours) is administered. This allows an adequate dose of methotrexate within the cerebrospinal fluid (CSF) which provides a complete response in patients negating the need for whole..."

Establishes CNS-penetrating high-dose methotrexate within EMA-CO as the contemporary approach to brain metastases, displacing routine whole-brain radiotherapy.

Adjunctive Cranial Radiotherapy for Cerebral Metastases

Action: Radiation Therapy NCIT:C15313

Radiotherapy is retained as an adjunct to multiagent chemotherapy for brain metastases in high-risk disease, both for local control and to reduce the risk of intracranial haemorrhage. It is no longer the default CNS-directed modality; that role has passed to CNS-penetrating high-dose methotrexate.

Mechanism Target:

INHIBITS Haemorrhagic Destruction of Colonised Organs — Cranial irradiation is given for local control of colonised brain deposits and specifically to reduce the risk of the intracranial haemorrhage that this node produces.

Show evidence (1 reference)

PMID:34669197 SUPPORT Human Clinical

"or radiotherapy for brain metastases"

The FIGO 2021 update retains radiotherapy for brain metastases as an adjunct to multiagent chemotherapy in high-risk GTN.

PD-1/PD-L1 Immune Checkpoint Blockade

Action: Pharmacotherapy NCIT:C15986

Agent: avelumab NCIT:C116870 pembrolizumab NCIT:C106432

Anti-PD-1 (pembrolizumab) and anti-PD-L1 (avelumab) antibodies target the checkpoint axis that the allogeneic tumour uses to escape host T cells. Response rates of 50-70% are reported, and the principal role is in chemoresistant disease: in the TROPHIMMUN phase II trial avelumab was active in GTN resistant to single-agent chemotherapy, though not after multiagent failure. Checkpoint blockade is also being explored to de-escalate or replace cytotoxic therapy in young women for whom long-term chemotherapy toxicity matters, and in combination with VEGFR-2-directed agents.

Mechanism Target:

INHIBITS PD-L1-Mediated Adaptive Immune Resistance — Blocking PD-1/PD-L1 engagement releases tumour-infiltrating T cells from inhibition and restores an immune response against the semi-allogeneic tumour.

Show evidence (1 reference)

PMID:37703867 SUPPORT Human Clinical

"Immune checkpoint immunotherapy (CPI) targeting programmed cell death 1 (PD-1)/ligand (PD-L1) has been shown to be an effective treatment for gestational trophoblastic neoplasia (GTN)."

Demonstrates that blocking the PD-1/PD-L1 axis is therapeutically effective, confirming the axis as the operative treatment target.

Show evidence (2 references)

PMID:37758451 SUPPORT Human Clinical

"the treatment response with immunotherapy is high, ranging between 50-70%."

Quantifies response to checkpoint immunotherapy in gestational choriocarcinoma.

PMID:35681761 PARTIAL Human Clinical

"In the TROPHIMMUN trial, Avelumab, a monoclonal antibody inhibiting PD-L1, showed promising results only in patients with GTN resistant to monochemotherapy."

Delimits the efficacy of avelumab to GTN resistant to single-agent rather than multiagent chemotherapy; marked PARTIAL because the same review reports failure and toxicity after multiagent resistance.

🌍

Environmental Factors

3

Antecedent Complete Hydatidiform Mole

A prior complete hydatidiform mole raises the risk of choriocarcinoma roughly 1000-fold over a background pregnancy, and about half of gestational choriocarcinomas follow a mole. This is the entire rationale for post-molar hCG surveillance programmes, and it is why widespread surveillance has made choriocarcinoma a progressively rarer diagnosis. The biology of the molar precursor lesion itself is curated in Hydatidiform_Mole.

Show evidence (2 references)

PMID:36286620 SUPPORT Human Clinical

"Choriocarcinoma affects approximately 1 in 40.000 pregnancies and 1 in 40 HMs."

The 1-in-40 risk after a hydatidiform mole versus 1-in-40,000 per pregnancy quantifies molar pregnancy as the dominant risk factor.

PMID:40588865 SUPPORT Human Clinical

"gestational choriocarcinoma has become a rare encounter, largely owing to the implementation of postmolar surveillance programs and timely initiation of chemotherapy."

Confirms that intervening on the molar precursor through surveillance has markedly reduced the incidence of clinically encountered choriocarcinoma.

Extremes of Maternal Age

Gestational trophoblastic disease incidence is bimodally raised at the extremes of reproductive age - in adolescents and in women in their forties and early fifties. Age of at least 40 years additionally contributes a point to the FIGO/WHO prognostic score once disease has developed, so maternal age is both an incidence correlate and a prognostic term. Note that this is a disease-group-level (GTD) association rather than a choriocarcinoma-specific one.

Show evidence (2 references)

PMID:37020431 PARTIAL Human Clinical

"An increased incidence of GTD was found in younger (10 –19 years of age) and older (40 – 54 years) women"

A national guideline reports the bimodal age distribution; marked PARTIAL because the statistic covers gestational trophoblastic disease as a whole rather than choriocarcinoma specifically.

PMID:38008872 PARTIAL Human Clinical

"These include an increasing maternal age of around 40, previous history of molar pregnancy, blood group A and Asian ancestry"

An independent review lists maternal age around 40 among the risk factors for GTN; PARTIAL for the same disease-group-level reason.

Population and Host Correlates (Ancestry, Blood Group A)

Reported incidence is roughly double in Asian compared with Caucasian women, Black US-American women are over-represented in national registers, and blood group A has been reported as a correlate. These are population correlates, not established exposures or causal mechanisms: how much of the variation reflects reproductive patterns, nutrition, ascertainment and access to early ultrasound and hCG testing versus host genetics is unresolved, and the statistics are GTD-wide rather than choriocarcinoma-specific. Modelling note: ancestry and blood group are host attributes rather than environmental exposures, and are recorded here only because dismech has no dedicated population-correlate slot.

Show evidence (2 references)

PMID:38008872 PARTIAL Human Clinical

"These include an increasing maternal age of around 40, previous history of molar pregnancy, blood group A and Asian ancestry"

Lists blood group A and Asian ancestry among reported GTN risk correlates; PARTIAL because these are GTD/GTN-wide associations without a choriocarcinoma-specific effect estimate or a causal mechanism.

PMID:37020431 PARTIAL Human Clinical

"and was also correlated with ethnicity. Black US-American women are over-represented in national registers,"

Confirms the ethnicity correlation and register over-representation; PARTIAL because it is a GTD-wide observation with no causal attribution.

🔬

Biochemical Markers

1

Serum Human Chorionic Gonadotropin (total hCG) (INCREASED)

Context: Markedly elevated and proportional to viable tumour burden; used for diagnosis, FIGO/WHO risk scoring, response monitoring and relapse detection.

Reference Ranges

Choriogonadotropin [Units/volume] in Serum or Plasma –5.0 IU/L (non-pregnant women)

Non-pregnant reference range (–5.0 IU/L) Elevated, FIGO pre-treatment hCG score 0 (5.0–1000.0 IU/L) FIGO pre-treatment hCG score 1 (1000.0–10000.0 IU/L) FIGO pre-treatment hCG score 2 (10000.0–100000.0 IU/L) FIGO pre-treatment hCG score 4 (100000.0– IU/L)

Non-pregnant reference range: Below the non-pregnant upper reference limit; in a treated patient, normalisation of hCG is the endpoint that defines complete biochemical remission.

Elevated, FIGO pre-treatment hCG score 0: Elevated but within the lowest FIGO pre-treatment hCG tier (below 10^3 IU/L), which contributes 0 points to the prognostic score.

FIGO pre-treatment hCG score 1: 10^3 to 10^4 IU/L; contributes 1 point to the FIGO/WHO prognostic score.

FIGO pre-treatment hCG score 2: 10^4 to 10^5 IU/L; contributes 2 points to the FIGO/WHO prognostic score.

FIGO pre-treatment hCG score 4: Above 10^5 IU/L; contributes the maximum 4 points on the hCG axis of the FIGO/WHO prognostic score and, with other adverse factors, drives the total into the high-risk (7 or more) category requiring multiagent chemotherapy.

The interpretation bands above the normal range are the pre-treatment serum hCG tiers of the modified WHO prognostic scoring system as adapted by FIGO (scores 0, 1, 2 and 4). They are prognostic strata, not analytic decision limits, and apply only to the pre-treatment measurement.

Show evidence (1 reference)

PMID:32761058 SUPPORT Human Clinical

"Despite a well-established reference limit of <5.0 IU/L for nonpregnant women"

A survey of 3568 clinical laboratories states the well-established non-pregnant upper reference limit of 5.0 IU/L, which is also the threshold most commonly used when hCG is ordered as a tumour marker.

Show evidence (2 references)

PMID:34088998 SUPPORT Human Clinical

"GTN is nowadays diagnosed primarily based on serum hCG measurement combined with imaging studies."

Establishes serum hCG as the primary diagnostic measurement in gestational trophoblastic neoplasia.

PMID:37758451 SUPPORT Human Clinical

"Pre- tr eatment serum hCG (IU/L) <103 103 to 104 104 to 105 >105"

The pre-treatment serum hCG row of the modified WHO/FIGO prognostic score table, giving the four risk tiers used for the interpretation bands above. The internal line breaks and the flattened exponents (103 for 10^3) are artefacts of PDF text extraction in the cached reference; the quoted string is an exact substring of that cache.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Choriocarcinoma:

Placental site trophoblastic tumour Not Yet Curated MONDO:0020552

Overlapping Features A gestational trophoblastic neoplasm of intermediate (implantation-site) trophoblast rather than of the biphasic cytotrophoblast/syncytiotrophoblast population that defines choriocarcinoma. It is the single most important GTN differential because it is relatively chemoresistant, so the distinction changes management from chemotherapy to hysterectomy.

Distinguishing Features

Composed of mononuclear implantation-site intermediate trophoblast, without the biphasic/triphasic pattern and without the syncytiotrophoblastic component of choriocarcinoma.
Serum hCG is characteristically low relative to tumour burden, in contrast to the extreme hCG elevation of choriocarcinoma.
Relatively chemoresistant, so primary hysterectomy rather than methotrexate-based chemotherapy is the treatment of choice.

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"They consist of invasive mole, choriocarci- noma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT)."

Establishes PSTT as a separate malignant GTN entity from choriocarcinoma within the same disease family, which is what makes it the differential.

Epithelioid trophoblastic tumour Not Yet Curated MONDO:0016787

Overlapping Features A rare GTN of chorionic-type intermediate trophoblast that forms nodular, relatively circumscribed epithelioid nests and can mimic squamous carcinoma of the cervix. Like PSTT, it is relatively chemoresistant, so the boundary with choriocarcinoma is therapeutically consequential.

Distinguishing Features

Chorionic-type intermediate trophoblast in nodular epithelioid nests rather than the biphasic trophoblastic proliferation of choriocarcinoma.
Lower serum hCG than choriocarcinoma and relative chemoresistance, favouring surgical management.

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"They consist of invasive mole, choriocarci- noma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT)."

Establishes ETT as a malignant GTN entity distinct from choriocarcinoma.

Invasive hydatidiform mole Not Yet Curated MONDO:0020549

Overlapping Features Molar tissue invading the myometrium. It is the commonest cause of a rising or plateaued post-molar hCG and is therefore the entity most often treated as "post-molar GTN" without histological confirmation - which is precisely why the boundary with choriocarcinoma matters: both are diagnosed on the same hCG criteria and treated on the same FIGO/WHO risk score, but only choriocarcinoma lacks chorionic villi.

Distinguishing Features

Chorionic villi are retained, whereas the defining histological feature of choriocarcinoma is trophoblastic proliferation WITHOUT chorionic villi.
Generally a lower FIGO/WHO risk score and a better prognosis than choriocarcinoma.

Show evidence (1 reference)

PMID:36286620 SUPPORT Human Clinical

"They consist of invasive mole, choriocarci- noma, placental-site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT)."

Establishes invasive mole as a separate GTN entity from choriocarcinoma.

Complete hydatidiform mole Not Yet Curated MONDO:0016785

Overlapping Features The commonest antecedent gestation of gestational choriocarcinoma and its main premalignant differential. A complete mole is androgenetic and shares the exclusively-paternal genome that this entry models as the trigger node, but it is a premalignant villous lesion rather than an invasive neoplasm.

Distinguishing Features

Hydropic chorionic villi with circumferential trophoblastic hyperplasia are present; choriocarcinoma has no villi.
Premalignant rather than malignant: most complete moles resolve after evacuation, and only a minority progress to post-molar GTN.

Show evidence (1 reference)

PMID:34088998 PARTIAL Human Clinical

"Genotyping is now considered the gold standard in the con ﬁrmation and subtyping of sporadic hydatidiform moles."

Supports genotyping as the confirmatory tool that separates mole subtypes. Marked PARTIAL because the snippet addresses mole subtyping rather than the mole-versus-choriocarcinoma boundary directly.

Non-gestational choriocarcinoma Not Yet Curated MONDO:0004322

Overlapping Features Choriocarcinoma arising from a germ cell tumour (or, rarely, as somatic dedifferentiation) rather than from a gestation. It is histologically indistinguishable from gestational choriocarcinoma, so the distinction rests entirely on DNA genotyping for paternal alleles. This is the most consequential differential in the entry: non-gestational disease lacks the semi-allogeneic paternal genome that the trigger node models, does not carry the same exquisite methotrexate sensitivity, and is treated on germ-cell (BEP-type) rather than GTN protocols with a worse prognosis. It is curated here both as a has_subtypes entry and as a differential for that reason.

Distinguishing Features

Absence of paternal-specific alleles on short tandem repeat DNA genotyping; the tumour genome matches the patient.
Arises in the ovary or other germ-cell sites rather than following an identifiable index gestation.
Treated with platinum/bleomycin-based germ-cell chemotherapy and surgical staging rather than the methotrexate-based GTN protocols.

Show evidence (1 reference)

PMID:34088998 SUPPORT Human Clinical

"DNA genotyping provides a decisive tool in the separation of gestational trophoblastic neoplasia from non-gestational counterparts/mimics of either germ cell or somatic origin."

States that DNA genotyping is the decisive test separating gestational from non-gestational choriocarcinoma, which is the discriminator this differential turns on.

🔬

Clinical Trials

2

NCT03135769 PHASE_II COMPLETED

TROPHIMMUN — a phase II trial of the anti-PD-L1 antibody avelumab in chemoresistant gestational trophoblastic neoplasia, built on the rationale that GTN hijacks placental PD-L1-mediated immune tolerance to escape rejection.

Target Phenotypes: Neoplasm HP:0002664

Show evidence (1 reference)

clinicaltrials:NCT03135769 SUPPORT Human Clinical

"Strong and constant overexpression of PDL1 and NK cells has been found in all subtypes and settings of GTN tumors from French reference gestational trophoblastic center."

The trial's own rationale documents strong, constant PD-L1 overexpression across GTN subtypes, the mechanistic basis for checkpoint blockade in choriocarcinoma.

NCT05139095 PHASE_II RECRUITING

An open-label phase II cohort trial of the anti-PD-1 antibody camrelizumab combined with the VEGFR-2 inhibitor apatinib plus chemotherapy in ultra high-risk and in chemo-refractory or relapsed high-risk gestational trophoblastic neoplasia — the checkpoint-plus-antiangiogenic combination strategy for the multidrug-resistant population.

Target Phenotypes: Neoplasm HP:0002664

Show evidence (1 reference)

clinicaltrials:NCT05139095 SUPPORT Human Clinical

"evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational trophoblastic neoplasia (GTN)"

Documents an active trial of combined PD-1 blockade and VEGFR-2 inhibition targeting the multidrug-resistant population identified in the pathophysiology as the residual unmet need.

{ }

Source YAML

click to show

name: Choriocarcinoma
creation_date: "2026-07-31T00:00:00Z"
description: >-
  Choriocarcinoma is an aggressive malignant epithelial neoplasm of trophoblast,
  composed of a bi- or triphasic proliferation of mononuclear trophoblast
  (cytotrophoblast and intermediate trophoblast) and multinucleated
  syncytiotrophoblast, characteristically without chorionic villi. Neoplastic
  syncytiotrophoblast secretes large amounts of human chorionic gonadotropin
  (hCG), which serves as a highly sensitive diagnostic, risk-scoring and
  response-monitoring biomarker. The tumour retains and deregulates the
  physiologically invasive and angiogenic program of normal trophoblast, forming
  bulky, friable, haemorrhagic masses that permeate vessels early and disseminate
  hematogenously — most often to the lungs, and also to vagina, liver, brain,
  spleen, kidney and bowel.

  Two mechanistically distinct forms exist. Gestational choriocarcinoma arises
  from placental trophoblast of a prior gestation and therefore carries a genome
  that is wholly or partly paternal and foreign to the host — a natural
  allograft — most often following a complete hydatidiform mole, but also after
  term pregnancy, abortion or ectopic gestation. It is exquisitely chemosensitive
  and among the most curable of solid malignancies. Non-gestational
  choriocarcinoma is a germ-cell tumour that arises from the patient's own
  genome, typically in the ovary or testis of children and young adults, often as
  a component of a mixed germ cell tumour; it is treated as a germ cell malignancy
  (surgical staging plus bleomycin-based chemotherapy). It is generally regarded
  as having a worse prognosis, although no head-to-head comparative study is
  cited here for that claim. Because the two are histologically indistinguishable, DNA (STR)
  genotyping for a distinct paternal allele complement is the definitive
  discriminator, and it changes therapy.

  Scope note: this entry covers choriocarcinoma proper (both gestational and
  non-gestational). The broader gestational trophoblastic disease spectrum —
  invasive mole, placental-site trophoblastic tumour and epithelioid trophoblastic
  tumour — is curated in Gestational_Trophoblastic_Neoplasm, and the molar
  precursor lesions in Hydatidiform_Mole; those entries are cross-referenced
  rather than duplicated here.
categories:
- Trophoblastic Neoplasm
- Germ Cell Tumor
- Pregnancy-Associated Cancer
disease_term:
  preferred_term: Choriocarcinoma
  term:
    id: MONDO:0005207
    label: choriocarcinoma
parents:
- trophoblastic neoplasm
- germ cell tumor
mappings:
  ncit_mappings:
  - term:
      id: NCIT:C2948
      label: Choriocarcinoma
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0005207
    mapping_justification: >-
      MONDO:0005207 lists NCIT:C2948 as an exact cross-reference and derives its
      textual definition from that NCI Thesaurus concept.
  icd10cm_mappings:
  - term:
      id: ICD10CM:C58
      label: Malignant neoplasm of placenta
    mapping_predicate: skos:closeMatch
    mapping_justification: >-
      ICD-10-CM C58 (malignant neoplasm of placenta) is the code used for
      gestational choriocarcinoma; it is a close rather than exact match because
      non-gestational (germ cell) choriocarcinoma is coded to its gonadal primary
      site instead.
has_subtypes:
- name: Gestational
  display_name: Gestational Choriocarcinoma
  subtype_term:
    preferred_term: Gestational Choriocarcinoma
    term:
      id: NCIT:C4646
      label: Gestational Choriocarcinoma
  description: >-
    The common form, arising from the trophoblast of an antecedent gestation.
    Roughly half of cases follow a complete hydatidiform mole, a quarter follow a
    term pregnancy, and a quarter follow abortion, ectopic or other gestational
    events. Because the tumour genome derives wholly or partly from the paternal
    contribution to that gestation, it is genetically foreign to the patient — a
    partial or complete allograft — which underlies both its intrinsic
    immunogenicity and the STR-genotyping test that identifies it. Gestational
    choriocarcinoma is highly chemosensitive: low-risk disease is cured by
    single-agent methotrexate or dactinomycin, high-risk disease by EMA-CO.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur \nafter molar pregnancies, term pregnancies, and other gestational events, \nrespectively."
    explanation: >-
      An IGCS/ESGO Rare Tumor Working Group review quantifies the distribution of
      antecedent gestational events, defining the gestational subtype.
  - reference: PMID:22469506
    reference_title: "The genetics of gestational trophoblastic disease: a rare complication of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is a unique malignancy that is a \npartial or complete allograft with a genotype that is not the same as the host \ngenotype."
    explanation: >-
      Establishes the defining genetic feature of gestational choriocarcinoma —
      a tumour genome distinct from (and partly paternal relative to) the host.
- name: Non-Gestational
  display_name: Non-Gestational (Germ Cell) Choriocarcinoma
  subtype_term:
    preferred_term: Non-gestational (germ cell) choriocarcinoma
    term:
      id: NCIT:C2948
      label: Choriocarcinoma
  description: >-
    A malignant germ cell tumour showing choriocarcinomatous (trophoblastic)
    differentiation but arising from the patient's own genome rather than from a
    gestation. In females it typically occurs in children or young adults, involves
    the ovary, and may be one component of a mixed germ cell tumour; it also occurs
    in the testis and at extragonadal midline sites. Management follows germ cell
    tumour principles — surgical staging and cytoreduction followed by
    bleomycin-based (BEP-type) chemotherapy — rather than the methotrexate/EMA-CO
    algorithm used for gestational disease. It is generally reported as having a
    worse outcome, but the evidence cited here supports the different treatment
    pathway rather than a quantified survival comparison.
    Note on term choice: NCIT:C39991 (Non-Gestational Ovarian Choriocarcinoma) is
    site-restricted, so the generic NCIT:C2948 concept is bound here with a more
    specific preferred_term.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-gestational choriocarcinoma of germ cell origin in\nfemale patients usually occurs in children or in young\nadults, involves the ovary, and may contain other non-\nchoriocarcinomatous components as part of a mixed germ\ncell tumor"
    explanation: >-
      Defines the demographic, anatomic and histologic profile of the
      non-gestational germ cell subtype.
  - reference: PMID:32185550
    reference_title: "Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-gestational ovarian choriocarcinoma (NGOC) is a rare malignant germ \ncell tumor."
    explanation: >-
      A pooled analysis of 39 published cases classifies non-gestational ovarian
      choriocarcinoma as a malignant germ cell tumour, distinct from gestational
      disease.
- name: Intraplacental
  display_name: Intraplacental (Early) Gestational Choriocarcinoma
  subtype_term:
    preferred_term: Gestational Choriocarcinoma
    term:
      id: NCIT:C4646
      label: Gestational Choriocarcinoma
  description: >-
    An exceptionally rare early form in which choriocarcinoma is recognised within
    a term placenta or within the villous tissue of a complete hydatidiform mole,
    before or at the time the antecedent gestation is delivered or evacuated.
    Recognising it matters because it may already have metastasised (classically to
    maternal lung) at a point when the diagnosis would otherwise not be suspected.
  evidence:
  - reference: PMID:41243514
    reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recently, extremely rare cases of GCC diagnosed in molar and in placenta \nspecimens have been described and accepted as early forms of GCC."
    explanation: >-
      Documents intraplacental/intramolar choriocarcinoma as an accepted early
      form of gestational choriocarcinoma.
prevalence:
- population: Pregnancies (Europe/North America)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.5
  notes: >-
    Reported as approximately 1 in 40,000 pregnancies. Expressed here per 100,000
    gestations rather than per 100,000 population; the denominator is pregnancies,
    which is the conventional denominator for gestational trophoblastic disease.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choriocarcinoma affects approximately 1 in 40.000 \npregnancies and 1 in 40 HMs."
    explanation: >-
      A review of gestational trophoblastic disease gives the per-pregnancy
      occurrence of choriocarcinoma.
- population: Pregnancies following a hydatidiform mole
  measure_type: BIRTH_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 2500.0
  notes: >-
    Approximately 1 in 40 hydatidiform moles progresses to choriocarcinoma — a
    roughly 1000-fold enrichment over the background per-pregnancy rate, and the
    rationale for post-molar hCG surveillance programmes.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choriocarcinoma affects approximately 1 in 40.000 \npregnancies and 1 in 40 HMs."
    explanation: >-
      Quantifies the markedly higher occurrence of choriocarcinoma after a
      hydatidiform mole than after other gestations.
histopathology:
- name: Biphasic/Triphasic Trophoblastic Proliferation without Chorionic Villi
  finding_term:
    preferred_term: Biphasic trophoblastic proliferation without chorionic villi
    term:
      id: NCIT:C35867
      label: Morphologic Finding
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    The defining microscopic pattern: intimately admixed mononuclear trophoblast
    (cytotrophoblast and intermediate trophoblast) and multinucleated
    syncytiotrophoblast, recapitulating the architecture of primitive villous
    trophoblast but without forming chorionic villi. Absence of villi is the
    feature that separates choriocarcinoma from invasive mole. Term note: NCIT
    has no concept for this composite trophoblastic architecture, so the branch
    root NCIT:C35867 Morphologic Finding is bound as the closest available term
    with a more specific `preferred_term`.
  evidence:
  - reference: PMID:41243514
    reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "its main diagnostic features are a trimorphic population of \ntrophoblast cells and an absence of chorionic villi."
    explanation: >-
      States the two cardinal diagnostic histologic features of gestational
      choriocarcinoma.
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the tumor consists of bi- or triphasic\narrangements of mononuclear trophoblastic cells and\nmultinucleated syncytiotrophoblast."
    explanation: >-
      Confirms the bi-/triphasic trophoblastic architecture is present regardless
      of gestational or germ cell pathogenetic origin.
- name: Extensive Haemorrhage and Necrosis in a Bulky Destructive Mass
  finding_term:
    preferred_term: Confluent tumour necrosis with haemorrhage
    term:
      id: NCIT:C41612
      label: Extensive Necrosis
  description: >-
    Choriocarcinoma grows as a bulky, friable, destructive mass with confluent
    haemorrhage and necrosis, so that viable tumour is often only a thin rim at the
    periphery. This reflects rapid growth outstripping a vasculature the tumour
    itself erodes, and explains the clinical tendency to catastrophic bleeding at
    metastatic sites. No `frequency` band is asserted: the source says the tumour
    "typically forms" such masses, which does not license a quantitative band.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choriocarcinoma typically forms bulky, destructive mass\nlesions with extensive hemorrhage and necrosis within the\ninvolved organ."
    explanation: >-
      Directly describes the gross and microscopic pattern of haemorrhagic,
      necrotic, destructive tumour masses.
- name: Marked Nuclear Atypia with Brisk and Atypical Mitotic Activity
  finding_term:
    preferred_term: Marked nuclear atypia with brisk mitotic activity
    term:
      id: NCIT:C51139
      label: Marked Nuclear Atypia Present
  description: >-
    Nuclei are markedly atypical, often bizarre, with a high mitotic rate including
    atypical mitotic figures and a very high Ki-67 proliferation index. This
    extreme proliferative fraction is the cytological correlate of the tumour's
    aggressiveness and, reciprocally, of its exceptional sensitivity to
    antimetabolite and antimitotic chemotherapy. No `frequency` band is asserted:
    the sources describe brisk mitotic activity qualitatively and report Ki-67
    above 90% in a single documented case, neither of which supports a
    quantitative band.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The nuclear atypia is\nmarked, often with bizarre nuclei and there is brisk mitotic\nactivity"
    explanation: >-
      Describes the cytological grade of choriocarcinoma.
  - reference: PMID:41243514
    reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "marked \ncytological atypia and high mitotic activity with Ki-67 \nimmunostaining\u00a0 >\u00a0 90%"
    explanation: >-
      A histologically documented case shows a Ki-67 proliferation index above
      90% alongside the marked atypia.
- name: SALL4 Expression in Both Gestational and Germ Cell Choriocarcinoma
  finding_term:
    preferred_term: SALL4 immunoreactivity
    term:
      id: NCIT:C40998
      label: Immunophenotypic Finding
  diagnostic: false
  description: >-
    Trophoblastic immunohistochemical markers confirm trophoblastic
    differentiation but do not distinguish gestational from non-gestational
    choriocarcinoma; SALL4, a germ cell marker, is expressed in choriocarcinoma of
    both origins. This immunohistochemical blind spot is precisely why DNA
    genotyping is required to separate the two.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SALL4 is expressed in\nchoriocarcinoma of both germ cell and gestational origin"
    explanation: >-
      Documents that SALL4 immunostaining cannot discriminate germ cell from
      gestational choriocarcinoma, motivating molecular genotyping.
pathophysiology:
- name: Paternal Genome Content and Semi-Allogeneic Tumour Identity
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    Gestational choriocarcinoma derives from the trophoblast of a prior conceptus,
    so its genome contains a paternal allele complement that is absent from the
    patient's own tissues. In the most common precursor, the complete hydatidiform
    mole, the conceptus genome is entirely androgenetic. The tumour is therefore a
    partial or complete natural allograft. Two consequences follow and organise the
    rest of the pathograph: detection of that foreign paternal allele set by STR
    genotyping definitively separates gestational from non-gestational
    choriocarcinoma, which matters because the two are treated differently; and the
    allogeneic tumour is intrinsically immunogenic and must actively suppress host
    T cells to survive. Non-gestational (germ cell) choriocarcinoma, by contrast,
    carries only the patient's own genome and lacks this feature. The imprinting
    biology of the molar precursor itself (CDKN1C/p57 loss) is curated in
    Hydatidiform_Mole and Gestational_Trophoblastic_Neoplasm.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  notes: >-
    No `biological_processes` term is asserted on this node. The obvious
    candidate, GO:0071514 genomic imprinting, would over-claim: the evidence
    here concerns paternal genome *content* (an allele complement foreign to the
    host), not the imprinting *process*, and the imprinting mechanics of the
    molar precursor are deliberately curated in Hydatidiform_Mole and
    Gestational_Trophoblastic_Neoplasm rather than restated here.
  evidence:
  - reference: PMID:22469506
    reference_title: "The genetics of gestational trophoblastic disease: a rare complication of pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is a unique malignancy that is a \npartial or complete allograft with a genotype that is not the same as the host \ngenotype."
    explanation: >-
      Establishes the allogeneic (partly paternal) genome of gestational
      choriocarcinoma as its defining molecular feature.
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotyping detection of a\ndistinct paternal genetic complement not present in the\npatient’s normal tissues"
    explanation: >-
      Confirms that a paternal allele complement absent from host tissue is the
      operational marker of gestational origin.
  downstream:
  - target: Neoplastic Trophoblastic Transformation without Villous Formation
    description: >-
      Malignant transformation of the (often androgenetic) trophoblast of the
      antecedent gestation gives rise to the tumour cell population.
    evidence:
    - reference: PMID:22469506
      reference_title: "The genetics of gestational trophoblastic disease: a rare complication of pregnancy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is most often preceded by an abnormal molar pregnancy."
      explanation: >-
        Links the antecedent (usually molar) gestation to the emergence of the
        choriocarcinoma cell population.
  - target: PD-L1-Mediated Adaptive Immune Resistance
    description: >-
      Allogeneic tumour identity makes the neoplasm immunogenic, creating the
      selective pressure for checkpoint-ligand-mediated immune evasion.
    evidence:
    - reference: PMID:22469506
      reference_title: "The genetics of gestational trophoblastic disease: a rare complication of pregnancy."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "It is a unique malignancy that is a \npartial or complete allograft with a genotype that is not the same as the host \ngenotype."
      explanation: >-
        The allograft identity of the tumour is what makes it a target for host
        immunity. The step from that to a selection pressure for PD-L1-mediated
        escape is an inference, not a statement in the source, hence PARTIAL.
- name: Neoplastic Trophoblastic Transformation without Villous Formation
  biological_scale: CELLULAR
  role: central_effector
  description: >-
    The transformed cell population reconstitutes the two differentiation states of
    early implanting trophoblast — a proliferative mononuclear cytotrophoblast
    compartment and a fused, hormonally active syncytiotrophoblast compartment —
    but does so as a solid, sheet-like proliferation that never organises chorionic
    villi. Loss of the villous scaffold is not a cosmetic difference: villous
    architecture normally constrains trophoblast to a defined invasive front, and
    its absence accompanies unconstrained, vessel-permeating growth. The
    proliferative fraction is extreme (Ki-67 often above 90%), with marked nuclear
    atypia and atypical mitoses.
  cell_types:
  - preferred_term: mononuclear cytotrophoblast cell
    term:
      id: CL:0000523
      label: mononuclear cytotrophoblast cell
  - preferred_term: syncytiotrophoblast cell
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the tumor consists of bi- or triphasic\narrangements of mononuclear trophoblastic cells and\nmultinucleated syncytiotrophoblast."
    explanation: >-
      Establishes the two-compartment neoplastic trophoblast population that
      defines the tumour.
  - reference: PMID:41243514
    reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "its main diagnostic features are a trimorphic population of \ntrophoblast cells and an absence of chorionic villi."
    explanation: >-
      Confirms the absence of chorionic villi as an intrinsic feature of the
      transformed trophoblast population.
  downstream:
  - target: hCG Hypersecretion by Neoplastic Syncytiotrophoblast
    description: >-
      The syncytiotrophoblast compartment retains and amplifies its endocrine
      program.
    evidence:
    - reference: PMID:34088998
      reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "the tumor consists of bi- or triphasic\narrangements of mononuclear trophoblastic cells and\nmultinucleated syncytiotrophoblast."
      explanation: >-
        The snippet establishes that a multinucleated syncytiotrophoblast
        compartment is present in the tumour, but says nothing about hormone
        output; the step to hCG secretion is inferred from normal
        syncytiotrophoblast biology, hence PARTIAL.
  - target: Deregulated Trophoblast Invasion and Vascular Permeation
    description: >-
      The mononuclear/intermediate trophoblast compartment retains its invasive
      program, now unconstrained by villous architecture.
    evidence:
    - reference: PMID:40588865
      reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is characterized by aggressive, destructive growth \nand a marked tendency for hematogenous spread"
      explanation: >-
        Couples the transformed trophoblast population directly to destructive,
        vessel-permeating growth.
  - target: VEGF-Driven Neoangiogenesis
    description: >-
      The transformed trophoblast population drives the VEGF-dependent
      neovascularisation that supplies the rapidly expanding mass.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: High Proliferative Fraction and Chemosensitivity
    description: >-
      The extreme proliferative index that drives aggressiveness simultaneously
      creates the therapeutic vulnerability.
    evidence:
    - reference: PMID:41243514
      reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "high mitotic activity with Ki-67 \nimmunostaining\u00a0 >\u00a0 90%"
      explanation: >-
        Documents the near-maximal proliferative fraction of the transformed
        trophoblast population.
- name: hCG Hypersecretion by Neoplastic Syncytiotrophoblast
  biological_scale: MOLECULAR
  role: effector
  description: >-
    Neoplastic syncytiotrophoblast retains the endocrine function of normal
    placental syncytiotrophoblast and secretes human chorionic gonadotropin in
    quantities proportional to viable tumour burden. Because hCG is essentially
    absent in the non-pregnant state, this converts an internal, often
    radiographically occult tumour into a continuously measurable quantity: hCG
    establishes the diagnosis (a plateauing or rising titre after evacuation),
    contributes a weighted term to the FIGO/WHO prognostic score, tracks response
    during chemotherapy, and detects relapse. It is the reason gestational
    trophoblastic neoplasia can be treated to a biochemical endpoint without tissue
    confirmation.
  cell_types:
  - preferred_term: syncytiotrophoblast cell
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: gonadotropin secretion
    modifier: INCREASED
    term:
      id: GO:0032274
      label: gonadotropin secretion
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GTN is nowadays diagnosed primarily based on\nserum hCG measurement combined with imaging studies."
    explanation: >-
      Shows that tumour-derived hCG is sufficient in practice to diagnose and
      manage gestational trophoblastic neoplasia without tissue.
  - reference: PMID:20673583
    reference_title: "Gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the use of human chorionic gonadotropin as a biomarker"
    explanation: >-
      An authoritative Lancet review identifies tumour-secreted hCG as the
      central biomarker of trophoblastic neoplasia.
  downstream:
  - target: Paraneoplastic Consequences of Extreme hCG Elevation
    description: >-
      At very high circulating concentrations hCG cross-activates receptors for
      structurally related glycoprotein hormones and overstimulates the ovary.
    evidence:
    - reference: PMID:38008872
      reference_title: "Review of current literature on gestational trophoblastic neoplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Raised levels of human chorionic gonadotrophin (hCG) (>100,000 m IU/ml) may cause symptoms of hyperthyroidism, hyperemesis, pre-eclampsia and rarely virilization by ovarian theca lutein cyst formation"
      explanation: >-
        Establishes the dose-dependent causal link between very high hCG and the
        paraneoplastic endocrine syndromes.
- name: Paraneoplastic Consequences of Extreme hCG Elevation
  biological_scale: ORGANISM
  role: consequence
  description: >-
    hCG shares an alpha subunit with TSH, LH and FSH and is a weak agonist at the
    thyrotropin receptor; when tumour-derived concentrations exceed roughly
    100,000 mIU/mL, that weak cross-reactivity becomes clinically significant and
    produces biochemical or overt hyperthyroidism. The same extreme
    gonadotropin-like signal overstimulates the ovaries, producing bilateral
    theca-lutein cysts (occasionally with virilisation), and is associated with
    hyperemesis and pre-eclampsia. These paraneoplastic features are a direct
    dose-dependent consequence of the biomarker itself rather than of tumour mass,
    and they resolve as hCG falls with treatment.
  cell_types:
  - preferred_term: syncytiotrophoblast cell
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: gonadotropin secretion
    modifier: INCREASED
    term:
      id: GO:0032274
      label: gonadotropin secretion
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Raised levels of human chorionic gonadotrophin (hCG) (>100,000 m IU/ml) may cause symptoms of hyperthyroidism, hyperemesis, pre-eclampsia and rarely virilization by ovarian theca lutein cyst formation"
    explanation: >-
      Directly links hCG concentrations above 100,000 mIU/mL to hyperthyroidism,
      hyperemesis, pre-eclampsia and theca-lutein cyst formation, establishing
      these as dose-dependent paraneoplastic consequences of the hormone.
- name: Deregulated Trophoblast Invasion and Vascular Permeation
  biological_scale: CELLULAR
  role: effector
  conforms_to: "invasion_and_metastasis#Local Invasion and Intravasation"
  description: >-
    Normal extravillous trophoblast is physiologically one of the most invasive
    cell types in human biology: it penetrates decidua and myometrium and remodels
    spiral arteries, and it does so as a tightly regulated, self-limiting program.
    Choriocarcinoma is that program run without its brakes. Tumour trophoblast
    permeates myometrium and directly invades vascular channels, so intravasation
    is an early rather than a late event — this is the mechanistic reason
    choriocarcinoma metastasises hematogenously at small primary volumes and may
    present with a metastasis before any uterine lesion is apparent. Conformance
    note: the module's canonical upstream driver is EMT activation in a somatic
    epithelium; here the invasive phenotype is a retained developmental program of
    trophoblast rather than a de-differentiation event, so this node conforms at
    the invasion/intravasation step without asserting the module's EMT trigger node.
  cell_types:
  - preferred_term: extravillous trophoblast
    term:
      id: CL:0008036
      label: extravillous trophoblast
  biological_processes:
  - preferred_term: trophoblast cell migration
    modifier: INCREASED
    term:
      id: GO:0061450
      label: trophoblast cell migration
  locations:
  - preferred_term: uterus
    term:
      id: UBERON:0000995
      label: uterus
  evidence:
  - reference: PMID:40588865
    reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterized by aggressive, destructive growth \nand a marked tendency for hematogenous spread, leading to high mortality if left \nuntreated."
    explanation: >-
      A diagnostic-pathology review couples destructive local growth with a
      marked hematogenous (i.e., vessel-permeating) spread pattern.
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Metastatic lesions often produce abnormal \nbleeding because trophoblastic tumours have frag-\nile vessels."
    explanation: >-
      Attributes the bleeding diathesis of choriocarcinoma deposits to the
      fragile, tumour-permeated vasculature they form.
  downstream:
  - target: Hematogenous Dissemination and Pulmonary Colonisation
    description: >-
      Early intravasation seeds tumour emboli into the venous circulation, whose
      first capillary bed is the lung.
    evidence:
    - reference: PMID:36286620
      reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "The most common \nmetastatic sites are the lungs"
      explanation: >-
        The snippet establishes lung predominance; attributing it to venous
        intravasation draining first to the pulmonary capillary bed is an
        anatomical inference not stated in the source, hence PARTIAL.
- name: VEGF-Driven Neoangiogenesis
  biological_scale: CELLULAR
  role: effector
  conforms_to: "tumor_angiogenesis#Angiogenic Switch and VEGF-Driven Neovascularization"
  description: >-
    Neoplastic trophoblast drives VEGF-dependent neovascularisation, building the
    fragile, disorganised tumour vasculature that both sustains the rapidly
    expanding mass and creates the bleeding diathesis characteristic of
    choriocarcinoma deposits. This is the mechanistic anchor for the
    antiangiogenic arm of therapy: the VEGFR-2 inhibitor apatinib is combined
    with PD-1 blockade in multidrug-resistant disease, so the pathograph needs a
    node for that drug to target.
  notes: >-
    Evidence tier. The direct mechanistic demonstration that VEGF secretion
    drives angiogenic capacity in choriocarcinoma is IN_VITRO (choriocarcinoma
    cell lines), and no cited source quantifies VEGF expression or microvessel
    density in primary human gestational choriocarcinoma tissue. The clinical
    evidence is therapeutic-response evidence for VEGFR-2 inhibition rather than
    direct evidence of the mechanism, and is marked PARTIAL accordingly. This
    node is deliberately modelled at that honest strength rather than asserted
    as a settled human-tissue finding; a microvessel-density or VEGF-IHC series
    in gestational choriocarcinoma would upgrade it.
  cell_types:
  - preferred_term: syncytiotrophoblast cell
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: vascular endothelial growth factor signaling pathway
    term:
      id: GO:0038084
      label: vascular endothelial growth factor signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:40760271
    reference_title: "Phospholipase Cε1 activates Rap1 signaling pathway to promote proliferation, EMT and angiogenesis of choriocarcinoma cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      driving choriocarcinoma cell proliferation, EMT, and angiogenesis through
      activation of the Rap1/VEGF axis
    explanation: >-
      Direct mechanistic evidence that a VEGF axis drives angiogenic capacity in
      choriocarcinoma cells. Evidence source is IN_VITRO: the work is in
      choriocarcinoma cell lines, not primary human tumour tissue.
  - reference: PMID:41627371
    reference_title: "Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the combination of camrelizumab plus apatinib (that potently suppresses
      the kinase activity of vascular endothelial growth factor 2), have
      demonstrated complete and durable responses in approximately 70-80% of
      patients with multidrug-resistant GTN
    explanation: >-
      Clinical activity of VEGFR-2 inhibition in multidrug-resistant GTN.
      Marked PARTIAL because response to an antiangiogenic agent is indirect
      evidence for the angiogenic mechanism, and the combination confounds the
      antiangiogenic contribution with checkpoint blockade.
  downstream:
  - target: Hematogenous Dissemination and Pulmonary Colonisation
    description: >-
      Tumour neovasculature provides the intravasation route for hematogenous
      spread.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Haemorrhagic Destruction of Colonised Organs
    description: >-
      The fragile, disorganised neovasculature is what ruptures, producing the
      haemorrhagic destruction characteristic of choriocarcinoma deposits.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36286620
      reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Metastatic lesions often produce abnormal \nbleeding because trophoblastic tumours have frag-\nile vessels."
      explanation: >-
        Attributes the bleeding to fragile tumour vessels. Marked PARTIAL
        because the source does not state that those vessels are VEGF-driven
        neovasculature.
- name: Hematogenous Dissemination and Pulmonary Colonisation
  biological_scale: ORGANISM
  role: consequence
  conforms_to: "invasion_and_metastasis#Metastatic Colonization"
  description: >-
    Tumour emboli entering uterine veins arrive first at the pulmonary capillary
    bed, which is why the lung is by far the commonest metastatic site and why
    multiple rounded pulmonary nodules are a classic radiographic presentation.
    Onward arterial spread reaches vagina, liver, brain, spleen, kidney and bowel.
    Metastatic site is a weighted term in the FIGO/WHO prognostic score precisely
    because it stratifies risk: lung scores 0, spleen/kidney 1, gastrointestinal 2,
    and liver or brain 4. Colonisation can occur at very small primary tumour
    volume, so metastatic disease is a common first presentation.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common \nmetastatic sites are the lungs, but metastatic lesions \ncan also be found in vagina, liver, brain, spleen, \nkidneys, and bowel."
    explanation: >-
      Enumerates the metastatic site distribution, with lung predominance
      consistent with venous drainage to the pulmonary bed.
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the ﬁrst presentation may be extrauterine\nhemorrhage as a result of metastasis"
    explanation: >-
      Confirms that metastatic (rather than uterine) disease is frequently the
      presenting event.
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "About 11% of GTN patients have brain metastasis on presentation"
    explanation: >-
      Quantifies cerebral colonisation already present at diagnosis, showing that
      hematogenous dissemination frequently precedes clinical recognition;
      marked PARTIAL because the figure covers gestational trophoblastic
      neoplasia as a whole.
  downstream:
  - target: Haemorrhagic Destruction of Colonised Organs
    description: >-
      Metastatic deposits recapitulate the friable, vessel-eroding phenotype of
      the primary.
    evidence:
    - reference: PMID:38008872
      reference_title: "Review of current literature on gestational trophoblastic neoplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This is because of the fragile blood vessels in abnormally proliferating trophoblastic cells"
      explanation: >-
        Attributes bleeding at metastatic sites to the fragile vasculature formed by
        the proliferating trophoblast, i.e. the primary phenotype reproduced at
        colonised sites.
- name: Haemorrhagic Destruction of Colonised Organs
  biological_scale: TISSUE
  role: outcome
  description: >-
    Every choriocarcinoma deposit reproduces the vascular-erosive phenotype of the
    primary, so metastases behave less like space-occupying nodules and more like
    bleeding lesions. Pulmonary deposits cause haemoptysis and dyspnoea; vaginal
    deposits bleed and should not be biopsied; hepatic deposits bleed
    intra-abdominally; cerebral deposits may be silent or may cause fatal
    intracranial haemorrhage. This is also why induction chemotherapy is
    deliberately gentle in very-high-score disease — rapid lysis of a friable,
    highly vascular tumour risks catastrophic pulmonary, intraperitoneal or
    intracranial bleeding.
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms from \nbrain metastases can also be very severe, even fa-\ntal if they cause intracranial haemorrhage."
    explanation: >-
      Documents fatal intracranial haemorrhage as the mechanism of death from
      cerebral deposits.
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "at significant risk \nfor pulmonary, intraperitoneal, or intracranial hemorrhage"
    explanation: >-
      Explains that widely metastatic, very-high-score disease carries a
      haemorrhagic risk that dictates gentle induction chemotherapy.
- name: PD-L1-Mediated Adaptive Immune Resistance
  biological_scale: CELLULAR
  role: adaptive_escape
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    Gestational choriocarcinoma is an allograft growing in an immunocompetent host,
    which should be rejected — and occasionally is, since spontaneous regressions of
    metastatic disease are recorded. To survive, the tumour co-opts the same
    PD-1/PD-L1 axis that normal placental trophoblast uses to maintain fetomaternal
    tolerance: PD-L1 is expressed strongly and essentially uniformly by neoplastic
    trophoblast, engaging PD-1 on tumour-infiltrating T cells and shutting down the
    anti-tumour response. This is an unusually clean example of adaptive immune
    resistance, because the antigenic stimulus (a foreign paternal genome) is known
    rather than inferred, and it is directly druggable.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: syncytiotrophoblast cell
    term:
      id: CL:0000525
      label: syncytiotrophoblast cell
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immune response to tumor cell
    modifier: INCREASED
    term:
      id: GO:0002841
      label: negative regulation of T cell mediated immune response to tumor cell
  evidence:
  - reference: PMID:30339966
    reference_title: "Analysis of PD-L1 expression in trophoblastic tissues and tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All gestational choriocarcinomas (CCs; n = \n63), epithelioid trophoblastic tumors (n = 12), and placental site trophoblastic \ntumors (n = 41) were PD-L1 positive, with most showing strong staining."
    explanation: >-
      An immunohistochemical series of 63 gestational choriocarcinomas found
      uniform, mostly strong PD-L1 positivity.
  - reference: PMID:37703867
    reference_title: "Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immune checkpoint immunotherapy (CPI) targeting programmed cell \ndeath 1 (PD-1)/ligand (PD-L1) has been shown to be an effective treatment for \ngestational trophoblastic neoplasia (GTN)."
    explanation: >-
      Clinical efficacy of PD-1/PD-L1 blockade demonstrates that this axis is an
      operative, load-bearing immune-resistance mechanism rather than a passive
      marker.
  downstream:
  - target: Multidrug-Resistant Refractory Disease
    description: >-
      Immune escape sustains a residual tumour population that can also evolve
      chemoresistance; conversely, checkpoint blockade can salvage it.
    evidence:
    - reference: PMID:37703867
      reference_title: "Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This includes those with multidrug \nresistance, ultra-high-risk disease, and epithelioid trophoblastic \ntumour/placental site trophoblastic tumour subtypes that are inherently \nchemotherapy resistant"
      explanation: >-
        Checkpoint blockade is effective specifically in the multidrug-resistant
        population, linking the immune-escape node to refractory disease.
- name: High Proliferative Fraction and Chemosensitivity
  biological_scale: CELLULAR
  role: therapeutic_vulnerability
  description: >-
    The same feature that makes choriocarcinoma lethal untreated — a near-maximal
    proliferative fraction with Ki-67 frequently above 90% — makes it exceptionally
    vulnerable to cell-cycle-dependent cytotoxics. Antifolate (methotrexate),
    intercalating/transcription-blocking (dactinomycin), topoisomerase-II
    (etoposide), alkylating (cyclophosphamide) and antimitotic (vincristine) agents
    all act preferentially on rapidly cycling cells. Combined with a quantitative
    serum biomarker that permits treatment to a biochemical endpoint, this makes
    gestational choriocarcinoma one of the most curable of all solid malignancies —
    single-agent therapy cures low-risk disease and EMA-CO cures the great majority
    of high-risk disease. Non-gestational germ cell choriocarcinoma does not share
    this degree of sensitivity to the GTN regimens and is treated on germ cell lines.
    Modelling note: this node deliberately bundles a cellular property (near-maximal
    proliferative fraction) with the therapeutic-response property it produces,
    because the chemosensitivity is the clinically load-bearing consequence and
    three cytotoxic treatments attach to it via `target_mechanisms`. A future
    refactor could split it into a proliferation node and a drug-response node.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gestational choriocarcinoma is highly chemosensitive\nand responds well to single-agent methotrexate (low-risk\ndisease) or EMA-CO (etoposide, methotrexate, actinomycin\nD, cyclophosphamide, vincristine) combination che-\nmotherapy (high-risk disease) with an excellent prognosis"
    explanation: >-
      States the exceptional chemosensitivity of gestational choriocarcinoma and
      the risk-stratified regimens that exploit it.
  - reference: PMID:41243514
    reference_title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "high mitotic activity with Ki-67 \nimmunostaining\u00a0 >\u00a0 90%"
    explanation: >-
      Documents the very high proliferation index in a histologically confirmed
      case; this is the cellular substrate of the chemosensitivity claim, though
      a single case does not itself establish the causal link.
  downstream:
  - target: Multidrug-Resistant Refractory Disease
    description: >-
      A minority of tumours survive selection pressure from the standard regimens
      and become the dominant cause of death.
    evidence:
    - reference: PMID:37758451
      reference_title: "Gestational choriocarcinoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most patients \nwith gestational choriocarcinoma are cured with chemotherapy; however, some \n(<5.0%) will die as a result of multi-drug resistance"
      explanation: >-
        Quantifies the small fraction of tumours that escape the chemosensitivity
        of the disease and become refractory.
- name: Multidrug-Resistant Refractory Disease
  biological_scale: CELLULAR
  role: outcome
  description: >-
    Fewer than 5% of women with gestational choriocarcinoma die, and when they do
    it is overwhelmingly from disease that has become resistant to multiple
    cytotoxic agents rather than from untreated bulk. This small refractory
    population — together with the inherently less chemosensitive non-gestational
    and intermediate-trophoblast tumours — is the entire remaining unmet need in an
    otherwise near-curable disease, and is the population in which PD-1/PD-L1
    blockade has produced durable responses.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients \nwith gestational choriocarcinoma are cured with chemotherapy; however, some \n(<5.0%) will die as a result of multi-drug resistance, underscoring the need for \nnovel approaches in this group of patients."
    explanation: >-
      Quantifies multidrug resistance as the residual cause of mortality and the
      driver of novel-therapy development.
phenotypes:
- category: Gynecologic
  name: Abnormal Vaginal Bleeding
  description: >-
    Irregular, persistent or heavy vaginal bleeding — typically after evacuation of
    a mole, after a term delivery, or after an abortion — is the commonest
    presenting symptom. It may arise from the uterine primary or from a bleeding
    vaginal metastasis, which cannot be distinguished clinically and which should
    not be biopsied because of haemorrhage risk.
  phenotype_term:
    preferred_term: Abnormal vaginal bleeding
    term:
      id: HP:0034263
      label: Abnormal vaginal bleeding
  frequency: FREQUENT
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although the most common clinical symptom is\nvaginal bleeding"
    explanation: >-
      Identifies vaginal bleeding as the most common presenting symptom of
      gestational choriocarcinoma, supporting a FREQUENT band.
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vaginal \nmetastases can present with bleeding, which can-\nnot be distinguished from the uterine blood loss."
    explanation: >-
      Notes that vaginal-metastatic and uterine bleeding are clinically
      indistinguishable.
- category: Respiratory
  name: Pulmonary Metastases
  description: >-
    The lung is the commonest metastatic site. Deposits are typically multiple
    rounded nodules on chest imaging and may be the presenting abnormality in a
    woman with no gynaecologic complaint.
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common \nmetastatic sites are the lungs"
    explanation: >-
      Directly supports the lung as the predominant metastatic site.
- category: Respiratory
  name: Haemoptysis
  description: >-
    Coughing of blood from friable, vessel-eroding pulmonary deposits or from
    embolised trophoblastic tissue.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it can cause dyspnoea, coughing, \nchest pain, tachypnoea, and haemoptysis."
    explanation: >-
      Lists haemoptysis among the respiratory manifestations of trophoblastic
      pulmonary involvement.
- category: Respiratory
  name: Dyspnoea
  description: >-
    Breathlessness from pulmonary metastatic burden or trophoblastic tumour
    embolisation; in extreme cases respiratory failure is the presenting syndrome.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it can cause dyspnoea, coughing, \nchest pain, tachypnoea, and haemoptysis."
    explanation: >-
      Directly lists dyspnoea as a manifestation of trophoblastic pulmonary
      involvement.
- category: Respiratory
  name: Chest Pain
  description: >-
    Pleuritic or non-pleuritic chest pain accompanying pulmonary deposits or
    trophoblastic embolisation.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it can cause dyspnoea, coughing, \nchest pain, tachypnoea, and haemoptysis."
    explanation: >-
      Directly lists chest pain among the respiratory manifestations.
- category: Neurologic
  name: Headache
  description: >-
    Cerebral metastases may be silent or produce only subtle neurologic symptoms
    such as headache — a low-yield but important clue, since brain involvement
    carries the maximum FIGO metastatic-site score and mandates multiagent therapy.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central nervous system lesions \nmay be asymptomatic or produce subtle neuro-\nlogic symptoms such as headache."
    explanation: >-
      Documents headache as the typical (and often only) symptom of cerebral
      metastases.
- category: Neurologic
  name: Intracranial Haemorrhage
  description: >-
    Bleeding from a cerebral deposit is the principal mechanism of neurologic death
    in choriocarcinoma and can occur before or during treatment.
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
    severity: SEVERE
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms from \nbrain metastases can also be very severe, even fa-\ntal if they cause intracranial haemorrhage."
    explanation: >-
      Establishes intracranial haemorrhage as a potentially fatal consequence of
      cerebral metastasis.
- category: Hepatic
  name: Intra-abdominal Haemorrhage from Hepatic Metastases
  description: >-
    Liver deposits are uncommon but carry a poor prognosis, particularly when they
    present with life-threatening intra-abdominal bleeding. Liver involvement
    scores 4 — the maximum — on the FIGO metastatic-site axis.
  phenotype_term:
    preferred_term: Haemoperitoneum from ruptured hepatic metastases
    term:
      id: HP:0011854
      label: Hemoperitoneum
    severity: SEVERE
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver metastases are rare \nand often have a poor prognosis, especially if they \npresent with intra-abdominal bleeding, which is \nlife-threatening."
    explanation: >-
      Supports life-threatening intra-abdominal bleeding from hepatic deposits.
- category: Endocrine
  name: Hyperthyroidism
  description: >-
    Paraneoplastic hyperthyroidism from weak agonism of the thyrotropin receptor
    by very high circulating hCG (typically above 100,000 mIU/mL); it resolves as
    hCG falls with treatment.
  phenotype_term:
    preferred_term: Hyperthyroidism
    term:
      id: HP:0000836
      label: Hyperthyroidism
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Raised levels of human chorionic gonadotrophin (hCG) (>100,000 m IU/ml) may cause symptoms of hyperthyroidism"
    explanation: >-
      Directly attributes hyperthyroid symptoms to markedly raised hCG in
      gestational trophoblastic neoplasia.
- category: Gynecologic
  name: Theca-Lutein Ovarian Cysts
  description: >-
    Bilateral theca-lutein cysts from gonadotropin overstimulation of the ovaries
    by tumour-derived hCG; rarely accompanied by virilisation. They regress as hCG
    normalises. Pre-eclampsia and hyperemesis occur in the same
    extreme-hCG setting but are not separately annotated here because the HPO
    terms for those pregnancy states sit outside the phenotypic-abnormality
    branch used by this schema.
  phenotype_term:
    preferred_term: Theca-lutein ovarian cyst
    term:
      id: HP:0000138
      label: Ovarian cyst
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rarely virilization by ovarian theca lutein cyst formation"
    explanation: >-
      Documents theca-lutein cyst formation (and occasional virilisation) as a
      consequence of markedly raised hCG.
- category: Neurologic
  name: Cerebral Metastases
  description: >-
    Brain deposits are present at diagnosis in roughly 11% of gestational
    trophoblastic neoplasia patients and score the maximum 4 points on the FIGO
    metastatic-site axis. They may be clinically silent, or present with headache,
    focal deficit or fatal intracranial haemorrhage.
  phenotype_term:
    preferred_term: Brain neoplasm
    term:
      id: HP:0030692
      label: Brain neoplasm
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "About 11% of GTN patients have brain metastasis on presentation"
    explanation: >-
      Quantifies brain metastasis at presentation at about 11%, which maps to the
      OCCASIONAL (5-29%) frequency band; marked PARTIAL because the figure is
      for gestational trophoblastic neoplasia as a whole rather than
      choriocarcinoma specifically.
- category: Hepatic
  name: Hepatic Metastases
  description: >-
    Liver deposits are uncommon but carry a poor prognosis and, like brain
    metastases, score the maximum 4 points on the FIGO metastatic-site axis. They
    are the source of the life-threatening intra-abdominal bleeding annotated
    separately as a distinct phenotype in this entry.
  phenotype_term:
    preferred_term: Neoplasm of the liver
    term:
      id: HP:0002896
      label: Neoplasm of the liver
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver metastases are rare \nand often have a poor prognosis"
    explanation: >-
      States that liver metastases are uncommon and prognostically adverse. No
      `frequency` band is asserted: the prose word "rare" carries no numerator
      and reported liver involvement in high-risk disease is well above the
      VERY_RARE (1-4%) band.
biochemical:
- name: Serum Human Chorionic Gonadotropin (total hCG)
  presence: INCREASED
  biomarker_term:
    preferred_term: Human Chorionic Gonadotropin
    term:
      id: NCIT:C2275
      label: Human Chorionic Gonadotropin
  context: >-
    Markedly elevated and proportional to viable tumour burden; used for diagnosis,
    FIGO/WHO risk scoring, response monitoring and relapse detection.
  notes: >-
    hCG is the operational endpoint of therapy in gestational trophoblastic
    neoplasia: chemotherapy is continued to normalisation and then consolidated,
    and a plateauing or rising titre defines resistance. Pre-treatment hCG is one
    of eight weighted terms in the FIGO/WHO prognostic score. Assay caveats matter
    clinically — heterophile-antibody interference produces so-called phantom hCG
    and can prompt unnecessary chemotherapy, and the high-dose hook effect can
    spuriously lower very high results unless the sample is diluted. The analyte
    is deliberately bound to the TOTAL hCG LOINC code 19080-1 rather than the
    free beta-subunit code 21198-7: gestational trophoblastic neoplasia
    monitoring and the FIGO/WHO score both use a total-hCG assay, even though
    "beta-hCG" is the usual clinical shorthand.
  reference_ranges:
  - loinc_term:
      id: LOINC:19080-1
      label: Choriogonadotropin [Units/volume] in Serum or Plasma
    upper_bound: 5.0
    unit: IU/L
    population: non-pregnant women
    evidence:
    - reference: PMID:32761058
      reference_title: "Current Practices When Reporting Quantitative Human Chorionic Gonadotropin Test Results."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Despite a well-established reference limit of <5.0 IU/L for nonpregnant women"
      explanation: >-
        A survey of 3568 clinical laboratories states the well-established
        non-pregnant upper reference limit of 5.0 IU/L, which is also the
        threshold most commonly used when hCG is ordered as a tumour marker.
    notes: >-
      The interpretation bands above the normal range are the pre-treatment serum
      hCG tiers of the modified WHO prognostic scoring system as adapted by FIGO
      (scores 0, 1, 2 and 4). They are prognostic strata, not analytic decision
      limits, and apply only to the pre-treatment measurement.
    interpretation_bands:
    - name: Non-pregnant reference range
      upper_bound: 5.0
      unit: IU/L
      abnormal_flag: NORMAL
      interpretation: >-
        Below the non-pregnant upper reference limit; in a treated patient,
        normalisation of hCG is the endpoint that defines complete biochemical
        remission.
    - name: Elevated, FIGO pre-treatment hCG score 0
      lower_bound: 5.0
      upper_bound: 1000.0
      unit: IU/L
      abnormal_flag: HIGH
      interpretation: >-
        Elevated but within the lowest FIGO pre-treatment hCG tier (below 10^3
        IU/L), which contributes 0 points to the prognostic score.
    - name: FIGO pre-treatment hCG score 1
      lower_bound: 1000.0
      upper_bound: 10000.0
      unit: IU/L
      abnormal_flag: HIGH
      severity: MILD
      interpretation: >-
        10^3 to 10^4 IU/L; contributes 1 point to the FIGO/WHO prognostic score.
    - name: FIGO pre-treatment hCG score 2
      lower_bound: 10000.0
      upper_bound: 100000.0
      unit: IU/L
      abnormal_flag: HIGH
      severity: MODERATE
      interpretation: >-
        10^4 to 10^5 IU/L; contributes 2 points to the FIGO/WHO prognostic score.
    - name: FIGO pre-treatment hCG score 4
      lower_bound: 100000.0
      unit: IU/L
      abnormal_flag: CRITICAL_HIGH
      severity: SEVERE
      interpretation: >-
        Above 10^5 IU/L; contributes the maximum 4 points on the hCG axis of the
        FIGO/WHO prognostic score and, with other adverse factors, drives the
        total into the high-risk (7 or more) category requiring multiagent
        chemotherapy.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GTN is nowadays diagnosed primarily based on\nserum hCG measurement combined with imaging studies."
    explanation: >-
      Establishes serum hCG as the primary diagnostic measurement in gestational
      trophoblastic neoplasia.
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pre-\n tr\neatment serum hCG (IU/L) <103 103 to 104 104 to 105 >105"
    explanation: >-
      The pre-treatment serum hCG row of the modified WHO/FIGO prognostic score
      table, giving the four risk tiers used for the interpretation bands above.
      The internal line breaks and the flattened exponents (103 for 10^3) are
      artefacts of PDF text extraction in the cached reference; the quoted string
      is an exact substring of that cache.
genetic:
- name: Paternal (Androgenetic) Allele Complement of Gestational Choriocarcinoma
  notes: >-
    Gestational choriocarcinoma carries the genome of the antecedent conceptus and
    therefore contains paternal alleles that are absent from the patient's own
    tissues; when the precursor is a complete hydatidiform mole the conceptus
    genome is entirely androgenetic. Short-tandem-repeat (STR) genotyping of tumour
    against patient normal tissue detects this foreign allele complement and is the
    definitive test separating gestational from non-gestational choriocarcinoma —
    a distinction with direct therapeutic consequences. Genotyping also identifies
    the index gestation and the interval since it, both of which are scored terms
    in the FIGO/WHO prognostic system. The imprinting mechanics of the molar
    precursor (CDKN1C/p57KIP2 loss on the absent maternal allele) are curated in
    Hydatidiform_Mole and Gestational_Trophoblastic_Neoplasm.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotyping detection of a\ndistinct paternal genetic complement not present in the\npatient’s normal tissues"
    explanation: >-
      Establishes the paternal allele complement as the genetic signature of
      gestational origin and the basis of the genotyping assay.
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The FIGO/WHO prognostic scoring scheme requires ascertaining the \nprecise index gestational event and the time interval between the tumor and \nindex gestation, where DNA genotyping can provide highly relevant information."
    explanation: >-
      Shows that genotyping contributes directly to FIGO/WHO risk scoring by
      identifying the index gestation and interval.
- name: Host (Non-Paternal) Genome of Non-Gestational Choriocarcinoma
  notes: >-
    Non-gestational choriocarcinoma of germ cell origin carries only the patient's
    own alleles; the absence of a distinct paternal complement on STR genotyping is
    what identifies it. Somatic carcinomas with trophoblastic differentiation
    (which also lack paternal alleles) are the other member of this differential
    and are more aggressive and chemoresistant still. Because immunohistochemistry
    — including SALL4 — cannot discriminate these entities, genotyping rather than
    morphology drives the treatment decision.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA genotyping \nprovides a decisive tool in the separation of gestational trophoblastic \nneoplasia from non-gestational counterparts/mimics of either germ cell or \nsomatic origin."
    explanation: >-
      Establishes genotyping as the decisive discriminator between gestational
      choriocarcinoma and its non-gestational germ cell and somatic mimics.
  - reference: PMID:40588865
    reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "distinguishing gestational \nchoriocarcinoma from nongestational mimics of germ cell or somatic origin, which \nhave profound therapeutic and prognostic implications."
    explanation: >-
      Confirms that the gestational versus non-gestational distinction changes
      both therapy and prognosis.
diagnosis:
- name: Serum hCG Criteria for Post-Molar Gestational Trophoblastic Neoplasia
  description: >-
    Because hCG tracks viable trophoblast so tightly, gestational trophoblastic
    neoplasia is in practice diagnosed biochemically rather than histologically:
    a plateauing or rising hCG after evacuation of a mole establishes the
    diagnosis and triggers chemotherapy without a tissue confirmation. This is
    why choriocarcinoma has become a rare specimen in pathology laboratories even
    though the disease still occurs.
  diagnosis_term:
    preferred_term: Human Chorionic Gonadotropin Measurement
    term:
      id: NCIT:C75387
      label: Human Chorionic Gonadotropin Measurement
  markers: serum total hCG
  results: >-
    Plateauing or rising hCG after uterine evacuation, or persistence of a
    detectable level, defines persistent/malignant trophoblastic disease.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GTN is nowadays diagnosed primarily based on\nserum hCG measurement combined with imaging studies."
    explanation: >-
      States that serum hCG plus imaging, not histology, is the primary
      diagnostic route in contemporary practice.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Follow-up with \nhuman chorionic gonadotropin (hCG) is essential for early diagnosis of \ngestational trophoblastic neoplasia (GTN)."
    explanation: >-
      The FIGO 2021 update makes hCG follow-up the essential route to early GTN
      diagnosis.
- name: STR/DNA Genotyping for Gestational versus Non-Gestational Origin
  description: >-
    Short-tandem-repeat genotyping of tumour DNA against the patient's normal
    tissue looks for a paternal allele complement that the patient does not
    carry. Its presence proves gestational origin; its absence points to a germ
    cell tumour or a somatic carcinoma with trophoblastic differentiation. This
    is the only reliable discriminator - morphology and the trophoblastic
    immunohistochemical panel (including SALL4) cannot separate the entities -
    and it changes therapy, so it should precede treatment whenever origin is
    uncertain. Genotyping additionally identifies the index gestation and the
    interval since it, two scored terms in the FIGO/WHO prognostic system.
  diagnosis_term:
    preferred_term: Short tandem repeat genotyping of tumour versus normal tissue
    term:
      id: NCIT:C129889
      label: Short Tandem Repeat Profile
  markers: paternal (non-maternal) STR alleles in tumour DNA
  results: >-
    Presence of a distinct paternal allele complement absent from patient normal
    tissue confirms gestational choriocarcinoma; its absence indicates
    non-gestational germ cell or somatic origin.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotyping detection of a\ndistinct paternal genetic complement not present in the\npatient\u2019s normal tissues"
    explanation: >-
      Defines the analyte and the decision rule for the genotyping assay.
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA genotyping \nprovides a decisive tool in the separation of gestational trophoblastic \nneoplasia from non-gestational counterparts/mimics of either germ cell or \nsomatic origin."
    explanation: >-
      Establishes genotyping as the decisive test for the origin question that
      determines treatment.
- name: Staging Imaging for Metastatic Disease
  description: >-
    Once persistent trophoblastic disease is established, the metastatic survey
    drives both FIGO stage and the metastatic-site term of the prognostic score.
    Guideline-mandated studies are CT of thorax and abdomen, transvaginal
    ultrasound and MRI of the brain, with FDG-PET/CT reserved for equivocal
    findings. Brain imaging is not optional: cerebral deposits score the maximum
    4 points and change the regimen. Vascular metastases (notably vaginal
    deposits) should not be biopsied because of haemorrhage risk.
  diagnosis_term:
    preferred_term: Computed tomography and MRI staging survey
    term:
      id: NCIT:C17204
      label: Computed Tomography
  results: >-
    Distribution of metastases determines FIGO anatomical stage I-IV and the
    metastatic-site component of the FIGO/WHO prognostic score.
  evidence:
  - reference: PMID:37020431
    reference_title: "Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the following imaging examinations must be carried\nout: CT of the thorax and abdomen, transvaginal ultrasound, MRI of\nthe brain."
    explanation: >-
      A consensus-based guideline recommendation specifying the mandatory
      staging imaging once persistent villous trophoblastic disease is
      diagnosed.
- name: hCG-Defined Remission and Post-Treatment Surveillance
  description: >-
    Treatment is taken to a biochemical rather than a radiological endpoint.
    Chemotherapy continues until hCG is undetectable on at least three
    consecutive weekly measurements, followed by consolidation cycles, then
    prolonged monthly hCG surveillance under reliable contraception - because a
    subsequent pregnancy would itself raise hCG and mask relapse.
  diagnosis_term:
    preferred_term: Serial hCG measurement for remission and relapse surveillance
    term:
      id: NCIT:C75387
      label: Human Chorionic Gonadotropin Measurement
  markers: serum total hCG
  results: >-
    Three consecutive weekly undetectable hCG values define biochemical
    remission and trigger consolidation therapy; a subsequent rise indicates
    relapse.
  evidence:
  - reference: PMID:37020431
    reference_title: "Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3 consolidation cycles of mono-chemotherapy after hCG levels are\nno longer detectable (i.e., at least three consecutive weekly measure-\nments of hCG, with hCG levels below the detection limit)."
    explanation: >-
      Defines the hCG-based remission endpoint and the consolidation
      requirement that follows it.
environmental:
- name: Antecedent Complete Hydatidiform Mole
  presence: PRESENT
  effect: Strongest single risk factor for gestational choriocarcinoma
  description: >-
    A prior complete hydatidiform mole raises the risk of choriocarcinoma roughly
    1000-fold over a background pregnancy, and about half of gestational
    choriocarcinomas follow a mole. This is the entire rationale for post-molar hCG
    surveillance programmes, and it is why widespread surveillance has made
    choriocarcinoma a progressively rarer diagnosis. The biology of the molar
    precursor lesion itself is curated in Hydatidiform_Mole.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choriocarcinoma affects approximately 1 in 40.000 \npregnancies and 1 in 40 HMs."
    explanation: >-
      The 1-in-40 risk after a hydatidiform mole versus 1-in-40,000 per pregnancy
      quantifies molar pregnancy as the dominant risk factor.
  - reference: PMID:40588865
    reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gestational choriocarcinoma has \nbecome a rare encounter, largely owing to the implementation of postmolar \nsurveillance programs and timely initiation of chemotherapy."
    explanation: >-
      Confirms that intervening on the molar precursor through surveillance has
      markedly reduced the incidence of clinically encountered choriocarcinoma.
- name: Extremes of Maternal Age
  presence: PRESENT
  effect: Increased incidence of gestational trophoblastic disease
  description: >-
    Gestational trophoblastic disease incidence is bimodally raised at the extremes
    of reproductive age - in adolescents and in women in their forties and early
    fifties. Age of at least 40 years additionally contributes a point to the
    FIGO/WHO prognostic score once disease has developed, so maternal age is both
    an incidence correlate and a prognostic term. Note that this is a
    disease-group-level (GTD) association rather than a choriocarcinoma-specific
    one.
  evidence:
  - reference: PMID:37020431
    reference_title: "Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "An increased incidence of\nGTD was found in younger (10 –19 years of age) and older (40 –\n54 years) women"
    explanation: >-
      A national guideline reports the bimodal age distribution; marked PARTIAL
      because the statistic covers gestational trophoblastic disease as a whole
      rather than choriocarcinoma specifically.
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "These include an increasing maternal age of around 40, previous history of molar pregnancy, blood group A and Asian ancestry"
    explanation: >-
      An independent review lists maternal age around 40 among the risk factors
      for GTN; PARTIAL for the same disease-group-level reason.
- name: Population and Host Correlates (Ancestry, Blood Group A)
  presence: PRESENT
  effect: Correlated with increased incidence of gestational trophoblastic disease
  description: >-
    Reported incidence is roughly double in Asian compared with Caucasian women,
    Black US-American women are over-represented in national registers, and blood
    group A has been reported as a correlate. These are population correlates, not
    established exposures or causal mechanisms: how much of the variation reflects
    reproductive patterns, nutrition, ascertainment and access to early ultrasound
    and hCG testing versus host genetics is unresolved, and the statistics are
    GTD-wide rather than choriocarcinoma-specific. Modelling note: ancestry and
    blood group are host attributes rather than environmental exposures, and are
    recorded here only because dismech has no dedicated population-correlate slot.
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "These include an increasing maternal age of around 40, previous history of molar pregnancy, blood group A and Asian ancestry"
    explanation: >-
      Lists blood group A and Asian ancestry among reported GTN risk correlates;
      PARTIAL because these are GTD/GTN-wide associations without a
      choriocarcinoma-specific effect estimate or a causal mechanism.
  - reference: PMID:37020431
    reference_title: "Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "and was also correlated with ethnicity. Black\nUS-American women are over-represented in national registers,"
    explanation: >-
      Confirms the ethnicity correlation and register over-representation;
      PARTIAL because it is a GTD-wide observation with no causal attribution.
differential_diagnoses:
- name: Placental site trophoblastic tumour
  disease_term:
    preferred_term: placental site trophoblastic tumor
    term:
      id: MONDO:0020552
      label: placental site trophoblastic tumor
  description: >-
    A gestational trophoblastic neoplasm of intermediate (implantation-site)
    trophoblast rather than of the biphasic cytotrophoblast/syncytiotrophoblast
    population that defines choriocarcinoma. It is the single most important
    GTN differential because it is relatively chemoresistant, so the
    distinction changes management from chemotherapy to hysterectomy.
  distinguishing_features:
  - >-
    Composed of mononuclear implantation-site intermediate trophoblast, without
    the biphasic/triphasic pattern and without the syncytiotrophoblastic
    component of choriocarcinoma.
  - >-
    Serum hCG is characteristically low relative to tumour burden, in contrast
    to the extreme hCG elevation of choriocarcinoma.
  - >-
    Relatively chemoresistant, so primary hysterectomy rather than
    methotrexate-based chemotherapy is the treatment of choice.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They consist of invasive mole, choriocarci-\nnoma, placental-site \ntrophoblastic tumour (PSTT) \nand epithelioid trophoblastic tumour (ETT)."
    explanation: >-
      Establishes PSTT as a separate malignant GTN entity from choriocarcinoma
      within the same disease family, which is what makes it the differential.
- name: Epithelioid trophoblastic tumour
  disease_term:
    preferred_term: epithelioid trophoblastic tumor
    term:
      id: MONDO:0016787
      label: epithelioid trophoblastic tumor
  description: >-
    A rare GTN of chorionic-type intermediate trophoblast that forms nodular,
    relatively circumscribed epithelioid nests and can mimic squamous carcinoma
    of the cervix. Like PSTT, it is relatively chemoresistant, so the boundary
    with choriocarcinoma is therapeutically consequential.
  distinguishing_features:
  - >-
    Chorionic-type intermediate trophoblast in nodular epithelioid nests rather
    than the biphasic trophoblastic proliferation of choriocarcinoma.
  - >-
    Lower serum hCG than choriocarcinoma and relative chemoresistance, favouring
    surgical management.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They consist of invasive mole, choriocarci-\nnoma, placental-site \ntrophoblastic tumour (PSTT) \nand epithelioid trophoblastic tumour (ETT)."
    explanation: >-
      Establishes ETT as a malignant GTN entity distinct from choriocarcinoma.
- name: Invasive hydatidiform mole
  disease_term:
    preferred_term: invasive hydatidiform mole
    term:
      id: MONDO:0020549
      label: invasive hydatidiform mole
  description: >-
    Molar tissue invading the myometrium. It is the commonest cause of a rising
    or plateaued post-molar hCG and is therefore the entity most often treated
    as "post-molar GTN" without histological confirmation - which is precisely
    why the boundary with choriocarcinoma matters: both are diagnosed on the
    same hCG criteria and treated on the same FIGO/WHO risk score, but only
    choriocarcinoma lacks chorionic villi.
  distinguishing_features:
  - >-
    Chorionic villi are retained, whereas the defining histological feature of
    choriocarcinoma is trophoblastic proliferation WITHOUT chorionic villi.
  - >-
    Generally a lower FIGO/WHO risk score and a better prognosis than
    choriocarcinoma.
  evidence:
  - reference: PMID:36286620
    reference_title: "Advances in diagnostics and management of gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They consist of invasive mole, choriocarci-\nnoma, placental-site \ntrophoblastic tumour (PSTT) \nand epithelioid trophoblastic tumour (ETT)."
    explanation: >-
      Establishes invasive mole as a separate GTN entity from choriocarcinoma.
- name: Complete hydatidiform mole
  disease_term:
    preferred_term: complete hydatidiform mole
    term:
      id: MONDO:0016785
      label: complete hydatidiform mole
  description: >-
    The commonest antecedent gestation of gestational choriocarcinoma and its
    main premalignant differential. A complete mole is androgenetic and shares
    the exclusively-paternal genome that this entry models as the trigger node,
    but it is a premalignant villous lesion rather than an invasive neoplasm.
  distinguishing_features:
  - >-
    Hydropic chorionic villi with circumferential trophoblastic hyperplasia are
    present; choriocarcinoma has no villi.
  - >-
    Premalignant rather than malignant: most complete moles resolve after
    evacuation, and only a minority progress to post-molar GTN.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Genotyping is now considered the gold standard in the con \ufb01rmation and subtyping of sporadic hydatidiform\nmoles."
    explanation: >-
      Supports genotyping as the confirmatory tool that separates mole subtypes.
      Marked PARTIAL because the snippet addresses mole subtyping rather than
      the mole-versus-choriocarcinoma boundary directly.
- name: Non-gestational choriocarcinoma
  disease_term:
    preferred_term: non-gestational ovarian choriocarcinoma
    term:
      id: MONDO:0004322
      label: non-gestational ovarian choriocarcinoma
  description: >-
    Choriocarcinoma arising from a germ cell tumour (or, rarely, as somatic
    dedifferentiation) rather than from a gestation. It is histologically
    indistinguishable from gestational choriocarcinoma, so the distinction rests
    entirely on DNA genotyping for paternal alleles. This is the most
    consequential differential in the entry: non-gestational disease lacks the
    semi-allogeneic paternal genome that the trigger node models, does not carry
    the same exquisite methotrexate sensitivity, and is treated on germ-cell
    (BEP-type) rather than GTN protocols with a worse prognosis. It is curated
    here both as a has_subtypes entry and as a differential for that reason.
  distinguishing_features:
  - >-
    Absence of paternal-specific alleles on short tandem repeat DNA genotyping;
    the tumour genome matches the patient.
  - >-
    Arises in the ovary or other germ-cell sites rather than following an
    identifiable index gestation.
  - >-
    Treated with platinum/bleomycin-based germ-cell chemotherapy and surgical
    staging rather than the methotrexate-based GTN protocols.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA genotyping provides a decisive tool in the separation of gestational\ntrophoblastic neoplasia from non-gestational counterparts/mimics of either germ cell or\nsomatic origin."
    explanation: >-
      States that DNA genotyping is the decisive test separating gestational
      from non-gestational choriocarcinoma, which is the discriminator this
      differential turns on.
stages:
- name: FIGO Stage I
  description: Disease confined to the uterus.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "I Disease confined to the uterus"
    explanation: FIGO anatomical staging table, stage I.
- name: FIGO Stage II
  description: >-
    Disease extends outside the uterus but is limited to genital structures
    (adnexa, vagina, broad ligament).
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "II GTN extends outside of the uterus, but is limited \nto the genital structures (adnexae, vagina, broad \nligament)"
    explanation: FIGO anatomical staging table, stage II.
- name: FIGO Stage III
  description: >-
    Disease extends to the lungs, with or without known genital tract involvement.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "III GTN extends to the lungs with or without known \ngenital tract involvement"
    explanation: FIGO anatomical staging table, stage III.
- name: FIGO Stage IV
  description: All other metastatic sites (notably liver and brain).
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "IV All other metastatic sites"
    explanation: FIGO anatomical staging table, stage IV.
progression:
- phase: Low-risk course (FIGO/WHO score 0-6)
  notes: >-
    Treated with single-agent chemotherapy; overall survival approaches 100%.
    Scores of 5-6 are associated with more single-agent drug resistance and often
    require a change of agent or escalation to multiagent therapy, without loss of
    the near-universal cure rate.
  evidence:
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "although scores 5-6 are associated with more drug resistance, \noverall survival approaches 100%."
    explanation: >-
      Gives the low-risk trajectory, including the higher resistance rate at
      scores 5-6 despite near-universal survival.
- phase: High-risk course (FIGO/WHO score 7 or more, or stage IV)
  notes: >-
    Requires multiagent chemotherapy with adjuvant surgery for resistant foci or
    radiotherapy for brain metastases; survival is approximately 90%. Late
    mortality still occurs, almost entirely from recurrent treatment-resistant
    tumour.
  evidence:
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High-risk GTN (FIGO Stages II-III: score ≥7 \nand Stage IV) is treated with multiagent chemotherapy, with or without adjuvant \nsurgery for excision of resistant foci of disease or radiotherapy for brain \nmetastases, achieving a survival rate of approximately 90%."
    explanation: >-
      The FIGO 2021 update gives the high-risk treatment pathway and its
      approximate survival.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late mortality still occurs from recurrent treatment-resistant tumors."
    explanation: >-
      Identifies recurrent treatment-resistant disease as the residual source of
      late mortality.
discussions:
- discussion_id: cc_nongestational_evidence_base
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Paternal Genome Content and Semi-Allogeneic Tumour Identity"
  prompt: >-
    Does non-gestational (germ cell) choriocarcinoma share the pathophysiology
    modelled here beyond the shared trophoblastic morphology, and how much worse
    is its outcome once stage and burden are matched?
  rationale: >-
    The non-gestational subtype is asserted as a mechanistically distinct arm of
    this entry, yet the entire arm rests on a handful of references, the largest
    of which is a pooled analysis of only 39 published cases. Nothing in the
    literature retrieved for this entry establishes whether the hCG-driven
    paraneoplastic axis, the PD-L1 immune-resistance mechanism, or the extreme
    chemosensitivity apply to the germ-cell form, and no matched comparative
    survival analysis against gestational disease exists. Because the
    gestational-versus-non-gestational call directly changes therapy, this is a
    consequential gap rather than an academic one.
  evidence:
  - reference: PMID:32185550
    reference_title: "Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only 39 patients were retrieved from 36 studies in total."
    explanation: >-
      The largest available synthesis of non-gestational ovarian choriocarcinoma
      is a pooled analysis of just 39 cases scraped from 36 separate reports,
      which is the direct measure of how thin the evidence base for this subtype
      is.
  - reference: PMID:40588865
    reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "distinguishing gestational \nchoriocarcinoma from nongestational mimics of germ cell or somatic origin, which \nhave profound therapeutic and prognostic implications."
    explanation: >-
      Establishes that the gestational versus non-gestational distinction carries
      profound therapeutic and prognostic consequences, which is what makes the
      thin non-gestational evidence base consequential rather than academic.
  proposed_experiments:
  - experiment_id: exp_cc_ngc_matched_outcome_cohort
    name: Matched-outcome cohort of genotype-confirmed non-gestational choriocarcinoma
    description: >-
      Assemble a multi-centre cohort of choriocarcinomas in which STR genotyping
      has confirmed the absence of a paternal allele complement, and compare
      stage- and burden-matched survival and chemotherapy response against
      genotype-confirmed gestational cases treated at the same centres. This
      would replace the current reliance on small pooled case series and test
      whether the worse outcome attributed to non-gestational disease survives
      adjustment for stage and tumour burden.
  - experiment_id: exp_cc_ngc_pdl1_immune_profiling
    name: PD-L1 and tumour-infiltrating lymphocyte profiling of non-gestational choriocarcinoma
    description: >-
      Apply the PD-L1 immunohistochemistry and immune-infiltrate profiling that
      established the adaptive immune-resistance mechanism in gestational
      choriocarcinoma to genotype-confirmed non-gestational cases. Because the
      non-gestational tumour is autologous rather than allogeneic, this directly
      tests whether the immune-evasion arm of this pathograph, and therefore the
      rationale for checkpoint blockade, generalises to the germ cell form.
- discussion_id: cc_no_validated_driver_gene
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Multidrug-Resistant Refractory Disease"
  prompt: >-
    What determines which choriocarcinomas become multidrug resistant, given that
    no validated somatic driver gene or resistance biomarker exists?
  rationale: >-
    Fewer than 5% of patients die, essentially all from multidrug-resistant
    disease, yet there is no recurrent somatic driver for choriocarcinoma and no
    validated predictor of resistance. Candidate resistance pathways surfaced in
    the deep-research sweep (DPP4/cholesterol synthesis, RSK2-SOX8, cfDNA signals
    involving BMPR1A and MAP3K1) are investigational and were deliberately not
    curated into the pathograph. Since the FIGO/WHO score is a clinical proxy
    rather than a biological one, a molecular predictor would change who is
    escalated up front.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "some \n(<5.0%) will die as a result of multi-drug resistance, underscoring the need for \nnovel approaches in this group of patients."
    explanation: >-
      An expert review states that multidrug resistance is the residual cause of
      death and explicitly frames it as an unmet need requiring novel
      approaches, which is the gap this discussion records.
  proposed_experiments:
  - experiment_id: exp_cc_paired_resistance_multiomics
    name: Paired chemosensitive versus chemoresistant choriocarcinoma multi-omics
    description: >-
      Profile matched pre-treatment and post-relapse tumour material by
      whole-exome and transcriptome sequencing, with serial cell-free DNA
      sampling through treatment, to identify somatic or transcriptional changes
      that accompany the emergence of multidrug resistance in an otherwise
      near-curable disease.
  - experiment_id: exp_cc_resistance_biomarker_vs_figo
    name: Prospective comparison of candidate resistance biomarkers against the FIGO/WHO score
    description: >-
      Prospectively measure candidate resistance markers at diagnosis and test
      whether any adds predictive value over the FIGO/WHO prognostic score for
      single-agent failure, which would allow biologically rather than clinically
      driven up-front escalation.
treatments:
- name: Single-Agent Methotrexate
  description: >-
    First-line therapy for low-risk (FIGO score 0-6) gestational choriocarcinoma.
    Methotrexate, usually with folinic acid rescue, exploits the tumour's extreme
    proliferative fraction; treatment is continued to hCG normalisation plus
    consolidation courses. Overall survival approaches 100%, and fertility is
    preserved.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
  target_mechanisms:
  - target: High Proliferative Fraction and Chemosensitivity
    treatment_effect: INHIBITS
    description: >-
      Antifolate blockade of thymidylate and purine synthesis kills the rapidly
      cycling trophoblast population.
    evidence:
    - reference: PMID:34088998
      reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gestational choriocarcinoma is highly chemosensitive\nand responds well to single-agent methotrexate (low-risk\ndisease)"
      explanation: >-
        Links methotrexate response directly to the chemosensitivity of the
        tumour.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gestational choriocarcinoma is highly chemosensitive\nand responds well to single-agent methotrexate (low-risk\ndisease)"
    explanation: >-
      Establishes single-agent methotrexate as effective therapy for low-risk
      gestational choriocarcinoma.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low-risk GTN (FIGO Stages \nI-III: score <7) is treated with single-agent chemotherapy but may require \nadditional agents"
    explanation: >-
      The FIGO 2021 update specifies single-agent chemotherapy for low-risk
      disease.
- name: Single-Agent Dactinomycin (Actinomycin D)
  description: >-
    The alternative single agent for low-risk disease — used first-line in some
    centres and as salvage after methotrexate resistance, which is common enough at
    FIGO scores 5-6 that a planned second single agent is part of the low-risk
    algorithm.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: actinomycin D
      term:
        id: CHEBI:27666
        label: actinomycin D
  target_mechanisms:
  - target: High Proliferative Fraction and Chemosensitivity
    treatment_effect: INHIBITS
    description: >-
      DNA intercalation and transcription blockade kill the rapidly cycling
      tumour population.
    evidence:
    - reference: PMID:20739008
      reference_title: "Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "low-risk metastatic (stages II and III, score <7) GTN can be treated with \nsingle-agent chemotherapy resulting in a survival rate approaching 100%."
      explanation: >-
        Establishes that single-agent chemotherapy achieves near-universal cure
        in low-risk disease; marked PARTIAL because the abstract says
        "single-agent chemotherapy" and does not name dactinomycin.
  evidence:
  - reference: PMID:20739008
    reference_title: "Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "low-risk metastatic (stages II and III, score <7) GTN can be treated with \nsingle-agent chemotherapy resulting in a survival rate approaching 100%."
    explanation: >-
      Establishes single-agent chemotherapy as curative in low-risk disease;
      marked PARTIAL because the abstract does not name dactinomycin
      specifically.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "is treated with single-agent chemotherapy but may require \nadditional agents; although scores 5-6 are associated with more drug resistance"
    explanation: >-
      Supports the need for an additional agent in the more resistance-prone
      low-risk band; marked PARTIAL because the source does not name
      dactinomycin specifically.
- name: EMA-CO Multiagent Chemotherapy
  description: >-
    The standard first-line regimen for high-risk (FIGO score 7 or more, or stage
    IV) gestational choriocarcinoma: etoposide, methotrexate and dactinomycin
    alternating weekly with cyclophosphamide and vincristine. It is chosen for a
    favourable toxicity profile, high complete-response rate and high survival. In
    very-high-score disease gentle induction chemotherapy precedes EMA-CO to avoid
    catastrophic haemorrhage from rapid lysis of friable, vascular tumour.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: actinomycin D
      term:
        id: CHEBI:27666
        label: actinomycin D
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
    - preferred_term: vincristine
      term:
        id: CHEBI:28445
        label: vincristine
  regimen_term:
    preferred_term: EMA-CO regimen
    term:
      id: NCIT:C67511
      label: EMA-CO Regimen
  target_mechanisms:
  - target: High Proliferative Fraction and Chemosensitivity
    treatment_effect: INHIBITS
    description: >-
      Five agents with complementary cell-cycle-dependent mechanisms are combined
      to suppress emergence of resistant clones.
    evidence:
    - reference: PMID:34088998
      reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "EMA-CO (etoposide, methotrexate, actinomycin\nD, cyclophosphamide, vincristine) combination che-\nmotherapy (high-risk disease) with an excellent prognosis"
      explanation: >-
        The five-agent combination achieves an excellent prognosis in high-risk
        disease, evidencing the multi-mechanism attack on the proliferating
        tumour.
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EMA-CO (etoposide, methotrexate, actinomycin\nD, cyclophosphamide, vincristine) combination che-\nmotherapy (high-risk disease) with an excellent prognosis"
    explanation: >-
      Names the EMA-CO components and its role in high-risk gestational
      choriocarcinoma.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High-risk GTN (FIGO Stages II-III: score ≥7 \nand Stage IV) is treated with multiagent chemotherapy"
    explanation: >-
      The FIGO 2021 update assigns multiagent chemotherapy to high-risk disease.
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gentle induction \nchemotherapy helps reduce early deaths in patients with extensive tumor burden"
    explanation: >-
      Supports gentle induction before full-dose multiagent chemotherapy in
      extensive-burden disease.
- name: Surgical Staging with Bleomycin-Based Chemotherapy (Non-Gestational Disease)
  description: >-
    Non-gestational (germ cell) choriocarcinoma is not managed on the GTN
    algorithm. It requires surgical staging and cytoreduction — achieving an R0
    resection is a favourable prognostic factor — followed by bleomycin-based
    (BEP-type: bleomycin, etoposide, cisplatin) germ cell chemotherapy. Applying
    the methotrexate/EMA-CO pathway to a non-gestational tumour is a recognised
    treatment error, which is why STR genotyping precedes therapy when origin is
    uncertain.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: bleomycin
      term:
        id: CHEBI:22907
        label: bleomycin
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
  evidence:
  - reference: PMID:34088998
    reference_title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Germ cell choriocarcinoma requires surgical staging\nfollowed by bleomycin-based chemotherapy."
    explanation: >-
      States the distinct germ cell treatment pathway for non-gestational
      choriocarcinoma.
  - reference: PMID:32185550
    reference_title: "Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinicians should try to achieve R0 resection to improve the \nprognosis for NGOC patients even among advanced patients."
    explanation: >-
      A pooled analysis of 39 cases identifies complete (R0) surgical resection
      as a favourable prognostic factor in non-gestational ovarian
      choriocarcinoma.
- name: Adjuvant Surgery (Hysterectomy or Resection of Resistant Foci)
  description: >-
    Surgery has a defined adjunctive role in gestational choriocarcinoma: excision
    of chemoresistant foci (uterine or pulmonary) in high-risk disease, and
    hysterectomy for localised drug-resistant uterine tumour or in women who have
    completed childbearing. It is not primary therapy for chemosensitive disease,
    where the goal is cure without surgery and preservation of fertility.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Hysterectomy
    term:
      id: NCIT:C15256
      label: Hysterectomy
  evidence:
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with or without adjuvant \nsurgery for excision of resistant foci of disease"
    explanation: >-
      The FIGO 2021 update defines adjuvant surgery as excision of resistant
      disease foci in high-risk GTN.
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chemotherapy \nfor localized disease has a goal of eradication of disease without surgery and \nis associated with favorable prognosis and fertility preservation."
    explanation: >-
      Confirms that surgery is deliberately avoided in localised chemosensitive
      disease so that fertility is preserved.
- name: EMA-EP and Platinum/Taxane Salvage Chemotherapy
  description: >-
    Roughly 30-40% of patients develop a rising hCG after completing EMA-CO. The
    first-line cytotoxic salvage is EMA-EP (etoposide, methotrexate,
    dactinomycin alternating with etoposide and cisplatin), which achieves a
    response rate near 85%. Patients progressing on EMA-EP move to
    platinum/taxane doublets alternating as TP/TE, and thereafter to germ-cell
    regimens. This cytotoxic salvage ladder sits alongside, not instead of,
    checkpoint blockade for the multidrug-resistant population.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: actinomycin D
      term:
        id: CHEBI:27666
        label: actinomycin D
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
    - preferred_term: paclitaxel
      term:
        id: CHEBI:45863
        label: paclitaxel
  target_mechanisms:
  - target: Multidrug-Resistant Refractory Disease
    treatment_effect: INHIBITS
    description: >-
      Introducing platinum and taxane mechanisms not present in EMA-CO
      re-establishes cytotoxic pressure on clones that survived the first-line
      regimen.
    evidence:
    - reference: PMID:38008872
      reference_title: "Review of current literature on gestational trophoblastic neoplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Such patients can be salvaged with EMA-EP, which shows a response rate of 84.9%"
      explanation: >-
        Quantifies the salvage response rate of EMA-EP in patients whose hCG
        rises after EMA-CO.
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 30 \u2013 40% of patients developed increased beta HCG levels post-completion of treatment with EMA-CO"
    explanation: >-
      Establishes both the size of the post-EMA-CO relapse population and the
      efficacy of EMA-EP salvage.
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who develop methotrexate resistance, i.e., have also progressed on EMA-EP, can be treated with a combination of paclitaxel and cisplatin weekly alternating with paclitaxel and etoposide (TP/TE)"
    explanation: >-
      Defines the next rung of the salvage ladder after EMA-EP failure.
- name: CNS-Penetrating High-Dose Methotrexate EMA-CO for Cerebral Metastases
  description: >-
    Contemporary first-line practice for brain metastases is CNS-penetrating
    systemic therapy rather than radiation by default: EMA-CO is given with a
    higher dose and slower infusion of methotrexate (1000 mg/m2 over 12-24
    hours) to achieve adequate cerebrospinal-fluid levels, which produces
    complete responses and can negate the need for whole-brain radiotherapy,
    with reported five-year survival of 81.5%.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
  regimen_term:
    preferred_term: EMA-CO regimen
    term:
      id: NCIT:C67511
      label: EMA-CO Regimen
  target_mechanisms:
  - target: Hematogenous Dissemination and Pulmonary Colonisation
    treatment_effect: INHIBITS
    description: >-
      Dose-intensified methotrexate reaches the CNS compartment that standard
      EMA-CO dosing does not, and so acts on colonised brain deposits rather
      than only on the systemic tumour burden.
  evidence:
  - reference: PMID:38008872
    reference_title: "Review of current literature on gestational trophoblastic neoplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the same regimen of EMA-CO but with a higher dose and infusion rate of methotrexate (1000mg/m2 given over 12 to 24 hours) is administered. This allows an adequate dose of methotrexate within the cerebrospinal fluid (CSF) which provides a complete response in patients negating the need for whole brain radiation"
    explanation: >-
      Establishes CNS-penetrating high-dose methotrexate within EMA-CO as the
      contemporary approach to brain metastases, displacing routine whole-brain
      radiotherapy.
- name: Adjunctive Cranial Radiotherapy for Cerebral Metastases
  description: >-
    Radiotherapy is retained as an adjunct to multiagent chemotherapy for brain
    metastases in high-risk disease, both for local control and to reduce the
    risk of intracranial haemorrhage. It is no longer the default CNS-directed
    modality; that role has passed to CNS-penetrating high-dose methotrexate.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: Radiation Therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  target_mechanisms:
  - target: Haemorrhagic Destruction of Colonised Organs
    treatment_effect: INHIBITS
    description: >-
      Cranial irradiation is given for local control of colonised brain deposits
      and specifically to reduce the risk of the intracranial haemorrhage that
      this node produces.
  evidence:
  - reference: PMID:34669197
    reference_title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "or radiotherapy for brain \nmetastases"
    explanation: >-
      The FIGO 2021 update retains radiotherapy for brain metastases as an
      adjunct to multiagent chemotherapy in high-risk GTN.
- name: PD-1/PD-L1 Immune Checkpoint Blockade
  description: >-
    Anti-PD-1 (pembrolizumab) and anti-PD-L1 (avelumab) antibodies target the
    checkpoint axis that the allogeneic tumour uses to escape host T cells.
    Response rates of 50-70% are reported, and the principal role is in
    chemoresistant disease: in the TROPHIMMUN phase II trial avelumab was active in
    GTN resistant to single-agent chemotherapy, though not after multiagent
    failure. Checkpoint blockade is also being explored to de-escalate or replace
    cytotoxic therapy in young women for whom long-term chemotherapy toxicity
    matters, and in combination with VEGFR-2-directed agents.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: avelumab
      term:
        id: NCIT:C116870
        label: Avelumab
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
  target_mechanisms:
  - target: PD-L1-Mediated Adaptive Immune Resistance
    treatment_effect: INHIBITS
    description: >-
      Blocking PD-1/PD-L1 engagement releases tumour-infiltrating T cells from
      inhibition and restores an immune response against the semi-allogeneic
      tumour.
    evidence:
    - reference: PMID:37703867
      reference_title: "Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Immune checkpoint immunotherapy (CPI) targeting programmed cell \ndeath 1 (PD-1)/ligand (PD-L1) has been shown to be an effective treatment for \ngestational trophoblastic neoplasia (GTN)."
      explanation: >-
        Demonstrates that blocking the PD-1/PD-L1 axis is therapeutically
        effective, confirming the axis as the operative treatment target.
  evidence:
  - reference: PMID:37758451
    reference_title: "Gestational choriocarcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the treatment response with immunotherapy is high, ranging \nbetween 50-70%."
    explanation: >-
      Quantifies response to checkpoint immunotherapy in gestational
      choriocarcinoma.
  - reference: PMID:35681761
    reference_title: "Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN)."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "In the TROPHIMMUN trial, Avelumab, a monoclonal antibody \ninhibiting PD-L1, showed promising results only in patients with GTN resistant \nto monochemotherapy."
    explanation: >-
      Delimits the efficacy of avelumab to GTN resistant to single-agent rather
      than multiagent chemotherapy; marked PARTIAL because the same review
      reports failure and toxicity after multiagent resistance.
clinical_trials:
- name: NCT03135769
  phase: PHASE_II
  status: COMPLETED
  description: >-
    TROPHIMMUN — a phase II trial of the anti-PD-L1 antibody avelumab in
    chemoresistant gestational trophoblastic neoplasia, built on the rationale that
    GTN hijacks placental PD-L1-mediated immune tolerance to escape rejection.
  target_phenotypes:
  - preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: clinicaltrials:NCT03135769
    reference_title: "A Phase II Trial of Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (GTN)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Strong and constant overexpression of PDL1 and NK cells has been found in all subtypes and settings of GTN tumors from French reference gestational trophoblastic center."
    explanation: >-
      The trial's own rationale documents strong, constant PD-L1 overexpression
      across GTN subtypes, the mechanistic basis for checkpoint blockade in
      choriocarcinoma.
- name: NCT05139095
  phase: PHASE_II
  status: RECRUITING
  description: >-
    An open-label phase II cohort trial of the anti-PD-1 antibody camrelizumab
    combined with the VEGFR-2 inhibitor apatinib plus chemotherapy in ultra
    high-risk and in chemo-refractory or relapsed high-risk gestational
    trophoblastic neoplasia — the checkpoint-plus-antiangiogenic combination
    strategy for the multidrug-resistant population.
  target_phenotypes:
  - preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: clinicaltrials:NCT05139095
    reference_title: "Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia: a Cohort, Open-label, Phase 2 Trial"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational trophoblastic neoplasia (GTN)"
    explanation: >-
      Documents an active trial of combined PD-1 blockade and VEGFR-2 inhibition
      targeting the multidrug-resistant population identified in the
      pathophysiology as the residual unmet need.
classifications:
  icdo_morphology:
    classification_value: Carcinoma
    evidence:
    - reference: PMID:40588865
      reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Gestational choriocarcinoma is the most common form of gestational \ntrophoblastic neoplasm."
      explanation: >-
        Confirms choriocarcinoma as a trophoblastic (epithelial) neoplasm;
        marked PARTIAL because the source states the tumour class rather than
        the ICD-O morphology code itself, which is taken from the MONDO
        ICDO:9100/3 cross-reference.
    notes: >-
      Choriocarcinoma is ICD-O morphology code 9100/3, an epithelial
      (trophoblastic) malignancy. The dismech ICDOMorphologyEnum has no
      trophoblastic axis value, so the closest available parent, Carcinoma, is
      assigned; MONDO:0005207 carries the ICDO:9100/3 cross-reference.
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:40588865
      reference_title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gestational choriocarcinoma is the most common form of gestational \ntrophoblastic neoplasm."
      explanation: >-
        Choriocarcinoma is a malignant neoplasm, placing it in the
        oncology/haematology chapter of Harrison's.
references:
- reference: PMID:37758451
  title: "Gestational choriocarcinoma."
- reference: PMID:40588865
  title: "Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology."
- reference: PMID:34088998
  title: "Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine."
- reference: PMID:34669197
  title: "Diagnosis and management of gestational trophoblastic disease: 2021 update."
- reference: PMID:36286620
  title: "Advances in diagnostics and management of gestational trophoblastic disease."
- reference: PMID:32185550
  title: "Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma."
- reference: PMID:41243514
  title: "Early gestational choriocarcinoma: report of two cases and review of the literature."
- reference: PMID:30339966
  title: "Analysis of PD-L1 expression in trophoblastic tissues and tumors."
- reference: PMID:35681761
  title: "Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN)."
- reference: PMID:37703867
  title: "Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm."
- reference: PMID:22469506
  title: "The genetics of gestational trophoblastic disease: a rare complication of pregnancy."
- reference: PMID:32761058
  title: "Current Practices When Reporting Quantitative Human Chorionic Gonadotropin Test Results."
- reference: PMID:20673583
  title: "Gestational trophoblastic disease."
- reference: PMID:20739008
  title: "Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia."
- reference: PMID:38008872
  title: "Review of current literature on gestational trophoblastic neoplasia."
- reference: PMID:37020431
  title: "Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022)."

📚

References & Deep Research

References

16

PMID:37758451

Gestational choriocarcinoma.

No top-level findings curated for this source.

PMID:40588865

Gestational Choriocarcinoma: A Timely Review of Diagnostic Pathology.

No top-level findings curated for this source.

PMID:34088998

Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.

No top-level findings curated for this source.

PMID:34669197

Diagnosis and management of gestational trophoblastic disease: 2021 update.

No top-level findings curated for this source.

PMID:36286620

Advances in diagnostics and management of gestational trophoblastic disease.

No top-level findings curated for this source.

PMID:32185550

Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma.

No top-level findings curated for this source.

PMID:41243514

Early gestational choriocarcinoma: report of two cases and review of the literature.

No top-level findings curated for this source.

PMID:30339966

Analysis of PD-L1 expression in trophoblastic tissues and tumors.

No top-level findings curated for this source.

PMID:35681761

Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN).

No top-level findings curated for this source.

PMID:37703867

Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm.

No top-level findings curated for this source.

PMID:22469506

The genetics of gestational trophoblastic disease: a rare complication of pregnancy.

No top-level findings curated for this source.

PMID:32761058

Current Practices When Reporting Quantitative Human Chorionic Gonadotropin Test Results.

No top-level findings curated for this source.

PMID:20673583

Gestational trophoblastic disease.

No top-level findings curated for this source.

PMID:20739008

Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia.

No top-level findings curated for this source.

PMID:38008872

Review of current literature on gestational trophoblastic neoplasia.

No top-level findings curated for this source.

PMID:37020431

Gestational and Non-gestational Trophoblastic Neoplasia. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 032/049, April 2022).

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 33 citations 2026-07-31T23:55:07.726167

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Choriocarcinoma
MONDO ID: (if available)
Category:

Research Objectives

Please provide a comprehensive research report on Choriocarcinoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Choriocarcinoma: comprehensive disease-characteristics report

Evidence scope. Choriocarcinoma is biologically heterogeneous. This report distinguishes gestational choriocarcinoma (GC)—a pregnancy-derived gestational trophoblastic neoplasia (GTN)—from nongestational choriocarcinoma (NGC) arising as an ovarian, testicular, or extragonadal germ-cell tumor. Data labeled “GTD/GTN” may include invasive mole, placental-site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT), and therefore are not automatically choriocarcinoma-specific. Most high-quality clinical evidence concerns gestational disease.

The following ontology-oriented table summarizes the most readily computable findings.

Domain	Key evidence-backed finding	Suggested ontology identifiers/terms	Evidence scope/limitations
Disease identity	Choriocarcinoma is a malignant trophoblastic neoplasm; MONDO association available as MONDO:0005207. In clinical practice, reports should distinguish gestational choriocarcinoma from nongestational germ-cell choriocarcinoma, because etiology, molecular origin, and treatment context differ (OpenTargets Search: choriocarcinoma, tempfer2023gestationalandnongestational pages 4-5, shahzadi2023reviewofcurrent pages 2-4)	MONDO:0005207; suggested terms: choriocarcinoma, gestational choriocarcinoma, nongestational choriocarcinoma, uterine corpus choriocarcinoma, ovarian choriocarcinoma, testicular choriocarcinoma	MONDO link is supported; subtype ontologies beyond MONDO:0005207 were not comprehensively validated here. Literature retrieved was much richer for gestational disease than for nongestational germ-cell disease.
Major subtypes / taxonomy	Major clinically relevant groupings: gestational choriocarcinoma (usually postmolar but may follow any pregnancy), nongestational ovarian/testicular/extragonadal choriocarcinoma as a germ-cell tumor component, and precursor hydatidiform mole / postmolar GTN, which must not be conflated with frank choriocarcinoma (tempfer2023gestationalandnongestational pages 4-5, gonzalez2024gestationaltrophoblasticdisease pages 5-7, shahzadi2023reviewofcurrent pages 2-4)	Suggested disease terms: gestational trophoblastic neoplasia (GTN), hydatidiform mole, complete hydatidiform mole, partial hydatidiform mole, invasive mole, choriocarcinoma	Much of the molecular literature concerns precursor moles or broader GTN rather than pure choriocarcinoma. Nongestational biology is underrepresented in the retrieved evidence.
Etiology / causal factors	Gestational disease arises from abnormal trophoblastic proliferation after pregnancy; complete hydatidiform moles are typically androgenetic and carry higher risk of progression to invasive mole/choriocarcinoma than partial moles. Recurrent molar disease is associated with maternal-effect/imprinting genes such as NLRP7 and KHDC3L in precursor disease (tempfer2023gestationalandnongestational pages 4-5, shibata2020uniquefeaturesand pages 8-9, gonzalez2024gestationaltrophoblasticdisease pages 5-7)	Suggested terms: abnormal fertilization, genomic imprinting defect, androgenetic conceptus, trophoblast neoplasm	Strongest causal evidence is for precursor villous disease, not for a single universal driver mutation of choriocarcinoma itself.
Risk factors	Higher GTD incidence/risk is reported at maternal age extremes (10–19 and 40–54 years), prior molar pregnancy, and ethnicity/geography differences; Asian women have about double the incidence reported for women of Caucasian descent in the cited guideline, and Black US women are overrepresented in some registers (tempfer2023gestationalandnongestational pages 4-5, shahzadi2023reviewofcurrent pages 2-4)	Suggested exposure/risk terms: advanced maternal age, teenage pregnancy, prior molar pregnancy, Asian ancestry	Retrieved evidence is disease-group level for GTD/GTN, not choriocarcinoma-only risk quantification. Protective factors were not well established in retrieved sources.
Epidemiology	In highly developed countries, hydatidiform mole prevalence was cited as 1 per 591 pregnancies and GTD prevalence 1 per 714 live births; Dutch population incidence over 20 years was 1.67 cases/1000 births/year for GTD (tempfer2023gestationalandnongestational pages 4-5)	Suggested epidemiology terms: incidence, prevalence, reproductive-age female predominance	These are GTD-level figures, not choriocarcinoma-specific incidence. Choriocarcinoma is rarer than GTD overall.
Core phenotypes / symptoms	Common clinical manifestations across GTN/choriocarcinoma include abnormal vaginal bleeding, elevated/plateauing/rising β-hCG, metastatic symptoms, and hemorrhage from tumor sites; brain, liver, and lung metastases are clinically important in high-risk disease (tempfer2023gestationalandnongestational pages 8-9, tempfer2023gestationalandnongestational pages 10-11, shahzadi2023reviewofcurrent pages 2-4)	Suggested HPO terms: Abnormal uterine bleeding, Elevated circulating human chorionic gonadotropin, Pulmonary metastases, Brain metastases, Liver metastases, Anemia, Hemorrhage	Direct HPO numeric IDs were not validated here; terms are suggested labels only. Evidence is strongest for GTN/high-risk cohorts rather than phenotype frequencies specific to choriocarcinoma.
Anatomy affected	Primary organ is typically uterus in gestational choriocarcinoma; metastatic evaluation routinely targets lung, brain, liver, abdomen/pelvis, and genital tract structures (tempfer2023gestationalandnongestational pages 8-9, shahzadi2023reviewofcurrent pages 2-4)	Suggested UBERON terms: uterus, endometrium, placenta/chorion, lung, brain, liver, vagina, adnexa	UBERON numeric IDs not validated here. Some anatomic staging language is FIGO/TNM rather than ontology-based.
Tissue / cell types	Disease involves malignant trophoblast lineage cells; trophoblast research models emphasize cytotrophoblast, syncytiotrophoblast, and extravillous trophoblast biology, with markers such as GATA3, TFAP2C, low HLA class I, and C19MC expression in trophoblast stem-cell systems (shibata2020uniquefeaturesand pages 8-9, OpenTargets Search: choriocarcinoma)	Suggested CL terms: trophoblast cell, cytotrophoblast, syncytiotrophoblast, extravillous trophoblast	CL numeric IDs were not validated. Many model findings come from trophoblast stem-cell or placental systems, not directly from tumor tissue.
Histopathology / IHC	Choriocarcinoma belongs to non-villous malignant GTD; in the broader differential, p57 is useful mainly to distinguish complete mole from partial mole/non-molar tissue because p57 is lost in androgenetic CHM and retained in PHM/non-molar gestations. Molecular pathology and IHC are guideline-recommended in GTD workup (tempfer2023gestationalandnongestational pages 4-5, gonzalez2024gestationaltrophoblasticdisease pages 5-7)	Suggested pathology terms: p57/CDKN1C immunostain, trophoblastic neoplasm, molecular genotyping, STR analysis, SNP array	p57 is a precursor-mole differential tool, not a definitive diagnostic marker for choriocarcinoma itself. Specific choriocarcinoma IHC panels were not comprehensively retrieved.
Molecular / genetic features	Recent transcriptomic work comparing complete moles with postmolar choriocarcinoma identified 33 differentially expressed genes and implicated TGF-β pathway dysregulation with strong SALL4 expression in postmolar choriocarcinoma; Open Targets evidence also links TP53, GATA3, and DHFR to choriocarcinoma-related evidence (OpenTargets Search: choriocarcinoma, jinkai2024prognosticatinggestationaltrophoblastic pages 9-10)	Suggested gene terms: SALL4, TP53, GATA3, DHFR; suggested pathway terms: TGF-beta signaling pathway	Molecular evidence remains sparse and is based on small transcriptomic comparisons and disease-target aggregation; no single recurrent causal mutation was established from retrieved data.
Epigenetics / imprinting	Abnormal genomic imprinting is central in precursor molar disease; CHM pathogenesis is linked to androgenesis and loss of maternally expressed p57/CDKN1C. Reviews also highlight dysregulated p53/apoptosis pathways, BCL-2/caspases, growth factor receptors, and microRNAs such as miR-196b and miR-21 in GTD/CHM (shibata2020uniquefeaturesand pages 8-9, gonzalez2024gestationaltrophoblasticdisease pages 5-7, nasser2024molecularbasisof pages 12-13)	Suggested terms: genomic imprinting, DNA methylation abnormality, microRNA dysregulation, loss of maternal allele expression	Most retrieved epigenetic evidence concerns hydatidiform mole rather than established choriocarcinoma. Extrapolation should be cautious.
Mechanisms / pathophysiology	Proposed mechanisms include dysregulated trophoblast proliferation/invasion, TGF-β signaling changes, angiogenesis imbalance, oxidative stress, EMT-related programs, and marked immune-checkpoint biology with frequent PD-L1 expression in GTN. A 2024 prognostic review cited PD-L1 expression at 92.3% in GTN and described HLA-G as a biomarker of chemotherapy resistance in gestational choriocarcinoma (jinkai2024prognosticatinggestationaltrophoblastic pages 9-10, baas2024immunotherapyforgestational pages 2-3, nasser2024molecularbasisof pages 12-13)	Suggested GO terms: trophoblast cell proliferation, cell migration, cell invasion, epithelial to mesenchymal transition, angiogenesis, response to oxidative stress, immune evasion, TGF-beta receptor signaling pathway, programmed cell death ligand 1 pathway	Mechanistic evidence is mixed across gestational choriocarcinoma, other GTN subtypes, and precursor lesions. GO numeric IDs not validated.
Immune biology	GTN demonstrates strong PD-L1 expression and immune infiltration, providing biologic rationale for checkpoint blockade. Anti-PD-1/PD-L1 therapy has become a salvage standard for multidrug-resistant GTN in some expert settings (baas2024immunotherapyforgestational pages 2-3, baas2024immunotherapyforgestational pages 2-2, baas2024immunotherapyforgestational pages 6-7, tempfer2023gestationalandnongestational pages 10-11)	Suggested terms: PD-L1 expression, PD-1 checkpoint pathway, tumor-infiltrating lymphocytes, immune checkpoint inhibitor response	Evidence is strongest in refractory GTN cohorts, not frontline choriocarcinoma-only populations. Biomarker predictors of response remain incompletely defined.
Diagnostic biomarkers	Serial serum β-hCG is central for diagnosis, monitoring, and remission assessment. Postmolar GTN/choriocarcinoma diagnostic criteria include plateau or rise in hCG over specified intervals; after therapy, remission monitoring requires serial negative hCG measurements (tempfer2023gestationalandnongestational pages 9-10, tempfer2023gestationalandnongestational pages 15-16, tempfer2023gestationalandnongestational pages 8-9, NCT06028672 chunk 1, NCT05635344 chunk 1)	Suggested LOINC/biomarker terms: serum beta-human chorionic gonadotropin (β-hCG), serial quantitative hCG monitoring	Exact thresholds/definitions vary slightly by guideline/trial. hCG criteria are most validated in postmolar GTN.
Diagnostic criteria	Guideline criteria for persistent postmolar villous GTD include: four or more consecutive hCG values with plateau over ≥3 weeks, rise in hCG on 2 consecutive measurements (day 0 and 7), or persistent hCG values over 6 months; trial eligibility criteria similarly define plateau/rise patterns for GTN (tempfer2023gestationalandnongestational pages 15-16, NCT06028672 chunk 1, NCT05635344 chunk 1)	Suggested terms: FIGO 2000 criteria, postmolar GTN, hCG plateau, hCG rise	These criteria chiefly define postmolar GTN rather than all histologically confirmed choriocarcinoma presentations.
Imaging / staging	Recommended staging includes gynecologic exam with palpation, transvaginal ultrasound, CT thorax and abdomen, and MRI brain; FDG-PET/CT may be used if metastasis is suspected. Postoperative malignant GTD should also follow current TNM classification in addition to FIGO staging (tempfer2023gestationalandnongestational pages 4-5, tempfer2023gestationalandnongestational pages 8-9)	Suggested imaging terms: pelvic ultrasound, CT chest, CT abdomen, brain MRI, FDG-PET/CT, TNM stage, FIGO stage	Guidance is strong for gestational trophoblastic neoplasia. Imaging approach for nongestational germ-cell choriocarcinoma may differ by site and oncology service.
FIGO stages / risk strata	FIGO stage: I uterus-confined, II genital structures, III lungs, IV other metastatic sites. Prognostic score uses age, antecedent pregnancy, interval since pregnancy, pretreatment hCG, metastasis number/site, tumor size, and prior chemotherapy; 0–4 low risk, 5–6 intermediate risk, ≥7 high risk (tempfer2023gestationalandnongestational pages 4-5, shahzadi2023reviewofcurrent pages 2-4)	Suggested terms: FIGO stage I-IV, WHO/FIGO prognostic score, low-risk GTN, intermediate-risk GTN, high-risk GTN	Core evidence is GTN-wide. Some centers now debate refinements beyond classic FIGO 2000 scoring.
First-line treatment strata	Guideline: low-risk disease typically receives methotrexate with folinic/folic acid rescue; methotrexate-resistant cases may switch to actinomycin-D or polychemotherapy. For FIGO 5–6, methotrexate may be used, but EMA-CO is recommended when FIGO 5–6 coexists with distant metastases, hCG >411,000 IU/L, or diagnosis of choriocarcinoma (tempfer2023gestationalandnongestational pages 15-16, shahzadi2023reviewofcurrent pages 2-4)	Suggested NCIT terms: Methotrexate, Actinomycin D, Folic Acid, EMA-CO regimen	Guidance is primarily for gestational disease. Dose/schedule details may vary among regions and centers.
High-risk / metastatic treatment	EMA-CO remains standard for high-risk GTN; one 2023 review cited 93% complete remission with EMA-CO in high-risk GTN and noted ~40% salvage of incomplete responses with platinum-based chemotherapy. Brain-metastatic disease may require higher-dose methotrexate-containing regimens (shahzadi2023reviewofcurrent pages 2-4)	Suggested NCIT terms: EMA-CO, EMA-EP, EP/EMA, BEP, platinum-based combination chemotherapy	Numbers are from GTN/high-risk reviews, not pure choriocarcinoma-only prospective datasets.
Choriocarcinoma-specific treatment note	A recent review citing historical stage-specific outcomes reported 83% cure in stage I choriocarcinoma with single-agent chemotherapy, with additional remissions after further chemotherapy or surgery; stage II-IV disease required combined surgery and chemotherapy (gonzalez2024gestationaltrophoblasticdisease pages 10-11, gonzalez2024gestationaltrophoblasticdisease pages 8-10)	Suggested NCIT terms: single-agent chemotherapy, hysterectomy, metastasectomy, combined modality therapy	Source summarizes older outcome series; exact regimen details and cohort era were not fully resolved from retrieved excerpt.
Immunotherapy	Checkpoint inhibitors are a major recent development. Across 133 GTN patients treated with CPI, 85 achieved complete remission; among 118 high-risk/relapsed/multidrug-resistant patients, 77 achieved CR; among 15 low-risk patients, 8 achieved remission. Pembrolizumab, avelumab, camrelizumab, toripalimab, and combinations with apatinib/chemotherapy are reported (baas2024immunotherapyforgestational pages 1-2, baas2024immunotherapyforgestational pages 3-4)	Suggested NCIT terms: Pembrolizumab, Avelumab, Camrelizumab, Toripalimab, immune checkpoint inhibitor therapy, anti-PD-1 therapy, anti-PD-L1 therapy	Data are mostly single-arm, retrospective, or case-based, and encompass GTN broadly, including PSTT/ETT and refractory disease.
Fertility / follow-up	After chemotherapy completion with undetectable hCG, guideline follow-up is monthly hCG for 1 year with oral hormonal contraception during that period. Pregnancy after GTD is generally possible; recurrence risk cited as 0.7–2.6% after one prior GTD and ~10% after two GTDs; live birth rate cited as 75% after GTD history (tempfer2023gestationalandnongestational pages 8-9, tempfer2023gestationalandnongestational pages 10-11)	Suggested terms: fertility preservation, contraception after GTN, hCG surveillance, pregnancy after GTD	Evidence is GTD-wide, not choriocarcinoma-only. Immunotherapy-era fertility data remain limited.
Prognosis	A 2023 review states GTN can achieve near-100% cure with adequate treatment and emphasizes markedly reduced mortality over time; high-risk disease still requires urgent multi-agent therapy, and ultra-high-risk/refractory disease remains a challenge (shahzadi2023reviewofcurrent pages 2-4, baas2024immunotherapyforgestational pages 6-7)	Suggested prognostic terms: complete remission, overall survival, relapse, chemotherapy resistance, ultra-high-risk disease	Prognosis is excellent in specialized centers for gestational disease, but not necessarily generalizable to nongestational germ-cell choriocarcinoma.
Current real-world trials	Recruiting/active studies include NCT06028672 (toripalimab + actinomycin-D vs actinomycin-D for FIGO 5–6 GTN), NCT05139095 (camrelizumab + apatinib + chemotherapy for ultra-high-risk or relapsed high-risk GTN), NCT05635344 (single-dose neoadjuvant pembrolizumab before second evacuation for low-risk postmolar GTN), and NCT04562558 (biweekly actinomycin-D vs multiday methotrexate in low-risk GTN) (NCT06028672 chunk 1, NCT05139095 chunk 1, NCT05635344 chunk 1)	Suggested NCIT/clinical trial terms: toripalimab, camrelizumab, apatinib, pembrolizumab, actinomycin-D, methotrexate, neoadjuvant immunotherapy	These studies are GTN-focused and often include but are not limited to choriocarcinoma. Most are not specific to nongestational choriocarcinoma.
Model systems	Choriocarcinoma-derived cell lines (JAR, JEG-3, BeWo) remain widely used as trophoblast surrogates, but reviews caution they differ substantially from normal trophoblast. Newer human trophoblast stem cells and trophoblast organoids better recapitulate placental biology; xenograft and germ-cell tumor models exist but incompletely model gestational choriocarcinoma (shibata2020uniquefeaturesand pages 8-9)	Suggested model terms: JAR cell line, JEG-3 cell line, BeWo cell line, trophoblast stem cell, trophoblast organoid, xenograft model	Model limitation is important: placental/trophoblast systems are not synonymous with malignant gestational choriocarcinoma, and many animal models do not capture human villous hemochorial placentation.

Table: This table condenses the most evidence-supported, ontology-oriented facts for a choriocarcinoma knowledge-base entry. It emphasizes where evidence is strong for gestational trophoblastic neoplasia and where caution is needed when extrapolating to pure choriocarcinoma or nongestational germ-cell disease.

1. Disease information

Definition and classification

Choriocarcinoma is a highly vascular, malignant trophoblastic neoplasm composed of cytotrophoblast and syncytiotrophoblast, typically without chorionic villi. Gestational tumors arise from placental trophoblast after a complete mole, abortion/ectopic pregnancy, or term/preterm pregnancy. NGC is a germ-cell malignancy and should be managed within ovarian/testicular germ-cell-tumor frameworks rather than assumed to share GC’s pregnancy-derived biology.

Identifiers and terminology

MONDO: MONDO:0005207, choriocarcinoma. Related MONDO records found include placental choriocarcinoma (MONDO:0006374), uterine-corpus choriocarcinoma (MONDO:0004491), ovarian choriocarcinoma (MONDO:0003507), and testicular choriocarcinoma (MONDO:0003508). (OpenTargets Search: choriocarcinoma)
MeSH: Choriocarcinoma.
ICD-10: C58, malignant neoplasm of placenta; site-specific nongestational tumors may instead be coded under ovary, testis, or other primary site. O01 and D39.2 describe molar/uncertain-behavior placental disease and are not equivalent to choriocarcinoma.
Common synonyms: chorionepithelioma, chorioepithelioma, gestational choriocarcinoma, trophoblastic choriocarcinoma, malignant gestational trophoblastic tumor.
Category: rare malignant neoplasm; reproductive/placental disease; GTN when gestational; germ-cell tumor when nongestational.
OMIM/Orphanet: no single Mendelian OMIM disease entry adequately represents sporadic choriocarcinoma. Maternal-effect genes associated with recurrent hydatidiform mole concern a precursor syndrome, not a universal inherited choriocarcinoma syndrome.

The information synthesized here is aggregated disease-level evidence from guidelines, reviews, studies, and trial records—not individual EHR data.

2. Etiology, risk, and protective factors

Causal framework

GC results from malignant transformation/proliferation of pregnancy-derived trophoblast. A complete hydatidiform mole (CHM) is usually androgenetic and lacks a maternal nuclear genome; CHM has substantially greater malignant potential than partial mole. Loss of maternally expressed CDKN1C/p57 is characteristic of androgenetic CHM, but it is a precursor-lesion mechanism rather than a somatic driver found in every GC. (shibata2020uniquefeaturesand pages 8-9, gonzalez2024gestationaltrophoblasticdisease pages 5-7)

NGC arises through germ-cell-tumor development. Adult germ-cell tumors commonly show chromosome 12p gain, but this cannot be transferred uncritically to GC. Ovarian germ-cell tumors show age- and histology-dependent copy-number changes, with 12p gain among recurrent abnormalities. (pinto2023molecularbiologyof pages 7-9)

Risk factors

Established or consistently reported GTD/GTN risk correlates include previous molar pregnancy, maternal age at either extreme—especially ≥40 years—and Asian ancestry/geographic setting. A 2023 guideline reported increased incidence at ages 10–19 and 40–54, approximately twice the incidence in Asian versus White women, and overrepresentation of Black American women in some registers. These are primarily GTD-level, not choriocarcinoma-only, associations. (tempfer2023gestationalandnongestational pages 4-5, shahzadi2023reviewofcurrent pages 2-4)

A prior term pregnancy, long interval since antecedent pregnancy, high pretreatment hCG, large tumor burden, brain/liver metastasis, and previous failed chemotherapy are adverse prognostic variables, not necessarily etiologic risk factors. (tempfer2023gestationalandnongestational pages 4-5)

Genetics and gene–environment interaction

Biallelic maternal-effect variants in NLRP7 and KHDC3L cause susceptibility to recurrent hydatidiform mole through disturbed imprint establishment. They increase the opportunity for postmolar GTN but are not established as common inherited causes of sporadic GC. No validated population-scale GWAS, protective allele, or clinically actionable germline penetrance estimate was identified for choriocarcinoma itself.

No infectious cause is established. Smoking, alcohol, diet, exercise, occupational toxins, radiation, and pollution are not validated major causal factors. Consequently, no specific dietary, pharmacologic, or genetic protective factor is established beyond effective management and surveillance of precursor GTD. Evidence for a reproducible gene–environment interaction is insufficient.

3. Phenotypes

GC usually affects reproductive-age patients and can arise weeks to years after pregnancy. Onset may be acute through hemorrhage or more insidious through persistent hCG elevation. Suggested phenotype annotations include:

Abnormal uterine/vaginal bleeding—common presenting sign; severity ranges from spotting to life-threatening hemorrhage. Suggested HPO: Abnormal uterine bleeding, Vaginal bleeding.
Elevated serum/urine hCG—central laboratory abnormality; may cause nausea, ovarian theca-lutein cysts, or hyperthyroid manifestations at very high concentrations. Suggested HPO: Elevated circulating human chorionic gonadotropin level, Hyperthyroidism.
Anemia/hemorrhage—from uterine or metastatic vascular deposits. Suggested HPO: Anemia, Hemorrhage.
Pulmonary disease—cough, dyspnea, chest pain, or hemoptysis; lung is the most frequent metastatic site. Suggested HPO: Dyspnea, Hemoptysis, Pulmonary metastases.
Neurologic disease—headache, focal deficit, seizure, or intracranial hemorrhage from brain metastasis. A recent GTN review estimated brain metastasis at presentation in about 11% of high-risk cohorts. Suggested HPO: Headache, Seizure, Focal neurologic deficit, Intracranial hemorrhage. (shahzadi2023reviewofcurrent pages 2-4)
Liver/GI metastasis—abdominal pain, gastrointestinal bleeding, or catastrophic intra-abdominal hemorrhage; these sites confer adverse FIGO points. (tempfer2023gestationalandnongestational pages 4-5, shahzadi2023reviewofcurrent pages 2-4)
Renal manifestations, reported across mole/choriocarcinoma, include proteinuria, nephrotic syndrome, impaired filtration, glomerulonephritis, and renal-vein thrombosis, but frequencies are poorly quantified.

Symptoms are rapidly progressive if untreated because trophoblast is invasive, angiogenic, and hematogenously disseminating. Quality-of-life burdens include bleeding, treatment toxicity, reproductive uncertainty, anxiety about hCG surveillance, and delayed conception. A recruiting study, NCT06169644, specifically evaluates psychological effects after GTN chemotherapy, reflecting an important evidence gap.

4. Genetic and molecular information

Causal genes and variants

There is no single validated causal gene or recurrent pathogenic germline variant for ordinary GC. Routine ACMG-style single-gene testing, carrier frequency, penetrance, anticipation, founder-effect, and germline-mosaicism annotations are therefore not applicable.

Open Targets associates DHFR, TP53, and GATA3 with choriocarcinoma. DHFR is also the pharmacologic target of methotrexate. These are disease/therapeutic associations, not proof that pathogenic variants in these genes cause GC. (OpenTargets Search: choriocarcinoma)

Candidate abnormalities reported across GTN include altered TP53, p21, RB, MYC, ERBB3, MDM2, and EGFR expression. A 2023 review notes the absence of activating EGFR kinase-domain mutations and therefore finds no established role for conventional EGFR-targeted therapy. (shahzadi2023reviewofcurrent pages 2-4)

Epigenetics and chromosomal biology

Gestational tumors retain genetic material from the conceptus and often paternal alleles. STR genotyping or SNP-based analysis can establish gestational origin by demonstrating nonmaternal alleles and can distinguish GC from a maternal somatic carcinoma or NGC. CHM’s androgenetic imprinting pattern and absent p57 expression explain precursor trophoblast overgrowth, but frank GC has a more complex molecular landscape. (gonzalez2024gestationaltrophoblasticdisease pages 5-7)

In molar/GTN tissue, reported epigenetic abnormalities include imprinting disruption, altered microRNAs, and promoter methylation. miR-196b is reduced in CHM and inversely linked to MAP3K1, whereas miR-21 is overexpressed and promotes trophoblast proliferation/invasion. These findings remain investigational and are not validated diagnostic tests for GC. (nasser2024molecularbasisof pages 12-13)

5. Environmental information

No toxin, radiation exposure, occupational agent, lifestyle behavior, or pathogen has been established as a direct cause. Geographic/ethnic differences may reflect reproductive patterns, nutrition, ascertainment, access to early ultrasound and hCG testing, or population genetics, but causal decomposition remains uncertain. There is no vaccine-relevant infectious agent.

6. Mechanism and pathophysiology

Causal chain

Upstream reproductive event: abnormal fertilization and androgenetic CHM, or trophoblast persisting after another pregnancy.
Failure of normal trophoblast control: imprinting and cell-cycle dysregulation, altered apoptosis, growth-factor signaling, and persistence despite pregnancy resolution.
Malignant trophoblast expansion: cytotrophoblast proliferates while syncytiotrophoblast produces large quantities of hCG.
Invasion/angiogenesis: EMT-like programs, extracellular-matrix invasion, TGF-β signaling, and angiogenic factors produce a hemorrhagic uterine mass.
Hematogenous dissemination: lung first, then brain, liver, kidney, spleen, and GI tract; fragile vascular deposits explain hemoptysis and intracranial or intra-abdominal bleeding.
Immune evasion: trophoblast’s physiologic maternal–fetal immune-tolerance machinery, including PD-L1 and HLA-G, is co-opted by tumor.

A transcriptomic comparison found 33 differentially expressed genes between CHM and postmolar GC, implicating TGF-β dysregulation and strong SALL4 expression in GC. The study’s conclusion was: “the TGF-β pathway appears to be a crucial step in the progression of placental malignancies.” This was a small tumor-series result requiring validation. (jinkai2024prognosticatinggestationaltrophoblastic pages 9-10)

A 2024 prognostic review reported PD-L1 expression in 92.3% of GTN and identified investigational resistance pathways involving DPP4/cholesterol synthesis, RSK2–SOX8, and HLA-G; cfDNA signals involving BMPR1A and MAP3K1 were linked to severity. (jinkai2024prognosticatinggestationaltrophoblastic pages 9-10)

GTD studies also report p53/apoptosis imbalance, BCL-2/caspase dysregulation, EGFR/ERBB2/CD117 changes, oxidative stress, reduced E-cadherin, increased Twist-1, and proangiogenic PlGF. These are plausible contributors but much of the evidence comes from CHM or cell lines rather than causal intervention in human GC. (gonzalez2024gestationaltrophoblasticdisease pages 5-7, nasser2024molecularbasisof pages 12-13)

Suggested GO processes: trophoblast-cell proliferation; cell migration; epithelial-to-mesenchymal transition; extracellular-matrix organization; angiogenesis; TGF-β receptor signaling; apoptotic signaling; response to oxidative stress; immune-response inhibition. Suggested CL cells: trophoblast, cytotrophoblast, syncytiotrophoblast, extravillous trophoblast, endothelial cell, tumor-infiltrating lymphocyte. Subcellular emphasis includes nucleus/chromatin for imprinting and transcription, plasma membrane for PD-L1/HLA-G and receptors, and mitochondria/cytosol for apoptosis and redox metabolism.

No reproducible GC-specific metabolomic, lipidomic, spatial-transcriptomic, proteomic, or CRISPR-screen signature has yet reached clinical implementation.

7. Anatomical structures affected

Primary: uterus/endometrium and antecedent placental implantation site in GC; ovary, testis, mediastinum, retroperitoneum, or CNS in NGC.
Secondary: vagina/adnexa and broad ligament (FIGO II), lung (FIGO III), and brain, liver, kidney, spleen, or GI tract (FIGO IV). (shahzadi2023reviewofcurrent pages 2-4)
Suggested UBERON terms: uterus, endometrium, placenta/chorion, vagina, ovary, testis, lung, brain, liver, kidney, spleen, gastrointestinal tract.
Tissue: malignant trophoblastic epithelium with hemorrhage and necrosis; laterality is generally not meaningful for uterine GC, but ovarian/testicular primaries can be unilateral.

8. Temporal development

GC can follow any pregnancy and may present after an interval of months or years. A longer interval is adverse in FIGO scoring: <4, 4–6, 7–12, and >12 months receive progressively higher scores. Disease can progress rapidly because of vascular invasion and early hematogenous spread. (tempfer2023gestationalandnongestational pages 4-5)

FIGO stages are: I, confined to uterus; II, extension to genital structures; III, lung metastasis with or without genital involvement; IV, all other metastatic sites. Clinical course after treatment is tracked through quantitative hCG rather than anatomic imaging alone. Remission is usually treatment-induced; spontaneous normalization after complete surgical evacuation can occur in selected postmolar disease, but routine observation of histologically proven GC is not standard.

The critical intervention window is immediately after an abnormal postpregnancy hCG trend or histologic diagnosis, before high-volume liver/brain disease develops.

9. Inheritance and population epidemiology

GC is predominantly sporadic and is not inherited in Mendelian fashion. The relevant “genome” may be conceptus-derived rather than the patient’s constitutional genome. NLRP7/KHDC3L-associated recurrent mole is recessive maternal-effect disease, but progression to GC is not fully penetrant.

A 2023 guideline reported hydatidiform-mole prevalence of 1/591 pregnancies, GTD prevalence of 1/714 live births, and Dutch GTD incidence of 1.67/1,000 births/year. These figures must not be mislabeled as choriocarcinoma-specific incidence. (tempfer2023gestationalandnongestational pages 4-5)

The sex distribution depends on subtype: GC occurs in patients with a pregnancy; NGC affects both sexes. Gestational disease clusters in reproductive years, while ovarian/testicular and extragonadal germ-cell tumors also occur in children, adolescents, and young adults.

10. Diagnostics

Core tests

Quantitative serum β-hCG, repeated in the same laboratory/assay where possible. Urine hCG and alternative assays help investigate heterophile-antibody “phantom hCG” or unusual hCG forms.
Pelvic examination and transvaginal ultrasound.
Staging imaging: CT chest and abdomen plus brain MRI; FDG-PET/CT is optional for unresolved suspected metastasis. (tempfer2023gestationalandnongestational pages 8-9)
Histopathology: biphasic malignant cytotrophoblast/syncytiotrophoblast, marked atypia, hemorrhage and necrosis, and no chorionic villi. Biopsy of highly vascular metastases should be avoided when diagnosis can be made safely through hCG and clinical context.
IHC: hCG highlights syncytiotrophoblast; broad cytokeratin, GATA3, inhibin, SALL4 and other trophoblast/germ-cell markers may support the diagnosis. p57 is principally a CHM differential marker, not a stand-alone GC test. In CHM diagnosis, adding p57 increased pathologist sensitivity to approximately 93–96% and specificity to 96–98%. (gonzalez2024gestationaltrophoblasticdisease pages 5-7)
STR/SNP genotyping: recommended when gestational origin is uncertain, especially for ovarian disease, remote pregnancy, unusual primary site, or distinction from a maternal carcinoma.

Diagnostic criteria and staging

Postmolar GTN criteria include four hCG values forming a plateau over at least three weeks, serial hCG rise, or persistent detectable hCG beyond six months; exact rise definitions vary slightly among guidelines. Histologically confirmed choriocarcinoma itself establishes GTN even without these serial criteria. (tempfer2023gestationalandnongestational pages 15-16, NCT06028672 chunk 1)

The FIGO/WHO prognostic score includes age, antecedent pregnancy, interval, hCG, largest tumor, number/site of metastases, and prior chemotherapy: 0–4 low, 5–6 intermediate, and ≥7 high risk in the cited guideline. Brain/liver metastasis and multiple failed regimens carry the highest weights. (tempfer2023gestationalandnongestational pages 4-5)

Differential diagnosis

Important alternatives are retained products/new pregnancy, invasive mole, PSTT/ETT, placental-site nodule, ectopic pregnancy, placental-site exaggerated reaction, hCG-producing germ-cell tumor, poorly differentiated carcinoma, melanoma, sarcoma, and phantom/pituitary hCG. WES/WGS, broad germline panels, CMA, mitochondrial testing, and repeat-expansion testing are not routine. Tumor sequencing may be useful only in refractory or diagnostically unresolved disease.

There is no population screening program. Surveillance after molar pregnancy is targeted secondary prevention.

11. Outcome and prognosis

Gestational disease is among the most curable metastatic solid tumors when managed in a specialist center. A 2023 review states that adequate treatment can approach 100% overall cure and reports 93% complete remission with EMA-CO in high-risk GTN; approximately 40% of incomplete responders were salvageable using platinum-based multi-agent chemotherapy. (shahzadi2023reviewofcurrent pages 2-4)

A 2024 review reported stage-I choriocarcinoma cure of 83% with single-agent chemotherapy, with further remissions after additional treatment; later stages require multi-modality management. The figure derives from earlier series and should not be interpreted as a contemporary population survival estimate. (gonzalez2024gestationaltrophoblasticdisease pages 10-11, gonzalez2024gestationaltrophoblasticdisease pages 8-10)

Adverse factors include liver/brain metastasis, very high hCG, large/multiple tumors, term-pregnancy antecedent, interval >12 months, choriocarcinoma histology, and prior failed chemotherapy. Untreated disease is frequently fatal from hemorrhage or organ involvement.

Reproductive prognosis is generally favorable: one review reported an 86.7% fertility rate among patients desiring conception after treatment for choriocarcinoma/invasive mole. GTD-wide data report a 75% live-birth rate, recurrence of 0.7–2.6% after one GTD and about 10% after two, with no clear excess of congenital malformations. (gonzalez2024gestationaltrophoblasticdisease pages 10-11, tempfer2023gestationalandnongestational pages 10-11)

Long-term morbidity includes chemotherapy-related myelosuppression, mucositis, alopecia, neuropathy, renal/hepatic injury, premature ovarian impairment, psychological distress, and a dose-related risk of therapy-related myeloid leukemia after etoposide. After MTX and EMA-CO, regular menses were reported in 12/12 and 32/34 women, respectively. (tempfer2023gestationalandnongestational pages 10-11)

12. Treatment

Risk-adapted gestational treatment

Low risk: methotrexate with folinic/folic-acid rescue or actinomycin-D. The cited guideline uses MTX 50 mg IM on days 1, 3, 5 and 7 with folic acid 15 mg orally on days 2, 4, 6 and 8; resistance prompts actinomycin-D 1.25 mg/m² every two weeks or EMA-CO. (tempfer2023gestationalandnongestational pages 15-16)
Comparative studies summarized in 2023 found complete-remission rates of 80% versus 65%, 73% versus 58%, and 90% versus 48% for actinomycin-D versus alternative MTX schedules. Five-day MTX cured 226/253 patients (89.3%) in one center. MTX remains common because it generally causes less alopecia/toxicity. (shahzadi2023reviewofcurrent pages 2-4)
FIGO 5–6/choriocarcinoma: multi-agent EMA-CO should be considered when distant metastasis, very high hCG, or choriocarcinoma histology is present because single-agent resistance is more likely. (tempfer2023gestationalandnongestational pages 15-16)
High risk: EMA-CO; EP/EMA or EMA-EP are important alternatives/salvage regimens. Ultra-high-risk disease may receive low-dose weekly etoposide/cisplatin induction to reduce fatal hemorrhage/tumor-collapse risk. (tempfer2023gestationalandnongestational pages 9-10)
Brain metastasis: higher-dose MTX with CNS penetration and individualized surgery/radiotherapy. A review reported five-year survival of 81.5% with intensive treatment. (shahzadi2023reviewofcurrent pages 2-4)

Suggested NCIt interventions: Methotrexate; Leucovorin/Folinic Acid; Dactinomycin; Etoposide; Cisplatin; Cyclophosphamide; Vincristine; EMA-CO; EMA-EP; EP/EMA; BEP; Combination Chemotherapy.

Surgery

Suction evacuation treats molar precursors, not metastatic GC. Hysterectomy can control uterine hemorrhage or isolated chemoresistant disease and is considered when fertility is not desired. Resection of isolated lung, brain, liver, or other resistant deposits can salvage selected patients. Surgery should complement—not replace—systemic therapy for most GC.

Immunotherapy: major 2023–2024 development

GTN strongly expresses PD-L1, providing unusually compelling biologic rationale for checkpoint blockade. Across 133 checkpoint-inhibitor-treated patients summarized in 2023/2024, 85 achieved complete remission: 77/118 with high-risk, relapsed, or multidrug-resistant disease and 8/15 with low-risk disease. One complete responder relapsed 22 months after stopping therapy. (baas2024immunotherapyforgestational pages 1-2)

A 66-patient refractory/relapsed cohort had 46 complete and six partial responses; 25 experienced grade 3–4 toxicity. Camrelizumab plus apatinib produced 10 complete responses among 20 high-risk patients, with grade-3 toxicity in 12. High-risk avelumab monotherapy performed poorly in a separate seven-patient study (one complete response), showing that checkpoint agents and settings are not interchangeable. (baas2024immunotherapyforgestational pages 3-4)

UK expert practice cited in the review uses pembrolizumab after failure of at least two multi-agent lines, including EMA-CO, and continues therapy to hCG/radiologic remission followed by consolidation. The review concludes: “anti-PD-1 salvage treatment in multidrug resistant disease is now a standard of care,” while emphasizing cost, fertility uncertainty, and limited long-term data. (baas2024immunotherapyforgestational pages 2-2, baas2024immunotherapyforgestational pages 6-7)

Current trials and real-world implementation

NCT06028672, recruiting: toripalimab 200 mg IV every two weeks plus actinomycin-D 1.25 mg/m² versus actinomycin-D alone for FIGO 5–6 GTN; estimated n=40; includes AMH, QLQ-C30 and reproductive-concern outcomes. https://clinicaltrials.gov/study/NCT06028672 (NCT06028672 chunk 1)
NCT05139095, recruiting phase II: camrelizumab plus apatinib and chemotherapy for ultra-high-risk or multiply treated high-risk GTN; estimated n=70. https://clinicaltrials.gov/study/NCT05139095 (NCT05139095 chunk 1)
NCT05635344/RESOLVE, recruiting phase II: one 200-mg pembrolizumab dose before second evacuation versus surgery alone for low-risk postmolar GTN; choriocarcinoma is excluded. https://clinicaltrials.gov/study/NCT05635344 (NCT05635344 chunk 1)
NCT04562558, active, not recruiting: biweekly actinomycin-D versus multiday MTX in low-risk GTN; n=228. https://clinicaltrials.gov/study/NCT04562558

No gene, RNA, CAR-T, or approved cell therapy is established. Pharmacogenomic guidance is not standard; DHFR biology is relevant to MTX, but no CPIC genotype-directed regimen exists.

13. Prevention

There is no known primary prevention, vaccine, prophylactic medication, or lifestyle program. Prophylactic chemotherapy after a successfully evacuated mole with falling/negative hCG is not recommended in the cited guideline. (tempfer2023gestationalandnongestational pages 15-16)

Secondary prevention consists of centralized pathology review, complete evacuation of molar pregnancy, and serial hCG. After mole, the guideline recommends weekly hCG until at least two consecutive negatives, followed by monthly testing for at least six months; higher-risk circumstances may warrant longer monitoring. (tempfer2023gestationalandnongestational pages 15-16)

Tertiary prevention includes risk-adapted chemotherapy, prompt evaluation of neurologic/hepatic symptoms, safe management of hemorrhage, and post-treatment hCG monitoring. After chemotherapy, at least three consecutive weekly undetectable values are followed by monthly hCG for one year with hormonal contraception, because pregnancy hCG would obscure relapse detection. (tempfer2023gestationalandnongestational pages 9-10, tempfer2023gestationalandnongestational pages 8-9)

Patients with recurrent moles should receive reproductive-genetics assessment for NLRP7/KHDC3L-related disease. Future pregnancy should include early ultrasound, placental histology when indicated, and postpartum hCG confirmation.

14. Other species and natural disease

Naturally occurring choriocarcinoma-like trophoblastic tumors are reported sporadically in domestic and laboratory mammals, but no common veterinary counterpart reproduces human gestational disease sufficiently for direct clinical translation. There is no zoonotic transmission. No breed-specific VBO association or conserved single causal ortholog was established from the retrieved evidence.

Comparative interpretation is limited because human placentation and trophoblast invasion differ markedly from those of common laboratory rodents. Nonhuman primates have closer placental biology, but their use is constrained by cost and ethics.

15. Model organisms and experimental systems

Cell lines: BeWo, JAR, and JEG-3 choriocarcinoma lines are widely used for hCG secretion, syncytialization, transport, invasion, viral-entry, and drug studies. Their major limitation is that they are transformed, karyotypically abnormal tumor cells and “are quite different from normal trophoblast cells,” as a placental-model review states. (shibata2020uniquefeaturesand pages 8-9)

Modern models: human trophoblast stem cells express GATA3/TFAP2C, low HLA class I, hypomethylated ELF5, and C19MC; they differentiate toward syncytiotrophoblast and extravillous trophoblast. First-trimester trophoblast organoids contain cytotrophoblast- and syncytiotrophoblast-like populations and can produce EVT-like cells. These systems better model normal lineage biology but are not full GC models. (shibata2020uniquefeaturesand pages 8-9)

In vivo: immunodeficient-mouse xenografts of choriocarcinoma lines can test tumor growth, metastasis and drug response. Germ-cell-tumor patient-derived xenografts preserve some histologic and chemosensitivity features, but pure choriocarcinoma PDX resources are scarce. Mouse placenta differs from human villous hemochorial placenta, limiting developmental inference.

Priority research needs: patient-derived GC organoids/PDXs; matched tumor–antecedent-pregnancy sequencing; single-cell and spatial profiling of malignant trophoblast and immune cells; prospective validation of PD-L1, HLA-G and cfDNA; and functional screens for MTX/EMA-CO resistance.

Key recent sources and expert interpretation

Tempfer et al., DGGG/OEGGG/SGGG guideline, published March 2023, DOI: https://doi.org/10.1055/a-1904-6461. This is the strongest retrieved source for diagnosis, FIGO risk, imaging, treatment and surveillance, but it is an S2k consensus guideline rather than a formally graded systematic guideline. (tempfer2023gestationalandnongestational pages 9-10, tempfer2023gestationalandnongestational pages 4-5, tempfer2023gestationalandnongestational pages 8-9)
Shahzadi et al., review published November 2023, DOI: https://doi.org/10.1186/s43046-023-00195-y. Its abstract states that EMA-CO “leads to complete remission in 93% of high-risk GTN patients.” (shahzadi2023reviewofcurrent pages 2-4)
Baas et al., immunotherapy review published online September 2023 and in the 2024 journal volume, DOI: https://doi.org/10.1159/000533972. Its abstract reports 133 CPI-treated patients and 85 complete remissions, establishing checkpoint blockade as the leading contemporary development. (baas2024immunotherapyforgestational pages 1-2)
Gonzalez et al., published July 2024, DOI: https://doi.org/10.3390/diseases12070159, provides current precursor-mole pathology, p57/genotyping, fertility and summarized treatment outcomes. (gonzalez2024gestationaltrophoblasticdisease pages 10-11, gonzalez2024gestationaltrophoblasticdisease pages 5-7)
Jin-Kai et al., published November 2024, DOI: https://doi.org/10.1016/j.eclinm.2024.102890, argues that FIGO 2000 should evolve toward molecular/biomarker-integrated prognostication while retaining its proven clinical utility. (jinkai2024prognosticatinggestationaltrophoblastic pages 9-10)
Nasser et al., published August 2024, DOI: https://doi.org/10.3390/ijms25168739, systematically reviews 71 studies of molecular GTD biology. Its evidence chiefly concerns moles and should not be presented as direct proof in GC. (nasser2024molecularbasisof pages 12-13)

Overall conclusion. Gestational choriocarcinoma is a rare, rapidly invasive and hemorrhagic trophoblastic cancer but is exceptionally chemosensitive. Serial quantitative hCG, FIGO/WHO risk stratification, complete metastatic imaging, and specialist-center treatment remain the clinical foundation. The most important recent advance is PD-1/PD-L1 blockade for multidrug-resistant disease. Conversely, claims about causal somatic genes, protective factors, single-cell states, metabolomics, or genotype-guided treatment remain preliminary. Nongestational choriocarcinoma must be separately classified and treated as germ-cell cancer rather than automatically assigned gestational algorithms.

References

(OpenTargets Search: choriocarcinoma): Open Targets Query (choriocarcinoma, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(tempfer2023gestationalandnongestational pages 4-5): Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, Ralf Dittrich, Jens Einenkel, Andreas Günthert, Heidemarie Haase, Jürgen Kratzsch, Michael Kreißl, Stephan Polterauer, Andreas Ebert, Eric Steiner, Falk Thiel, Michael Eichbaum, Tanja Fehm, Martin C. Koch, and Paul Gass. Gestational and non-gestational trophoblastic neoplasia. guideline of the dggg, oeggg and sggg (s2k-level, awmf registry no. 032/049, april 2022). Geburtshilfe und Frauenheilkunde, 83:267-288, Mar 2023. URL: https://doi.org/10.1055/a-1904-6461, doi:10.1055/a-1904-6461. This article has 2 citations and is from a peer-reviewed journal.
(shahzadi2023reviewofcurrent pages 2-4): Mehwish Shahzadi, Saqib Raza Khan, Muhammad Tariq, Sehrish Sarwar Baloch, Aisha Shahid, Munira Moosajee, and Zarka Samon. Review of current literature on gestational trophoblastic neoplasia. Journal of the Egyptian National Cancer Institute, Nov 2023. URL: https://doi.org/10.1186/s43046-023-00195-y, doi:10.1186/s43046-023-00195-y. This article has 16 citations.
(gonzalez2024gestationaltrophoblasticdisease pages 5-7): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 27 citations.
(shibata2020uniquefeaturesand pages 8-9): Shun Shibata, Eri H. Kobayashi, Norio Kobayashi, Akira Oike, Hiroaki Okae, and Takahiro Arima. Unique features and emerging in vitro models of human placental development. Reproductive Medicine and Biology, 19:301-313, Sep 2020. URL: https://doi.org/10.1002/rmb2.12347, doi:10.1002/rmb2.12347. This article has 33 citations and is from a peer-reviewed journal.
(tempfer2023gestationalandnongestational pages 8-9): Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, Ralf Dittrich, Jens Einenkel, Andreas Günthert, Heidemarie Haase, Jürgen Kratzsch, Michael Kreißl, Stephan Polterauer, Andreas Ebert, Eric Steiner, Falk Thiel, Michael Eichbaum, Tanja Fehm, Martin C. Koch, and Paul Gass. Gestational and non-gestational trophoblastic neoplasia. guideline of the dggg, oeggg and sggg (s2k-level, awmf registry no. 032/049, april 2022). Geburtshilfe und Frauenheilkunde, 83:267-288, Mar 2023. URL: https://doi.org/10.1055/a-1904-6461, doi:10.1055/a-1904-6461. This article has 2 citations and is from a peer-reviewed journal.
(tempfer2023gestationalandnongestational pages 10-11): Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, Ralf Dittrich, Jens Einenkel, Andreas Günthert, Heidemarie Haase, Jürgen Kratzsch, Michael Kreißl, Stephan Polterauer, Andreas Ebert, Eric Steiner, Falk Thiel, Michael Eichbaum, Tanja Fehm, Martin C. Koch, and Paul Gass. Gestational and non-gestational trophoblastic neoplasia. guideline of the dggg, oeggg and sggg (s2k-level, awmf registry no. 032/049, april 2022). Geburtshilfe und Frauenheilkunde, 83:267-288, Mar 2023. URL: https://doi.org/10.1055/a-1904-6461, doi:10.1055/a-1904-6461. This article has 2 citations and is from a peer-reviewed journal.
(jinkai2024prognosticatinggestationaltrophoblastic pages 9-10): Lin Jin-Kai, Jiang Fang, and Xiang Yang. Prognosticating gestational trophoblastic neoplasia: from figo 2000 to future models. eClinicalMedicine, 77:102890, Nov 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102890, doi:10.1016/j.eclinm.2024.102890. This article has 13 citations and is from a peer-reviewed journal.
(nasser2024molecularbasisof pages 12-13): Shadha Nasser, Mohammed Bahutair, R. Dube, Manjunatha Goud, Bellary Kuruba, Rasha Khougali Abdelrahman Aziz, Attia Salama, Mohamed Anas, Mohamed Anas Mohamed Faruk Patni, Subhranshu Sekhar Kar, and Rakhee Kar. Molecular basis of hydatidiform moles—a systematic review. International Journal of Molecular Sciences, 25:8739, Aug 2024. URL: https://doi.org/10.3390/ijms25168739, doi:10.3390/ijms25168739. This article has 13 citations.
(baas2024immunotherapyforgestational pages 2-3): Inge O. Baas, Anneke M. Westermann, Benoit You, Pierre-Adrien Bolze, Michael Seckl, and Ehsan Ghorani. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecologic and Obstetric Investigation, 89:230-238, Sep 2023. URL: https://doi.org/10.1159/000533972, doi:10.1159/000533972. This article has 49 citations and is from a peer-reviewed journal.
(baas2024immunotherapyforgestational pages 2-2): Inge O. Baas, Anneke M. Westermann, Benoit You, Pierre-Adrien Bolze, Michael Seckl, and Ehsan Ghorani. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecologic and Obstetric Investigation, 89:230-238, Sep 2023. URL: https://doi.org/10.1159/000533972, doi:10.1159/000533972. This article has 49 citations and is from a peer-reviewed journal.
(baas2024immunotherapyforgestational pages 6-7): Inge O. Baas, Anneke M. Westermann, Benoit You, Pierre-Adrien Bolze, Michael Seckl, and Ehsan Ghorani. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecologic and Obstetric Investigation, 89:230-238, Sep 2023. URL: https://doi.org/10.1159/000533972, doi:10.1159/000533972. This article has 49 citations and is from a peer-reviewed journal.
(tempfer2023gestationalandnongestational pages 9-10): Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, Ralf Dittrich, Jens Einenkel, Andreas Günthert, Heidemarie Haase, Jürgen Kratzsch, Michael Kreißl, Stephan Polterauer, Andreas Ebert, Eric Steiner, Falk Thiel, Michael Eichbaum, Tanja Fehm, Martin C. Koch, and Paul Gass. Gestational and non-gestational trophoblastic neoplasia. guideline of the dggg, oeggg and sggg (s2k-level, awmf registry no. 032/049, april 2022). Geburtshilfe und Frauenheilkunde, 83:267-288, Mar 2023. URL: https://doi.org/10.1055/a-1904-6461, doi:10.1055/a-1904-6461. This article has 2 citations and is from a peer-reviewed journal.
(tempfer2023gestationalandnongestational pages 15-16): Clemens Tempfer, Lars-Christian Horn, Sven Ackermann, Ralf Dittrich, Jens Einenkel, Andreas Günthert, Heidemarie Haase, Jürgen Kratzsch, Michael Kreißl, Stephan Polterauer, Andreas Ebert, Eric Steiner, Falk Thiel, Michael Eichbaum, Tanja Fehm, Martin C. Koch, and Paul Gass. Gestational and non-gestational trophoblastic neoplasia. guideline of the dggg, oeggg and sggg (s2k-level, awmf registry no. 032/049, april 2022). Geburtshilfe und Frauenheilkunde, 83:267-288, Mar 2023. URL: https://doi.org/10.1055/a-1904-6461, doi:10.1055/a-1904-6461. This article has 2 citations and is from a peer-reviewed journal.
(NCT06028672 chunk 1): xiang yang. Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6. Peking Union Medical College Hospital. 2023. ClinicalTrials.gov Identifier: NCT06028672
(NCT05635344 chunk 1): A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia. Imperial College London. 2024. ClinicalTrials.gov Identifier: NCT05635344
(gonzalez2024gestationaltrophoblasticdisease pages 10-11): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 27 citations.
(gonzalez2024gestationaltrophoblasticdisease pages 8-10): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 27 citations.
(baas2024immunotherapyforgestational pages 1-2): Inge O. Baas, Anneke M. Westermann, Benoit You, Pierre-Adrien Bolze, Michael Seckl, and Ehsan Ghorani. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecologic and Obstetric Investigation, 89:230-238, Sep 2023. URL: https://doi.org/10.1159/000533972, doi:10.1159/000533972. This article has 49 citations and is from a peer-reviewed journal.
(baas2024immunotherapyforgestational pages 3-4): Inge O. Baas, Anneke M. Westermann, Benoit You, Pierre-Adrien Bolze, Michael Seckl, and Ehsan Ghorani. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecologic and Obstetric Investigation, 89:230-238, Sep 2023. URL: https://doi.org/10.1159/000533972, doi:10.1159/000533972. This article has 49 citations and is from a peer-reviewed journal.
(NCT05139095 chunk 1): Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia. Peking Union Medical College Hospital. 2022. ClinicalTrials.gov Identifier: NCT05139095
(pinto2023molecularbiologyof pages 7-9): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Choriocarcinoma: comprehensive disease-characteristics report

1. Disease information

Definition and classification

2. Etiology, risk, and protective factors

Causal framework

Risk factors

Genetics and gene–environment interaction

3. Phenotypes

4. Genetic and molecular information

Causal genes and variants

Epigenetics and chromosomal biology

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnostics

Core tests

Diagnostic criteria and staging

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Risk-adapted gestational treatment

Surgery

Immunotherapy: major 2023–2024 development

Current trials and real-world implementation

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Key recent sources and expert interpretation

Artifacts